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• This thesis aimed to develop a framework to help people undertaking 
health technology assessment of health technologies in development 
(termed ‘analysts’) approach their work. 
• It used a literature review and learning from five case studies to develop 
a framework which described the features of this type of health 
technology assessment, a generic process for undertaking the work and 
described which methods might be appropriate.  Although the case 
studies are all diagnostic technologies, the framework would be 
appropriate for those working with small and medium-sized developers of 
any type of health technology. 
• Analysts need to be aware that HTA for developers of health technologies 
and their investors (termed ‘developers’) is different to HTA undertaken 
later in the technology’s lifecycle.  Compared to HTA undertaken at 
market access stage, HTA undertaken to inform developers (termed 
‘development-focused HTA’ or ‘DF-HTA’) informs a broader range of 
decisions and has to deal with a greater level of uncertainty, as the 
precise use of the technology may not yet be known and there is likely to 
be little evidence specific to the technology. 
• Although the process of DF-HTA will be familiar to analysts in that it 
involves the assessment of clinical and economic value, DF-HTA is more 
iterative in nature and does not have strict methodological guidelines to 
follow, as is often the case for HTA at market access stage.  Analysts can 
take a more positive stance and put themselves in the shoes of the 
developer to consider what analysis would be useful to the developer at 
this stage of development. 
• The methods would be familiar to those carrying out health technology 
assessment but need some modification when the work is to inform 
developers.  This is particularly relevant when resources for analysis are 
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constrained, which is often the case when assessing technologies in 
development, many of which are likely to fail.  In practice, this means 
that methods may be simpler.  There is also more emphasis on methods of 
stakeholder consultation as a result of the lack of clinical evidence. 
• The framework would benefit from validation through prospective use in 
further case studies by external groups of analysts.  This is particularly 
important because much HTA work undertaken for commercial developers 
is not published due to commercial sensitivity. 
Background and aims 
The development of health technologies is expensive and high risk, as many 
technologies in development fail to achieve commercial success.  There are 
many choices to be made during the development process and the decisions 
made at this time are likely to influence the future success of the technology.  It 
has been suggested that health technology assessment (HTA) undertaken during 
the development process may help to reduce the risk of failure or to accelerate 
failure and reduce research waste.  The form of HTA used to inform developers 
about some of the decisions they need to make during the development process 
has been termed ‘Early HTA’. However, the current ‘Early HTA’ literature 
includes work which is not intended to directly inform developers (such as HTA 
accompanying managed access agreements) and much of the HTA that is 
conducted to inform developers is not published.  As a result, there is a lack of 
clear guidance for the analyst on how to approach HTA to inform developers of 
medical technologies.   
This thesis proposes a framework to aid analysts (people undertaking HTA 
assessments) who are working with developers of medical technologies.  The 
term developers is used throughout to describe the individuals or companies who 
are developing a medical technology and their investors/funders.  Large 
pharmaceutical and medical device companies tend to have in-house HTA 
resource (often termed Health Economics and Outcome Research (HEOR) or 
market access teams).  For this reason, the framework is aimed primarily at 
academic and consultant analysts working with small or medium-sized 
enterprises (SMEs).   
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The framework comprises three sections: features, process and methods of HTA 
to inform developers (termed development-focused or DF-HTA).  Features means 
the characteristics of DF-HTA.  Process describes the broad activities of DF-HTA.  
Methods describes the analytical approach to those activities or how the analyst 
would undertake the activity.   
The framework was developed alongside five case studies in the assessment of 
diagnostic technologies which are included to illustrate the framework of 
features, process and methods. 
Methods 
A pearl-growing literature review was undertaken in October 2017 and refreshed 
in February 2019.  Pearl-growing involves searching the citations and references 
of articles of interest until no further papers are being retrieved.  The aim was 
to retrieve literature which informed an understanding of early health 
technology assessment and included both methods papers and applied studies.   
An iterative process was undertaken to develop a framework of DF-HTA including 
features, process and methods.  An initial list of features of DF-HTA was 
developed then refined and expanded using an iterative process informed by the 
content of articles identified as being particularly informative and the 
experience of undertaking the case studies.  Frameworks for the process of DF-
HTA identified in the literature review were used as the basis for the 
development of a generic process of DF-HTA.  Methods useful for DF-HTA were 
extracted from review articles.  Methods of research and development or other 
commercial activities were excluded.  Terminology was streamlined where 
similar terms were describing the same method.   
Five case studies were used to illustrate the framework of DF-HTA.  For each of 
the case studies the features were compared to the list of features and areas of 
non-conformity identified and discussed.  The process of DF-HTA included 
clinical value assessment in all cases and economic value assessment in four of 
the five case studies.  Methods were selected from the methods identified as 




A total of 152 early HTA papers were identified of which 88 were judged to be 
aimed at informing developers.  These comprised 56 methods, 61 applied and 35 
methods and applied papers in early HTA of which 43 methods, 25 applied and 
20 methods and applied were aimed to inform developers.   
A proposed framework of DF-HTA was developed including the features, a 
generic process and a range of methods suitable for DF-HTA.  Ten features 
characterising DF-HTA were identified including six which had not been 
previously identified: audience; timing; decisions informed; available evidence; 
underlying user objective; decision space; business model; resources for 
analysis; stance of analysis and burden of proof.  The proposed generic process 
of DF-HTA comprises two core aspects of DF-HTA identified in all the frameworks 
found in the literature – clinical value assessment and economic value 
assessment.  Clinical value assessment considers what impact the technology 
might have on clinical practice and ultimately upon health (and wider social) 
outcomes. Economic value assessment builds on the clinical value assessment to 
consider the economic impact of changes in healthcare resource use and other 
economic value drivers such as productivity effects.  Eight broad groups of 
methods useful in DF-HTA were identified from review articles: care pathway 
analysis; qualitative methods of stakeholder interaction; literature review; 
multi-criteria decision analysis; discrete choice experiments; expert opinion and 
elicitation; cost effectiveness analysis and value of information analysis.   
The framework was illustrated using the case studies.  The features of DF-HTA 
were evident in three case studies of technologies in development but not in two 
case studies concerning technologies already in clinical use.  The process and 
methods used in the case studies aligned with the generic process of DF-HTA.  
All the case studies began with a clinical value assessment using decision models 
to map the existing and potential clinical pathways.  For the three DF-HTA case 
studies parameter estimates came from the literature and expert opinion 
initially supplemented by evidence from small clinical studies specific to the 
technology where this was available.  The case studies show that an initial 
clinical model is able to distinguish technologies with potential value from those 
with little potential value.  Cost-effectiveness or cost consequence models were 
6 
 
able to identify potential economic value, indicate design factors which required 
clarification before further development and identify parameters likely to have 
a significant impact on potential economic value.  The two case studies which 
involved technologies which were already in clinical use were able to show, 
using similar methods to DF-HTA and in situations where evidence was limited, 
cost savings and consequences of expanding a testing programme and 
introducing a triage test.  These case studies demonstrate the need for 
alternatives to cost-effectiveness using methods appropriate at market 
access/adoption stage when resources are limited. 
Conclusion 
The main contribution of the thesis was to propose a framework of features, 
process and methods of DF-HTA.  A secondary contribution was to provide five 
empirical examples, three in DF-HTA and two in early economic evaluation of 
diagnostic technologies.  The case studies use simple models that can be readily 
used to provide an indication of the potential value of a technology whilst it is 
under development or during some form of expedited review.   
The main limitation concerns the likely incompleteness and 
unrepresentativeness of HTA studies to inform developers in the academic 
literature.  This is because of commercial confidentiality and a lack of an 
incentive to publish. 
This thesis suggests that developers should be encouraged to consult an HTA 
practitioner at an early stage in the development.  Where development is 
technology-driven (i.e. the technology is developed without a precise clinical 
need identified), DF-HTA can help developers to ‘position’ their technology, 
articulate value propositions and engage with stakeholders.  This process can 
sometimes change the design or intended direction of the technology in 
development and can inform evidence generation strategy.  For analysts, the 
framework should provide guidance on the nature, process and methods of HTA 
to meet the needs of the developer.  For policy-makers the thesis suggests that 
it is possible and desirable to encourage the articulation of a value proposition 
(particularly for translational research) within funding applications.  It is also 
essential to support translational research bodies which facilitate links between 
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commercial entities, academic and clinical researchers, clinicians, regulators 
and reimbursement agencies.  Policy-makers may also wish to fund the 
development of full disease models which could be used to rapidly and robustly 
evaluate any proposed technology (in technology-driven development) as well as 
determining areas of greatest need to inform specific calls for innovation (needs-
driven development). 
Further research exploring the features of in-house and unpublished DF-HTA and 
the usefulness of this framework of DF-HTA to developers and analysts would be 
valuable.  The decision-making process for the adoption of many technologies is 
not clear and transparent and research into the evidence relied upon by 
decision-makers in different settings would be useful.  The extent to which full 
disease models have been or could be used to assess the value proposition for 
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HTA Health Technology Assessment 
ICER Incremental Cost Effectiveness Ratio 
ICER Institute for Clinical and Economic Review 
ISD Information Services Division (of the NHS in Scotland) 
ISPOR International Society for Pharmacoeconomics and Outcomes Research 
IV intravenous 
IVDR In vitro devices regulation 
IVI Infusional intravenous 
JAK Janus kinase  
KRAS Kirsten Rat Sarcoma 
LDT Laboratory Developed Test 
MATCH Multi-disciplinary Assessment of TeCHnologies 
MCDA Multi-criteria Decision Analysis 
MDM Multi-disciplinary team meeting (also sometimes referred to as MDT or MDTM) 
MDR Medical Devices Regulation 
MeSH  Medical Subject Headings 
MHRA Medicines and Healthcare products Regulatory Agency 
MIC MedTech and In Vitro Diagnostics Co-operative 
MM Malignant melanoma 
ml Millilitre 
MPEP Molecular Pathology Evaluation Panel 
MRI Magnetic Resonance Imaging 
MSc Masters of Science 
MTA Medical technology assessment 
MTX Methotrexate 
n Number 
N/A Not applicable 
NFS Non-fusion surgery 
ng Nanogram 
NHS National Health Service 
NICE National Institute for Health and Care Excellence 
NIHR National Institute for Health Research  
NMB Net monetary benefit 
NRAS  Neuroblastoma RAS viral oncogene homolog 
OC Ovarian Cancer 
OR Odds Ratio 
OWSA One-way sensitivity analysis 
pA Probability of response to treatment A 
PAM Photo-acoustic mammography 
pB Response to treatment B 
PBAC Pharmaceutical Benefits Advisory Committee 
PCa Prostate Cancer 
PDL1 Programmed death ligand 1 
PEST Political Economic Social Technological 
PhD Doctor of philosophy 
PHI Prostate Health Index 
PICC Peripherally inserted central venous catheter 
PICO Population Intervention Comparator Outcome 
PMA Pre-market approval 
POC  Point of care  
PPV Positive predictive value 
PSA Probabilistic Sensitivity Analysis 
PSA  Prostate Specific Antigen 
PSS Personal Social Services 
QALY Quality Adjusted Life Year 
RA Rheumatoid Arthritis 
R&D Research and development 
RAS Rat Sarcoma 
RCT Randomised Controlled Trial 
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RECIST Response evaluation criteria in solid tumours 
resp Response 
Resp|Test+ve Response conditional upon test result being positive 
Resp|Test-ve  Response conditional upon test result being negative 
RNA Ribonucleic Acid 
ROC Receiver Operator Curve 
ROI Return on Investment 
RTX Rituximab 
SCBR Summary Clinical Benefit Rate 
sens sensitivity 
SHELF Sheffield Elicitation Framework 
SIGN Scottish Intercollegiate Guideline Network 
SMART Simple Multi-Attribute Rating Technique 
SMC Scottish Medicine Consortium 
SME Small and medium sized enterprises 
spec Specificity 
SWOT Strengths Weaknesses Opportunities Threats 
TAP Technology Appraisal Programme 
TCZ Tocilizumab 
TNFi Tumour necrosis factor inhibitor 
TPMT Thiopurine methyltransferase or thiopurine S-methyltransferase 
TRUS Trans-rectal ultrasound-guided 
TTS plot Test and Treat Superiority Plot 
UK United Kingdom 
US United States of America 
US$ US dollar 
VOI Value of Information 
WGS Whole genome sequencing 





A group of privately-funded, UK-based, developers of a diagnostic technology in 
malignant melanoma are currently making decisions about whether to continue 
development of their technology and, if so, how to proceed.  One clinical study 
is complete and several more are in the planning stage.  They are considering 
commissioning some health technology assessment (HTA) to demonstrate to 
healthcare decision-makers in the UK that the technology has the potential to 
be cost-effective.  Before cost-effectiveness can be addressed, the developers 
need to consider where the technology could be placed in the clinical pathway 
and what difference the technology could make to costs, health outcomes and 
other dimensions of health-care delivery.  With little clinical evidence to go on, 
how could an HTA analyst begin to help developers to answer these questions?  
Where can the analyst look for guidance as to how to undertake this 
assessment?   
1.1 Motivation 
This thesis was undertaken in the context of the Glasgow Molecular Pathology 
Node (GMP Node); a Medical Research Council/Engineering and Physical Sciences 
Research Council funded body charged (inter alia) with accelerating the 
translation of molecular pathology technologies.  The GMP Node brought 
together industry partners, Glasgow and Greater Clyde National Health Service 
(NHS) and the University of Glasgow.  The developers engaging with the GMP 
node were anticipated to be academic groups from within the university or small 
and medium sized enterprises (SME) industry partners developing molecular 
diagnostics.  The main focus of the thesis is to examine the features, process 
and methods of HTA which would be useful for all developers of health 
technologies.  However, there is a particular focus on academic and SME 
developers of diagnostic technologies given the GMP Node context.  The initial 
concept of the thesis was that HTA methodology would be used to prioritise 
development projects for GMP Node support.  However, the number of 
appropriate projects was, in the event, too limited to allow the thesis to focus 
on prioritisation but three GMP Node projects were assessed and are included as 
case studies.  A further two case studies of diagnostic technologies were 
identified from sources other than GMP node. 
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Developers of health technologies face many choices including: whether and how 
to develop the technology; where to market it; and, how to price it.  Decisions 
made during the development process are likely to influence the future success 
of the technology.  The development of health technologies is challenging.  
There are the challenges which face the developer of any technology such as 
designing a technology which is affordable, which works as planned and for 
which there is a demand.  Over and above these generic challenges, developers 
of health technologies need to navigate the complex international regulatory 
and reimbursement environment.  Developing medical technologies of all kinds is 
high risk, as investment costs are high and the chances of any individual 
technology in development reaching commercial success are low (Lehoux et al, 
2008; van Norman, 2016a, 2016b).   
HTA is widely used to inform decision making about the usage, reimbursement 
and adoption of health technologies at the time of initial market access or later 
in the technology lifecycle (INAHTA, 2020).  HTA has also been suggested as a 
means to inform developers about some of the decisions they need to make 
during the development process (Pietzsch and Pate-Cornell, 2008).  This form of 
HTA has been termed ‘Early HTA’ (Ijzerman and Steuten, 2011).  An analyst, 
unaccustomed to undertaking HTA to inform developers of health technologies, 
may look to the ‘Early HTA’ academic literature (for example, as defined by 
Ijzerman et al, 2017) for guidance on their approach and the methods to be 
adopted.   
The ‘Early HTA’ literature (Ijzerman et al, 2017) is diverse in audience, timing, 
methods and terminology.  As a result, it does not serve as a clear guide to the 
analyst on how to approach HTA to inform developers of medical technologies.  
Some earlier studies were clearly focused on commercial developers of 
pharmaceuticals (for example: Mauskopf et al, 1996; Annemans et al, 2000) and 
SME developers of medical devices (for example: Cosh et al, 2007; Craven et al, 
2009; Chapman, 2013).  However, in the last decade, authors linked to the 
Center for Translational Molecular Medicine (CTMM) have extended the scope of 
‘Early HTA’ to include public decision-makers, as well as developers, as the 
intended audience (Ijzerman and Steuten, 2011) and to include a broad range of 
methods such as Clinical Trial Simulation and Option Analysis (Markiewicz et al, 
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2014) which may be beyond the resources of many SME developers and the 
expertise of some HTA analysts and could be thought of as methods of research 
and development or commercial activities rather than assessment.  Whilst this 
wider scope is useful in capturing the full potential of HTA undertaken alongside 
the development of health technologies, it does result in a loss of focus on 
assessment activity and HTA that informs the developer.   
In addition to the diversity of the current ‘Early HTA’ literature, a second 
difficulty with the academic literature is that it is likely to be unrepresentative 
of much HTA undertaken to inform developers (Grutters et al, 2019; Love-Koh, 
2019).  Empirical examples of work undertaken in-house, in large 
pharmaceutical and medical device companies, are lacking in the published 
literature.  Moreover, most consultancy reports undertaken for small and 
medium-sized developers will not be published for commercial confidentiality 
reasons and because there is little incentive to do so.  For this reason, it is 
reasonable to assume that the published literature available to guide an analyst 
is incomplete and potentially skewed towards academic publications where the 
resources available for analysis may exceed those available to an SME developer.   
These difficulties in the literature suggest that there is a need to provide much 
greater clarity for developers and analysts in terms of how HTA can be used to 
inform development decisions in the early stages of development.  This thesis 
proposes a three-part frameworkfor HTA to aid developers of medical 
technologies. The first part sets out the features of HTA to inform developers.  
The second proposes a generic process and the final part sets out methods of 
HTA which would be appropriate for analysts to use.  The five case studies 
provide an opportunity to illustrate the frameworks of features, process and 
methods. 
1.2 Aims and objectives  
The overall aim of the thesis is to set out a framework of features, process and 
methods of HTA for developers of health technologies.  The case studies focusing 
on diagnostic technologies will contribute to the limited empirical literature in 
this field and provide an initial, partial validation of the proposed framework. 
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Through an extensive literature review and informed by the case studies this 
thesis will address the following research questions: 
1. What are the features of HTA undertaken to inform developers? 
2. What is the process of HTA undertaken to inform developers? 
3. What are appropriate methods of HTA to inform developers of health 
technologies and how do these methods link with the particular features of 
HTA to inform developers? 
4. To what extent do the case studies demonstrate the suggested features, 
process and methods of HTA to inform developers of health technologies? 
5. What are the wider implications of the results of the study? 
6. What recommendations for policy and future research arise from the study? 
1.3 Structure of the thesis 
This chapter introduces the thesis. 
Chapters 3-5 contain the methodological work developing the framework of 
features, process and methods of HTA for developers of health technologies. 
Chapter 3 sets out the methodology of the literature review. 
Chapter 4 addresses the first research question: 
1. What are the features of HTA undertaken to inform developers?  
Using insights from the literature review and the experience of the supervisors 
of the thesis, a list of characteristics of HTA for the developers of health 
technologies was developed.  This chapter supports the argument that HTA to 
inform a commercial developer or investor has ten key features.   
Chapter 5 addresses research questions two and three: 
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1) What is the process of HTA undertaken to inform developers? 
2) What are appropriate methods of HTA to inform developers of health 
technologies and how do these methods link with the particular features 
of HTA to inform developers? 
Chapter 5 completes the proposed framework for HTA to inform developers of 
health technologies (development-focused or DF-HTA).  It sets out a generic 
process for DF-HTA and categorises the methods of DF-HTA identified in the 
literature showing how they link with the features identified in Chapter 4.  .   
Chapter 6 introduces the case studies, compares them to the list of features 
developed in Chapter 4 and suggests a process and methods appropriate for the 
case studies using the elements of the framework set out in Chapter 5.  Chapter 
6 answers research question 4. 
4) To what extent do the case studies demonstrate the suggested features, 
process and methods of HTA to inform developers of health technologies? 
Chapters 7-11 contain the case studies.  Chapters 7, 8 and 9 contain case studies 
assessing tests of response to treatment in ovarian cancer and rheumatoid 
arthritis and an extension to molecular testing in colorectal cancer.  Chapters 10 
and 11 contain two case studies of diagnostic tests in prostate cancer and 
malignant melanoma. 
Chapter 12 summarises the main findings of the thesis identifying the 
contributions made.  It discusses the limitations of the work and identifies areas 
where further research would be beneficial as well as any policy implications, 
addressing research questions 5 and 6: 
5) What are the wider implications of the results of the study? 




1.4 What are the contributions of this thesis 
The contributions of this thesis are: 
1. Proposing a framework of features, process and methods of HTA to inform 
developers of health technologies.  The list of features extends the four 
features first suggested by Pietzsch and Pate-Cornell (2008) to ten 
features.  The remaining elements of the framework build on the work of 
the MATCH UK collaboration (Cosh et al, 2007; Vallejo-Torres et al, 2008 
and Chapman, 2013) to identify a process and methods of HTA to inform 
developers, with a particular focus on methods suitable in resource-
constrained environments.   
2. Presenting five empirical examples of HTA of diagnostic technologies.  
There are limited examples of HTA to inform developers in the academic 
literature and very few of these relate to diagnostic technologies.  Two 
generic models with potential for wider application were developed, one 





The development of health technologies is challenging.  There are the 
challenges faced by developers of all technologies of designing a technology 
which is affordable, which works as planned and for which there is a demand.  
Over and above these generic challenges developers of health technologies need 
to navigate the complex international regulatory and reimbursement 
environment.  Development of medical technologies is costly and a high 
proportion of both drugs and devices fail at all stages of development (Lehoux et 
al, 2008, DiMasi et al, 2016).  Section 2.1 sets out the development process for 
health technologies generally with some additional detail on the development of 
diagnostic technologies as these are the subject of the cases studies in this 
thesis.   
HTA is widely used to make decisions about the usage of health technologies by 
payers such as insurers or managed care associations or by national or regional 
reimbursement agencies (INAHTA, 2020).  This form of HTA often takes place 
when the development of a technology is complete although it may also happen 
later in a product lifecycle. Section 0 sets out a brief introduction to HTA.  It 
defines HTA and describes how it has traditionally been used to assess health 
technologies at the adoption stage (section 2.2.1).  There are a number of 
additional challenges associated with the HTA of diagnostic devices which are 
set out in section 2.2.2.  It has also been suggested that HTA could be used 
alongside the development process to inform developers and maximise the 
chances of success for the technology (Pietzsch and Pate-Cornell, 2008) or to 
allow the earlier termination of ‘uneconomic projects’ (Miller, 2005).  A body of 
academic literature has built up since the late 1990s which has been termed 
‘early HTA’ (Ijzerman et al, 2017).  However, the term early HTA includes HTA 
addressing diverse audiences and technologies at different stages of 
development.  Moreover, the published literature is likely to be 
unrepresentative of much HTA undertaken to inform developers, as both in-
house analysis and commissioned consultancy reports are not often published 
(Grutters et al, 2019).  The term, ‘Early HTA’ has also come to include a number 
of sophisticated analytical methods (Markiewicz et al, 2014) which are likely to 
be beyond the reach of many small and medium-sized enterprises, both in terms 
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of expertise and resources.  Section 2.2.3 sets out a brief introduction to this 
literature which is further explored in Chapters 4 and 5. 
2.1 Development of health technologies 
2.1.1 What are health technologies? 
A health technology is defined by the International Network of Agencies for 
Health Technology Assessment (INAHTA, 2020) as: 
‘an intervention that may be used to promote health, to prevent, 
diagnose or treat acute or chronic disease, or for 
rehabilitation.  Health technologies include pharmaceuticals, devices, 
procedures and organizational systems used in health care. 
Note that the definition is wide, including procedures and organisation as well as 
pharmaceuticals and devices.  For the purposes of this thesis the term ‘medical 
technology’ may be considered interchangeable with health technology.  The 
sections that follow focus on the development of drugs and medical devices.  
Drugs impact the patient using biochemical reactions whereas a device relies on 
its physicality to treat patients (Chapman, 2013).  Each jurisdiction will have its 
own specific definitions of drugs and devices but formal definitions from the US 
Food and Drug Administration (FDA) (U.S. Food and Drug Administration. 2017) 
are given below for information.  The FDA definition of a drug is a substance: 
• recognised in the official US Pharmacopoeia or National Formulary 
• intended for use in the diagnosis, cure, mitigation treatment or 
prevention of disease 
• (other than food) intended to affect the structure of any function of the 
body  
• Intended for use as a component of a medicine but not a device or a 
component, part or accessory of a device. 
A device is defined by the Federal Food Drug and Cosmetics Act in the US (U.S. 
Food and Drug Administration. 2017) as: 
‘An instrument, apparatus, implement, machine, contrivance, implant 
or an in vitro reagent’ 
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That meets three conditions: 
• recognised in the official US Pharmacopoeia or National Formulary 
• intended for use in the diagnosis of disease or other conditions or the 
cure, mitigation, treatment or prevention of disease 
• it is intended to affect the structure or function of the body of humans. 
The definition of medical devices is broad and includes large capital equipment 
such as imaging machines, implantable devices such as pacemakers, surgical 
instruments, laboratory equipment and diagnostics.   
For a known disease or condition, diagnostic devices can be used for diagnosis, 
for screening (in an asymptomatic population), or for monitoring people who 
have been diagnosed and perhaps treated (Campbell and Yue, 2016).  Campbell 
and Yue (2016) divide diagnostic devices into three broad categories:  in vitro 
diagnostic devices (based on samples from the human body such as blood, spit, 
or urine), imaging systems (radiology, mammography, computed tomography), 
and other in vivo diagnostic devices (in or on the human body).  MedtechEurope, 
a trade body, includes digital health technologies as a separate category of 
devices (MEDTECH EUROPE, 2019).   
2.1.2 Market for health technologies 
The market for health technologies is large and companies in this sector make an 
important contribution to their national economies.  In 2018, the US spent 16.9% 
of its gross domestic product on health (OECD, 2020a, 2020b).  The 
corresponding figure for the European Union (EU) was 8.8%.  7.2% of the health 
spend (equivalent to less than 1% of GDP) was spent on medical devices, 0.7% on 
in vitro diagnostics and the remaining 6.5% on other medical devices.  2% of the 
US GDP was spent on pharmaceuticals.  The European medical device industry 
was estimated to generate revenues of USD$115 billion in 2017 (MEDTECH 
EUROPE, 2019) representing 27% of the global market.  The US industry was 
estimated to generate a further 43%.  The estimated number of employees in 
pharmaceutical companies in the EU was 750,000 and a further 675,000 were 
employed in medical device companies.  The structure of the market differs 
between the pharmaceutical and medical device industries.  The top ten 
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pharmaceutical firms have a similar market share at around 40% (ABPI, undated, 
accessed 31 July 2020) to the top ten medical device companies’ 38.6% 
(statista.com, undated, a-c, accessed 31 July 2020).  However, there are more 
small medical device companies than pharmaceutical companies.  For example, 
in the EU in 2017 is was estimated that 27,000 companies were operating, 95% of 
which were SMEs (MEDTECH EUROPE, 2019) where an SME is defined as a 
company employing less than 250 employees and with revenue less than EUR 50 
million.  SMEs are unlikely to have in-house HTA expertise, hence the need for a 
focus on methods of HTA to address this. 
2.1.3 Development of drugs and medical devices 
For most medical technologies, the development process is both lengthy and 
costly.  For drugs, the process, based on FDA approval, can take 10 to 15 years 
(van Norman, 2016a) including 1-3 years of pre-clinical testing, 5-10 years of 
clinical testing and approximately 2 years to deal with pre-market approval by 
regulatory authorities.  A recent study estimated that the average cost of 
bringing a pharmaceutical to market was in excess of USD 1.3 billion (Di Masi et 
al, 2016).  This high cost is partly driven by high attrition rates, with 10,000 
potential drugs in pre-clinical testing in the United States required to bring one 
drug to market (Van Norman, 2016a).  The pharmaceutical sector invests heavily 
in research and development with an estimated investment of USD 64.6 billion 
invested by firms in the US in 2016 and a further USD 35.9 billion invested by the 
government.  The corresponding figures for Europe were USD 20.1 billion 
invested by firms and USD 11.3 billion by governments (OECD, 2019).   
For medical devices, pathways to market access are shorter and less costly than 
for drugs.  It has been estimated that an average time of three to seven years is 
required to bring a device to market (Fargen et al, 2013).  In 2004, Kaplan et al 
found that the pre-clinical stage of development (from initiation of an idea to 
the construction of a prototype) takes 2 to 3 years and may cost USD 10 to 20 
million.  A 2010 survey of 200 medical device manufacturers found that a Class II 
device requiring pre-market notification in the US cost USD 31 million and a 
Class III device requiring pre-market assessment cost USD 94 million (MEDTECH 
EUROPE, 2010).  It has been estimated that laboratory developed tests (LDT), 
which, at the time of writing, do not need FDA approval in the US, can be 
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developed for as little as USD 10,000 (Secretary’s Advisory Committee On 
Genetics, Health, And Society, 2010).  Diagnostic tests can be developed 
relatively quickly, as is evident from the recent proliferation of tests developed 
in response to the COVID-19 pandemic (for example, U.S. Food and Drug 
Administration. 2020a).  COVID-19 tests have been approved for Emergency Use 
Authorisation in the US (and similar measures elsewhere) involving a streamlined 
validation process (U.S. Food and Drug Administration. 2020b).  
Approximately 13,000 new patents were registered for medical devices in 2017 
compared to 6,300 for pharmaceuticals.  It was suggested in 2013 (Chapman, 
2013) that there was less scope for development of new pharmaceuticals as 
there were only 218 therapeutic targets.  There is some evidence that the 
number of therapeutic targets has increased in recent years (Santos et al, 2017; 
Wang, 2020) but as there are no equivalent data for devices this suggestion is 
difficult to support.  
Figure 2-1 is an overview of the process of development of a medical technology 
presented by Ijzerman and Steuten in 2011.  The process presented involves pre-
clinical and clinical stages.  The pre-clinical stage comprises basic research, 
targeting, proof of principal and prototype product development.  The clinical 
stage involves testing in humans.  Although this figure is representative of the 
process for pharmaceuticals and some medical devices there are some key 




Figure 2-1: Stages of development of a medical technology  
HTA – Health Technology Assessment.  Reproduced with permission from Ijzerman and 
Steuten, 2011. 
For drugs, pre-clinical testing involves the identification of a molecule which 
may have potential against a therapeutic target, bench and animal testing to 
establish proof of principal and the development of a drug suitable to begin 
clinical testing.  The stages of clinical testing for drugs are well established and 
involve Phases I to IV (van Norman, 2016a).  Through these phases, drugs are 
tested in a sequential manner that incrementally increases patient risk.  In 
Phase I, the drug is tested on healthy volunteers to determine the side-effect 
profile of the drug, the relative safety of the medication and its rate of 
metabolism.  Phase II generally involves randomisation of patients to placebo or 
treatment and is designed to collect preliminary data about whether a drug is 
effective against a target condition.  Further data will be collected about dose 
and safety.  Phase III trials are usually head-to-head randomised controlled trials 
(RCTs).  The new drug is set head-to-head with current standard of care in order 
to compare effectiveness and safety.  Assuming the Phase III trial is successful 
the drug should be approved and Phase IV studies will be mandated to monitor 
the efficacy and safety of the treatment in everyday clinical practice. 
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For devices, Kaplan et al suggested, in 2004, that, although large companies 
developed successive iterations of existing devices, most new device categories 
were initiated by a physician or bio-engineer as a solution to a clinical problem.  
It is worth noting here that an alternative approach is that a technology is 
developed prior to identifying a specific clinical need (for example, Kluytmans et 
al, 2019).  A preliminary prototype is built and patent process may be initiated, 
if appropriate.  Bench testing is followed by animal testing, if appropriate, and 
the device enters a cycle of testing and redesign until the prototype is ready for 
clinical testing.  One estimate of the costs of this process from 2004 was 
between USD 10 and 20 million (Kaplan et al, 2004), although this will vary 
greatly between devices.  The same authors suggested that many developers 
seek venture-capital funding due to the scale of the costs and that devices 
conceived in academic medical centres would often result in license agreements 
to exploit the technology as academic centres often lack the capabilities to 
develop the device beyond early prototype (Kaplan et al, 2004). 
Clinical evidence requirements for market access for medical devices are 
determined by the nature of the device, the risk it poses to patients and criteria 
set by the appropriate regulator.  Evidence requirements for market access for 
medical devices are not as stringent as the requirements for drugs and RCTs are 
not always required.  Most high-income countries have a system of medical 
device regulation which follows the structure of WHO guidance originally set out 
by the Global Harmonisation Task Force and now embodied in The Global Model 
Regulatory Framework (World Health Organisation, 2017).  This framework 
recommends definitions, classification of devices according to the risk posed to 
the patient and attributes of effective and efficient regulation.  Marketing 
authorization of medical devices in the EU is based on pre-market proof of 
compliance with technical and safety requirements.  In the EU this is called 
Conformité Européene (CE) which is mandatory for most categories of device.  In 
the US, higher risk devices such as pacemakers require a pre-market application 
(PMA) (van Norman, 2016b).  A PMA requires sufficient scientific evidence that 
the device is safe and effective in its intended use and will normally involve a 
series of studies from first-in-human use to large, multi-centre RCTs (Kaplan et 
al, 2004).  Hwang et al (2016) found that the time to approval was longer in the 
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US than in the EU and that devices approved first in the EU were associated with 
greater risk of recall for safety issues.  
Diagnostic devices have particular evidence requirements and, given the focus of 
the thesis, these are explained in more detail in 2.1.4. 
2.1.4 Development of diagnostic technologies 
Figure 2-2: Stages of development of a diagnostic technology  
 
Adapted from Miquel-Cases et al, 2017, with permission 
 
Figure 2-2 shows the stages of development of a diagnostic technology as: basic 
research, targeting, proof of principle, test design, clinical research and 
approval and reimbursement.  It is based on a figure presented by Miquel-Cases 
et al (2017) describing the development process for predictive biomarkers.  It is 
suitable for describing the process of development of any diagnostic technology 
including those using an imaging modality.  Basic research involves the 
identification of a biomarker of interest or imaging pattern.  Identification could 
be hypothesis-driven in that it is based on a pre-existing knowledge of the 
biological mechanism.  Alternatively, it may be data-driven in that it involves 
exploratory retrospective analysis of data collected from previous studies.  
Following basic research, a specific biomarker/imaging modality may be 
targeted.  Proof of principle demonstrates that the approach is feasible, 
allowing a prototype test to be designed ready for clinical testing.  Clinical 
research is shown as the final step prior to approval and reimbursement.  This is 
the step where the process for diagnostics is quite different to drugs where the 
Phase I to IV trials are well established.  Validation of the test may include 
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multiple overlapping stages of evidence generation including studies of 
analytical validity, clinical validity and clinical utility.  Different evidence 
requirements for different decision-makers are determined on a technology-
specific basis through negotiation with regulators (Trusheim et al, 2007; 
Faulkner et al, 2012 and Frueh, 2013).  For instance, during the current COVID-
19 pandemic, the FDA have facilitated usage of diagnostic tests under 
Emergency Use Authorizations (EUA) setting specific requirements for analytic 
and clinical validation (U.S. Food and Drug Administration, 2020a).  Figure 2-3 
illustrates the evidence development pathway of a diagnostic.  The clinical 
research stage from Figure 2-2 is expanded to include proof of analytical 
validity, clinical validity and clinical utility.  Analytical validity concerns 
whether the test measures what it claims to measure in a laboratory setting.  
Clinical validity is whether the test is able to distinguish clinically meaningful 
populations.  Clinical utility is established when the test leads to beneficial 




Figure 2-3: Evidence development pathway  
 
Reproduced from Graziadio et al, 2020, no permission required.  CEA – cost effectiveness 
analysis 
Clinical studies for diagnostics are often quite different in design to those for 
therapeutic products (Campbell and Yue, 2016).  The type of study depends on 
which of analytical validity, clinical validity or clinical utility the developers are 
trying to establish.  For analytic validity they may take the form of comparing 
the new diagnostic test to a standard test in the same patient or the same 
patient’s sample.  The Receiver Operator Curve (ROC) is widely used in 
diagnostic studies where there is a reference standard (Campbell and Yue, 2016) 
(see Figure 2-4).  The ROC curve plots the ability of the new diagnostic to 
identify the condition in disease-positive individuals (true positive rate or 
sensitivity) and to return a negative result when the disease is absent (false 
positive rate - specificity).  The area under this curve provides a measure of test 
accuracy which is frequently used in diagnostic studies (Zweig and Campbell, 
1993; Zhou et al, 2009).  The different points (combinations of true positive rate 
and false positive rate) forming the ROC curve result from the movement of the 
cut-off threshold of the diagnostic as illustrated in Figure 2-5.   
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Figure 2-5 illustrates how the movement of the cut-off threshold from left to 
right reduces false positives at the expense of sensitivity (true positive rate).  
For some uses of diagnostic tests it may be preferable to have higher true 
positive rate (sensitivity) to ensure that as many disease positive individuals as 
possible are identified.  This may also result in a high false positive rate.  High 
sensitivity may be desirable if you can give a cheap treatment, with few side 
effects which will prevent serious deleterious health outcomes if left untreated.  
High false positive rates can be an issue when the next step in the diagnostic 
pathway is invasive or expensive.  This is the case with the Prostate Specific 
Antigen (PSA) test in prostate cancer (Carlsson et al, 2007).  This test results in 
many false positives which then require further imaging and/or biopsy of the 
prostate in order to rule out clinically significant cancer (NICE, 2019).  In other 
situations, a low false positive rate (high specificity) may be required.  For 
example, where a negative result from the diagnostic test will result in the 
withholding of potentially curative treatment, it is important that false 
negatives are minimised.  An example here is a prognostic test in breast cancer 
designed to identify women with good prognosis who may be spared 
chemotherapy.  Effectively the optimal cut-off depends on the costs and 
consequences of false positives compared to false negatives.  This is something 
which can readily be explored in HTA alongside the development process.  The 
relationship between test threshold and sensitivity for a given ROC curve can be 
explored using an online interactive app from Kennis Research, 2020. 
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Figure 2-5: Impact of test cut-off on true positives and false negatives  
 
FN – false negative, FP – false positive, TN – true negative, TP – true positive 
2.1.5 Challenges in the development of diagnostic technologies 
The case studies presented in this thesis concern diagnostic technologies, which 
are defined by the National Institute of Health and Care Excellence in the UK 
(NICE) as: 
‘all types of measurements and tests that are used to evaluate a 
patient's condition’.   
Diagnostic is used as an umbrella term for tests which fulfil a range of roles.  
Table 2-1(mainly drawn from Trusheim et al, 2007) distinguishes 12 positions in 
the clinical pathway for diagnostic tests together with examples.   
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Table 2-1: Roles and examples of diagnostic tests 
Position in pathway Example 
Diagnosis in asymptomatic population 
(screening) 
Bone density test to encourage use of alendronate sodium to 
reduce the risk of bone fractures  
(Trusheim et al, 2007) 
Diagnosis in symptomatic or previously screened 
population – rule in 
Biomarker-guided surveillance for oesophageal adenocarcinoma 
in patients with gastrointestinal reflux  
(Rubenstein et al, 2005) 
Diagnosis in symptomatic or previously screened 
population – rule out 
Diagnosing and excluding ectopic pregnancy  
(Wedderburn et al, 2010) 
Prevention – identification of individuals at risk 
(primary) 
Identifying individuals at risk of developing Type 2 diabetes  
(de Graaf et al, 2015) 
Prevention - identification of patients with 
undiagnosed disease to allow earlier treatment 
(secondary prevention) 
Identifying individuals with undiagnosed Type 2 diabetes in 
order to initiate earlier treatment  
(de Graaf et al, 2015) 
Prevention – identification of patients at risk of 
developing complications  
(tertiary prevention) 
Identifying patients with Type 2 diabetes at risk of developing 
microvascular or macrovascular complications  
(de Graaf et al, 2015) 
Selection of treatment or prediction of response 
to treatment  
Testing for BCR-ABL-positive tyrosine kinase genotype to identify 
patients with chronic myeloid leukemia likely to respond to 
imatinib mesylate  
(Capdeville et al, 2002) 
Predicting adverse events Screening for HLA-B*5701 to prevent abacavir hypersensitivity 
in HIV patients  
(Hughes et al, 2004) 
Adaptation of dose to individual patient 
characteristics 
TPMT Genotyping for Azathioprine  
(Thompson et al, 2014) 
Monitoring response to treatment Bone density test to monitor response to alendronate sodium to 
reduce the risk of bone fractures  
(Trusheim et al, 2007) 
Monitoring adherence to treatment Serum concentration of anti-epileptic drugs such as phenytoin  
(Osterberg and Blaschke, 2005) 
Predicting disease progression 
(prognosis) 
Oncotype Dx to predict the level of risk of breast cancer 
progression in order to guide adjuvant chemotherapy 
treatment.  Patients identified who are unlikely to benefit from 
chemotherapy can avoid the side effects and cost of treatment 
(NICE, 2018d) 
 
Both licensing and reimbursement of diagnostic technologies are complex due to 
the difficulty in generating evidence linking health outcomes to test results.  
Historically, payers have not used a value-based approach in determining what 
they were willing to pay for a diagnostic technology.  This has resulted in 
disincentives for developers of diagnostic technologies (Towse et al, 2013).  In 
order to justify prices on any basis other than cost-plus, it is useful for 
developers to demonstrate and evidence the value added by the diagnostic 
technology.  The value added by a diagnostic technology is highly dependent on 
the context in which it is to be used, and this context can vary even within a 
single jurisdiction.  Evidence of the value generated must take account of this 
complexity and heterogeneity if decision-makers are to be persuaded to adopt 
new diagnostic technologies. 
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Commentators have suggested four broad challenges for developers in 
generating evidence about the value of a diagnostic technology.  First, evidence 
requirements for regulation of diagnostic technologies are complex, are 
becoming more onerous and vary across jurisdictions (Ansari, 2013).  Second, 
additional evidence may be required for reimbursement.  Payers may require the 
demonstration of clinical utility before approval and this evidence is not 
straightforward to produce (Steyerberg et al, 2010, 2015; Doble, 2016b).  Third, 
developers may find it hard to achieve profitable prices for diagnostic 
technologies due to historic cost-plus pricing and a lack of intellectual property 
protection (Sachs, 2015). Finally, value is difficult to define and different 
stakeholders may have different conceptions of value. 
Evidence for regulation 
The landscape of diagnostic regulation is ‘constantly changing’ (Ansari, 2013).  
The onus is on the developer to present sufficient evidence to satisfy regulatory 
authorities in different jurisdictions and it may require multiple studies until the 
diagnostic technology’s safety and performance are acceptable and the evidence 
base demonstrates this to multiple regulators’ satisfaction (Ansari, 2013).  The 
EU recently tightened regulation of diagnostic devices.  The new Medical Devices 
2017/745 (MDR) and In-Vitro Diagnostic Medical Devices 2017/746 (IVDR) 
regulations require clinical evidence before a diagnostic can be granted a CE 
mark and be made available in the EU (EU, 2017).  The US requires prospective 
clinical studies for high risk diagnostics (Sachs, 2015) whereas in the EU, clinical 
evidence does not necessarily take the form of prospective RCTs.  In the EU, the 
requirements under the IVDR are for clinical evidence to support a beneficial 
risk-benefit balance and performance characteristics.  In the US, pre-market 
approval requires clinical testing and evidence of efficacy and safety.  
Historically, some countries outside of the US and EU would have relied on 
certification in these jurisdictions to allow market access.  This is now 
happening less (Ansari, 2013).  More countries are introducing their own 
regulations and evidence requirements in large markets such as China and Japan 
are more stringent than those demanded by the US and Europe (Ansari, 2013).  
For example, in China, at least three prospective clinical studies are required 
before market access and in both China and Japan, studies are required 
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demonstrating the correlation of diagnostic test results to country gold standard.  
The situation in the UK is under review following the exit of the UK from the 
European Union with previous EU directives continuing to apply until the 
completion of a government review (MEDICINES AND HEALTHCARE PRODUCTS 
REGULATORY AGENCY, 2020). 
Evidence for reimbursement 
Whereas regulators require evidence of performance, clinical utility is often key 
for reimbursement.  Clinical utility is the ability of the diagnostic technology to 
deliver an improvement in clinical outcomes and/or a cost saving compared to 
current standard of care (Steyerberg et al, 2010, 2015; Doble, 2016b).  For 
diagnostic technologies, the ideal form of evidence of clinical utility is a 
prospective ‘end to end’ RCT where a testing strategy is compared to a non-
testing strategy and all the consequences flowing from the test including 
treatment and health outcomes are compared over an appropriate time horizon.  
This kind of trial is expensive and takes a long time (Parkinson et al, 2014).  As 
market access (i.e. regulatory approval) is possible without demonstrating 
clinical utility and copycat diagnostics can be produced by clinical laboratories 
in a relatively short time there is little incentive for developers to undertake 
good quality studies of clinical utility (Parkinson et al, 2014).  Such evidence as 
there is may be poorly designed and/or reported.  It has been claimed that the 
majority of test-treatment trials are subject to performance, ascertainment and 
attrition biases and sample size inadequacy (di Ruffano, 2017; Miquel-Cases et 
al, 2017).  There is a further difficulty that the clinical utility of a diagnostic 
technology is highly dependent on the context in which it is used.  In particular, 
the test may be used at different points in a clinical pathway, in combination 
with other diagnostic technologies with different impacts on treatment.  So even 
if there is RCT evidence and it has good internal validity, it may not be easily 
generalisable (Faulkner et al, 2012).  Decision-makers need to balance the 
requirement for sufficient evidence with the imperative to allow patients to 
benefit from potentially valuable technologies.  In some jurisdictions, forms of 
evidence of clinical utility other than RCTs, such as observational data or 
evidence from retrospective studies may be accepted by decision-makers (Frueh, 
2013; Academy of Medical Sciences, 2016). 
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Intellectual property protection 
It has been suggested that developers of diagnostic technologies currently face 
disincentives derived from three sources: pricing structures; intellectual 
property protection and differences in regulation between laboratory developed 
tests and commercially developed kits (Sachs, 2015).  First, reimbursement for 
diagnostic technologies has historically been on a cost-plus rather than a value 
basis and administrative codings within Medicare/Medicaid still support a cost-
plus approach (Ansari, 2013; Academy of Medical Sciences, 2016).  There has 
also been significant downward pressure on the amount reimbursed for 
diagnostics in the US led by a Congress committee influencing Medicaid and 
Medicare reimbursement rates which many private payers use as a point of 
reference (Sachs, 2015).  Furthermore, in some jurisdictions (e.g. Spain, China, 
India, Brazil), companion diagnostic tests have not been reimbursed at any level 
and patients or pharmaceutical companies have had to pay (Ansari, 2013).  
Second, patent protection for diagnostic technologies in the US has been 
reduced.  In 2010, the Gene Patents and Licensing Practices and Their Impact on 
Patient Access to Genetic Tests report (Secretary’s Advisory Committee On 
Genetics, Health, And Society, 2010) explored the balance between incentives 
for developers of diagnostic technologies on one hand and the risks to discovery 
science and patient access of restrictive patents on the other.  The report found 
that patents tended to restrict invention and patient access and that patent 
protection was not required to stimulate either discovery science of the 
development of new diagnostic tests.  It has been suggested that the sentiments 
expressed in this report are reflected in subsequent court decisions which 
strongly restrict the ability of diagnostic technologies to achieve patent 
protection (Eisenberg, 2015).  The final factor making it challenging for 
developers to achieve profitable prices for diagnostic tests stems from the 
different regulatory environment for commercially developed diagnostics and for 
laboratory developed tests (LDTs).  Laboratories in the US are not regulated by 
the FDA but by the Centres for Medicare Services under the Clinical Laboratory 
Improvement Amendments (CLIA) regulations (CENTER FOR MEDICARE AND 
MEDICAID SERVICES, 2020).  The tests CLIA-regulated laboratories develop are 
not scrutinised individually, rather it is the operations of the laboratory which 
are regulated.  They are able to reverse-engineer commercially available kits 
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and provide a service-offering without obtaining FDA approval (Secretary’s 
Advisory Committee On Genetics, Health, And Society, 2010).  The FDA has 
undertaken a consultation but has not yet required laboratory developed tests 
(LDTs) to undergo the pre-market approval process required for commercially 
developed diagnostics (USFDA, 2018).  This means that LDTs can be developed in 
a short period of time at greatly reduced cost (Secretary’s Advisory Committee 
On Genetics, Health, And Society, 2010; McCormack et al, 2014) allowing other 
developers to benefit from the research and development effort and 
expenditure of the first-mover.   
Differing concepts of value 
The full value of a test-based technology may not be reflected in the QALY 
metric.  Concepts such as personal utility and the use of cost-benefit analysis 
are contentious and under-developed in HTA (Fugel et al, 2016) meaning that 
the value of knowing (or not knowing), patient preferences (Oosterhoff, 2016) 
and spillover effects into later generations are not captured (Rogowski et al, 
2015).   
2.2 Health Technology Assessment 
The previous sections described the process of health technology development 
and set out a number of key challenges faced by developers of diagnostic 
technologies.  This thesis examines how health technology assessment could be 
used to help developers face those challenges by, for example, helping to shape 
an evidence generation strategy and the articulation and/or quantification of a 
value proposition.  This section sets out a brief introduction to HTA.  It defines 
HTA and describes how it has traditionally been used to inform decisions about 
whether or not to use, adopt or reimburse a ‘finished’ health technology 
(section 2.2.1).  There is then some more detail about HTA for diagnostic 
devices as the case studies involve this kind of medical technology (2.2.2).  The 
final sub-section sets out a brief introduction to the main focus of the thesis - 
HTA of technologies in development (2.2.3).   
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2.2.1 Definition and general process of HTA 
The World Health Organisation definition of HTA is:   
‘the systematic evaluation of properties, effects and/or impacts of 
health technologies and interventions. It covers both the direct, 
intended consequences of technologies and interventions and their 
indirect, unintended consequences. The approach is used to inform 
policy and decision-making in health care, especially on how best to 
allocate limited funds to health interventions and technologies’. 
(World Health Organisation, 2020) 
An ongoing project co-ordinated by the International Network of Agencies for 
Health Technology Assessment recently published a consensus definition of HTA 
which includes several additional and important aspects highlighted in bold 
below (INAHTA, 2020; O’Rourke et al, 2020).  
‘A multidisciplinary process that uses explicit methods to determine 
the value of a health technology at different points in its lifecycle. 
The purpose is to inform decision-making in order to promote an 
equitable, efficient, and high-quality health system. 
Note 1: A health technology is an intervention developed to prevent, 
diagnose or treat medical conditions; promote health; provide 
rehabilitation; or organize healthcare delivery. The intervention can 
be a test, device, medicine, vaccine, procedure, program or system. 
Note 2: The process is formal, systematic and transparent, and uses 
state-of-the-art methods to consider the best available evidence. 
Note 3: The dimensions of value for a health technology may be 
assessed by examining the intended and unintended consequences of 
using a health technology compared to existing alternatives. These 
dimensions often include clinical effectiveness, safety, costs and 
economic implications, ethical, social, cultural and legal issues, 
organisational and environmental aspects, as well as wider 
implications for the patient, relatives, caregivers, and the population. 
The overall value may vary depending on the perspective taken, the 
stakeholders involved, and the decision context. 
Note 4: HTA can be applied at different points in the lifecycle of a 
health technology, i.e., pre-market, during market approval, post-




Health Technology Assessment, as a discipline, first developed in the United 
States when Congress requested Technology Assessment of health technologies 
in the mid-1970s. (Stevens et al. 2003) and the term is now internationally 
used.  HTA draws on Evidence Based Medicine (EBM), a movement which has 
developed from the publication in 1972 of Archie Cochrane’s ‘Effectiveness and 
Efficiency’ (Cochrane, 1972) to today’s international organisation, the Cochrane 
Collaboration (Stevens et al, 2003).  Evidence synthesis methods such as 
systematic review and meta-analysis are core to HTA and often form the basis 
for the clinical effectiveness estimates in cost-effectiveness analysis and health 
economic modelling.  
Decisions supported by HTA include two broad categories: allocation of a set 
budget over a number of healthcare areas and decisions about the adoption, 
reimbursement or usage of individual technologies or programmes.  In the first 
category, the decisions may involve which programmes to include in a package 
of Universal Health Coverage (for example, maternity care, vaccination 
programmes) or decisions about prioritisation within a research budget.  The aim 
of the HTA would be to allocate the budget according to agreed criteria of 
effectiveness, value for money and other considerations, perhaps equity.  The 
second category includes assessment of individual technologies, such as 
pharmaceuticals, to determine whether they should be adopted.  Again, they 
would be likely to be assessed against pre-established criteria relating to 
evidence base, need, value for money and equity issues.  Medical devices and 
surgical procedures could also be assessed in this way.  There is also a growing 
interest in using HTA to determine whether a technology in current use should 
be excluded from reimbursement or coverage.   
The components of HTA vary according to the decision-maker but HTA to inform 
a decision about use of a particular technology may start with the definition of a 
decision problem to address.  Analysts may find it useful to use a structure to 
help them define the decision problem.  PICO (Population, Intervention, 
Comparator, Outcome) is a general structure applied broadly in evidence-based 
practice such as HTA.  The intervention is the technology to be assessed and the 
comparator is the current standard of care in that disease area.  Once the 
decision problem has been defined the next step is synthesis of the clinical 
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evidence, using techniques such as systematic review and meta-analysis.  Once 
the evidence on clinical effectiveness has been assembled and issues regarding 
evidence quality and generalisability addressed, cost-effectiveness can be 
considered.  Finally, other considerations such as legality and ethics may be 
addressed (Eddy, 2009).  
HTA informs a variety of healthcare decision-makers ranging from national 
healthcare providers like the National Health Service in the UK, to regional 
health authorities (for example in Spain and Canada) and local providers such as 
hospitals.  Insurance companies and commercial health care providers also need 
to make decisions about coverage and reimbursement.  HTA agencies may be 
established within or supported by the decision maker as with the National 
Institute for Health and Care Excellence (NICE) in the UK or may be external 
bodies such as the Institute for Clinical and Economic Review in the United 
States which is funded primarily by not for profit organisations (Institute for 
Clinical and Economic Review, 2020) and provides advice which is for guidance 
only.  Some agencies have a strong emphasis on cost-utility analysis (for 
example, UK, Netherlands, Canada) and some have acknowledged a financial 
limit to the amount they consider acceptable to pay for each year in full health 
delivered by a health technology.  Cost-utility analysis is the comparison of a 
proposed technology with the technology it aims to replace in terms of costs and 
health outcomes measured in Quality Adjusted Life Years (QALYs) (Drummond et 
al, 2015).  NICE in the UK and the Canadian Agency for Drugs and Technologies in 
Health (CADTH) have developed reference cases which specify methods to be 
adopted and much work has been done on establishing best-practice through 
bodies such as the International Society for Pharmacoeconomics and Outcomes 
Research (ISPOR).  There is a substantial body of work applying these methods 
across the range of health technologies. 
2.2.2 HTA of diagnostic technologies 
HTA of diagnostic technologies is broadly equivalent to HTA of other 
technologies but is complicated by four factors.  Firstly, because diagnostic 
technologies provide information for the clinician and patient rather than 
directly influencing health outcomes (Oosterhoff et al, 2016), the clinical and 
cost-effectiveness of the technology depends on how the clinician and patient 
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use the information provided by the test (Thompson et al, 2014; Rogowski et al, 
2016; Degeling et al, 2017).  Despite their potential influence, behavioural 
aspects have only rarely been incorporated in the assessment of companion 
diagnostics (Degeling et al, 2017).  Second, as discussed in section 2.1.4, HTA of 
companion diagnostics assesses the proposed test-treatment strategy or 
strategies incorporating the new diagnostic.  This is compared to one or more 
current strategies used in the relevant jurisdiction.  The incremental cost-
effectiveness does not separate the test and the treatment in terms of value-
added (Faulkner et al, 2012; Towse et al, 2013).  Whilst this is not an issue in 
HTA undertaken to inform coverage or adoption, when prices tend to have been 
set, it may cause difficulties in undertaking HTA during the development process 
when the value-added may be used to try and guide pricing strategy.  The third 
factor relates to the ability of the QALY to reflect the different aspects of value 
of a diagnostic technology.  This is a contentious area.  For example, it has been 
suggested that the QALY metric fails to capture aspects such as the ‘value of 
knowing’ (Fugel et al, 2016).  This is the value to the patient of information 
provided by the diagnostic over and above any change in the management of the 
condition and is specifically recognised in Australia as an aspect of value which 
may need to be quantified beyond the QALY framework (Medical Services 
Advisory Committee, 2017).  The final factor concerns the difficulties in 
generating evidence of clinical and cost effectiveness, which were discussed 
above in section 2.1.4.  These difficulties include additional complexity due to 
considerations of test performance (Payne et al, 2013), multiple test 
combinations (Degeling et al, 2017) and how to establish appropriate clinical 
pathways for both intervention arm and comparators (Abel et al, 2019; Graziadio 
et al, 2020). 
2.2.3 HTA of technologies in development 
HTA is most often used around the time of market access to inform public payers 
about whether and how a technology should be adopted and used.  It has also 
been recognised that there may be benefits to undertaking HTA at different 
points alongside the development process.  Annemans et al (2000), for example, 
suggested that pharmacoeconomic analysis could be undertaken when a 
promising drug was undergoing the earliest clinical trials.  Although there would 
be gaps in the evidence, the evaluation would allow developers to consider at an 
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early stage whether the drug was likely to be cost effective in a given 
jurisdiction and help shape evidence generation strategy.  It was recognised that 
multiple models could consider different indications, jurisdictions and dosages 
and help with the direction of development of the drug (Annemans et al, 2000).  
Authors associated with the Multi-disciplinary Assessment of TeCHnology 
(MATCH) programme, in the 2000s, extended this concept to the use of HTA 
methods to inform SMEs developing medical devices (for example: Cosh et al, 
2007; Craven et al, 2009; Chapman, 2013).   
It was Pietzsch and Paté-Cornell (2008) who first used the term ‘early HTA’.  
They also set out four characteristics distinguishing ‘early HTA’ from ‘classical 
HTA’ (as they termed HTA undertaken to inform payers at the time of market 
access – see section 2.2.1).  The four elements, set out in Table 2-2 were: the 
aim of the HTA, the decision support provided, the available evidence and the 
influence of the HTA on the technology performance.  Whilst the aim of classical 
HTA is to assess the ‘safety, effectiveness and cost-effectiveness profiles of a 
new technology’, the aim of early HTA is to assess the ‘(likely) safety, 
effectiveness and cost-effectiveness’.  Whilst classical HTA provides decision 
support for regulators, payers and patients about market clearance, payment 
and usage of a technology, early HTA provides decision support for 
manufacturers and investors about the design and management of a technology 
as well as regulatory and reimbursement strategy.  Available evidence for early 
HTA is bench and animal testing, early clinical experience and evidence from 
previous generations of the technology compared to evidence from clinical 
studies performed with new technology for classical HTA.  Finally, early HTA has 
the ability to influence the future clinical performance of a new technology 
whereas classical HTA has limited or no influence on performance.  In Pietzsch 
and Paté-Cornell’s case study (2008), they suggested that the complex model 
built could potentially influence the design of the technology by giving feedback 
to the development team about the performance levels, and in this case the 
training standards, which would be required to ensure the technology met the 





Table 2-2: Similarities and differences between 'Classical HTA'  and 'Early HTA'  
 Classical HTA Early HTA 
Aim Assess safety, effectiveness and cost-
effectiveness profiles of a new 
technology 
Assess safety, effectiveness and cost-
effectiveness profiles of a new 
technology 
Decision support Decision support for regulators, payers 
and patients about market clearance, 
payment and usage of a technology 
Decision support for manufacturers and 
investors about the design and 
management of a technology, as well as 
regulatory and reimbursement strategy 
Available evidence Usually evidence from clinical studies 
performed with new technology’ 
‘Evidence from early bench and animal 
testing, early clinical experience and 
evidence from previous generations of 
the technology  
Influence on technology 
performance 
Limited or no influence on clinical 
performance of a new technology 
Potentially significant influence on 
(future) clinical performance of a new 
technology 
Reproduced from Pietzsch & Paté-Cornell, 2008, with permission.  HTA – Health Technology 
Assessment 
In the last decade, authors linked to the Center for Translational Molecular 
Medicine (CTMM) have extended the scope of ‘Early HTA’ to include public 
decision-makers, as well as developers, as the intended audience (Ijzerman and 
Steuten, 2011) and to include a broad range of methods (Markiewicz et al, 
2014).  Whilst this wider scope is useful in capturing the full potential of HTA 
undertaken alongside the development of health technologies, it does result in a 
loss of focus on HTA to inform the developer.  The ‘Early HTA’ literature, as 
captured by Ijzerman et al (2017), is diverse in audience, timing, methods and 
terminology.  As a result, it does not serve as a clear guide to the analyst on how 
to approach HTA to inform developers of medical technologies.  In this thesis, 
the emphasis is on how HTA can inform the developer of a health technology.  
The key stakeholder is the developer.  It is, therefore, necessary to ‘unpick’ the 
body of work badged as ‘Early HTA’ and clarify which aspects of are relevant to 





3 Methodology of literature review 
3.1 Purpose of the literature review 
A literature review was undertaken to inform the first three research questions: 
1. What are the features of HTA undertaken to inform developers?  
2. What is the process of HTA undertaken to inform developers? 
3. What are appropriate methods of HTA to inform developers of health 
technologies and how do these methods link with the particular features 
of HTA to inform developers? 
3.2 Choice of literature review methodology 
3.2.1 Previous and alternative approaches 
Similar questions to the research questions above were addressed in four recent 
review articles that all used a database searching approach in their literature 
reviews (Hartz and John, 2008; Mikudina and Redekop, 2013; Markiewicz et al, 
2014; Ijzerman et al, 2017).  They used a range of search terms to describe the 
broad themes of 1) a health technology 2) during development 3) 
assessment/evaluation.  Ijzerman et al (2017) added a category of known 
methods of early HTA such as headroom and multi-criteria.  In each case the 
database searches were supplemented either by searches of key references of 
identified articles (Hartz and John, 2008; Markiewicz et al, 2014; Mikudina and 
Redekop, 2013; Ijzerman et al, 2017) and hand searches of key journals (Hartz 
and John, 2008).  Hartz and John (2008) and Mikudina and Redekop (2013) also 
searched Google Scholar and the websites of Horizon Scanning agencies.  Quality 
criteria were not applied by any of the authors to exclude studies because of the 
lack of a suitable instrument (Markiewicz et al, 2014) or because they were 




Study authors of these review articles raised two main issues with the use of a 
literature search based on database searches in this area.  The first issue was 
the sensitivity of the search due to the lack of clear definition of early HTA in 
Medical Subject Headings (MeSH) or clear key words (Markiewicz et al, 2014; 
Ijzerman et al, 2017).  The second issue (Hartz and John, 2008; Markiewicz et al, 
2014) was publication bias as an issue as companies would be unlikely to publish 
reasons for discontinuation of a project and much information would be 
confidential for commercial reasons.   
Further generic issues with systematic database literature searches are raised by 
Boell and Cecek-Kecmanovic (2010).  In particular, they raise the concern that, 
as research questions are necessarily fixed before the literature review starts, 
the researcher may be inhibited from pursuing further literature and the 
approach discourages learning from adjacent areas.  They claim that because 
databases are limited in their journal coverage and search terms are 
indeterminate, all relevant studies are unlikely to be retrieved.  Moreover, 
elaborate search strategies with high sensitivity come at the cost of low 
precision with only a small percentage of all retrieved results being relevant.   
Two approaches to literature review may address some of these drawbacks, 
pearl-growing and hermeneutic literature review.  Both of these approaches 
have previously been applied in health research.  By way of example, Claxton et 
al (2015) applied a pearl-growing approach in their work to estimate the cost-
effectiveness threshold for health care in the United Kingdom as the aim was to 
provide an overview of a wide-ranging area and any database search using 
search terms ran the risk of missing important parts of the literature as well as 
generating high numbers of papers to review.  They describe pearl-growing as  
‘the use of existing collections of studies to identify additional 
relevant parts of the literature. The approach uses a pool of ‘initial 
pearls’ to grow the literature both through references and citations 
until all relevant papers have been discovered. This approach, 
therefore, relies on the expertise of the authors of the existing 
literature to populate the pool of studies rather than the searcher’s 
potentially limited knowledge’ (Claxton et al, 2015). 
Greenhalgh and Shaw (2017) applied the hermeneutic approach in exploring the 
potential impact of telehealth technology in a population of patients with heart 
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failure as their aim was to provide a: ‘scholarly synthesis of the key questions, 
theoretical perspectives and empirical findings on the topic’.  Hermeneutics is 
concerned with the process of creative interpretive understanding (Boell and 
Cecek-Kecmanovic, 2010).  A hermeneutic review involves a circular and open-
ended process where understanding from reading allows a refinement of the 
research question and strategy and allows researchers to broaden the search 
when investigating general relationships or narrow it when a comprehensive 
survey of a particular aspect is desired (Boell and Cecek-Kecmanovic, 2010).  
Iterations of the process continue until saturation of understanding is reached 
(Boell and Cecek-Kecmanovic, 2010).   The hermeneutic review process is 
illustrated in Figure 3-1 (Boell and Cecek-Kecmanovic, 2010). 
Figure 3-1: Hermeneutic review process  
 
Adapted with permission from Boell and Cecek-Kecmanovic, 2010. 
3.2.2 Literature review method adopted in this study 
From previous authors’ experience it would be unlikely that a database search 
with appropriate sensitivity and specificity would be achieved.  An alternative 
approach was taken which combined pearl-growing (i.e. following references 
and citations from key articles in the field) with the hermeneutic approach. 
Ijzerman and Steuten’s 2011 paper was used as the ‘pearl’ so formed the basis 
of the search.  It was selected as it was a comprehensive review article in the 
field of interest which provided an introduction to the intellectual concepts of 
the area and the structure of those concepts (Boell and Cecek-Kecmanovic, 









as the first source for the review.  Citations on Google Scholar were compared to 
other databases (Web of Science and Scopus) and Google Scholar was found to 
be more comprehensive.   
The aim was to retrieve literature which informed an understanding of early 
health technology assessment (as much early HTA is intended to inform 
developers) and included both methods papers and applied studies separately 
and in combination.  Inclusion criteria for applied studies were that a study 
needed to include an application of early HTA.  Methodological papers were 
included where they introduced a new method or discussed a known method of 
early HTA.  A judgement was then made whether the early HTA paper was also 
intended to inform developers.  A paper was included if it was explicitly aimed 
at the developer of the technology or if the decisions it informed concerned 
aspects of a technology in development other than its cost-effectiveness in a 
given jurisdiction at a fixed price.  No quality criteria for inclusion were applied 
as the aim was to increase understanding of methods in use rather than rely on 
any conclusions reached in the studies.  Abstracts of citations were reviewed and 
relevant articles were selected for full review. Where sufficient understanding 
of a method and the context of its use had been achieved no further examples 
were sought.  Continuing the pearl-growing approach the references and 
citations of the literature acquired in previous steps were reviewed until 
saturation had been reached.  This point is reached when additional publications 
make only a ‘marginal contribution to further understanding’ (Boell and Cecek-
Kecmanovic, 2010).  The main literature searches were conducted in October 
2017 (see Appendices 1 and 2) with the citations of all studies listed in 




3.2.3 Results of the literature search 
See Appendix 1 for a flowchart of the pearl-growing literature review with 
papers retrieved at each stage in each category of interest.  A total of 152 
papers were identified as set out in Table 3-1.  Lists of the papers identified in 
each category are provided in Appendix 2.   
Table 3-1: Results of literature search 
 Methods papers Applied papers Methods and applied 
papers 
Total 
Early HTA 56 61 35 152 
Of which HTA to 
inform developers 
43 25 20 88 
 
Chapters 4 and 5 discuss the papers retrieved in the literature search in order to 
inform the development of a framework of features, process and methods of 
HTA to inform developers.  Early HTA papers are retained in the dataset as there 
is much overlap between some features, process and methods of early HTA and 
HTA to inform developers.  Moreover, two of the case studies could be classed as 
early HTA rather than HTA to inform developers given that they were primarily 
concerned with a reimbursement perspective.  It is thus, informative to have 
both sets of papers. 
3.2.4 Limitations of the literature review  
The literature search may not have identified all relevant methods and 
applications of HTA to inform developers.  The aim of the search was not to 
identify all applied papers but to gain an overview of methods in use.  Two 
recent systematic reviews (Ijzerman et al, 2017 and Markiewicz et al, 2014) 
were included in the review, both of which used broad database search 
approaches.  It is, therefore, likely that methods represented in the literature 
have been covered.  However, the academic literature is likely to contain only a 
small proportion of HTA undertaken to inform developers.  This is because work 
undertaken to inform developers is generally both commercial in confidence and 
may also not be suitable for publication due to the use of what may be 
perceived as less robust methods at earlier stages of development.  Published 
work appears to include much work supported by translational research bodies 
where more resources may be available for analysis. 
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A difficult feature of the literature review involved setting the scope of what 
constituted HTA, early HTA and HTA to inform developers and how HTA fitted 
with and could be distinguished from research and development activities and 
commercial activities in medical technology firms.  This is important as early 
HTA is not a well-defined term (Ijzerman and Steuten, 2011) and many of the 
methods previously identified in the literature (e.g. Markiewicz et al, 2014) as 
early HTA would appear to be methods of research and development or 
commercial activities rather than assessment activities.  This makes it difficult 
for analysts to determine what methods may be appropriate in undertaking HTA 
to inform developers.  Error! Reference source not found. puts forward a 
suggestion of the relationship between these various activities. 
 
Figure 3-2 Relationship between development activities and HTA 
 
DF-HTA – development-focused HTA, HTA – health technology assessment.  This figure 
illustrates the relationship between the research and development process, other 
commercial activities and HTA.  It should be noted that these activities are all interlinked 
and sharp distinctions have been shown for didactic purposes only.  There is an overlap 
between research and development and DF-HTA as, for example, some stakeholder 
consultation exercises will not only allow assessment of the technology but will also 
contribute to its design/usability.  There is overlap between other commercial activities and 
DF-HTA as an activity such as strategic planning, for example, may contribute to the 
identification of scenarios to model in DF-HTA as well as assisting the developers’ 
marketing strategy.  There is overlap between the various kinds of HTA.  Much DF-HTA is 
also Early HTA as there is little evidence specific to the technology.  Some DF-HTA is also 
useful to users so there is overlap between DF-HTA and use-focused HTA. 
 
One category of studies identified as early HTA (Ijzerman and Steuten, 2011, 
Markiewicz et al, 2014) but generally undertaken to inform reimbursement 
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agencies was horizon scanning activities.  The approach taken with horizon 
scanning was to exclude it from the literature review. 
A greater difficulty was in setting a boundary between HTA activities and 
research and development activities such as portfolio management and 
technical/engineering product development activities.  Some methods identified 
as early HTA in methodological articles, such as clinical trial simulation (Hartz 
and John, 2008; Ijzerman and Steuten, 2011; Mikudina and Redekop, 2014) and 
real options analysis (Bartelmes et al, 2009; Ijzerman and Steuten, 2011; 
Markiewicz et al, 2014) appeared to fall outside the boundary of HTA.  The 
approach taken with both these methods was to exclude both clinical trial 




4 Developing a framework of HTA to inform 
developers: part one - features 
4.1 Introduction 
Chapter 4 addresses the first research question:  
1. What are the features of HTA undertaken to inform developers? 
An adapted form of this chapter was published in 2020 in the International 
Journal for Technology Assessment in Health Care.   
HTA conducted to inform developers of health technologies is typically 
characterised in the academic literature as “early” health technology 
assessment. The label “development-focused HTA” (DF-HTA) is preferable as is it 
explicitly describes the purpose of the analysis, rather than alluding to just one, 
arguably not defining, characteristic.  DF-HTA has a number of distinct features 
when compared to HTA conducted to inform reimbursement and usage decisions 
(use-focused HTA).  In order to conduct effective DF-HTA, it is important that 
analysts, who are often more familiar with use-focused HTA, are made aware of 
these differences.  This is particularly important as DF-HTA analyses conducted 
or commissioned by commercial technology developers and in-house analyses 
undertaken in pharmaceutical and large medical device companies are typically 
not published due to a desire to maintain confidentiality and lack of incentive to 
publish (Grutters et al, 2019).  Assessments of medical devices developed by 
SMEs or academic groups may be published if some public funding has been 
provided.  Consequently, the studies which are published are likely to be a 
biased sample of the work undertaken and may not be particularly useful as a 
reference source for HTA analysts new to working with developers.  
There is some useful methodological content in the published literature.  For 
example, the MATCH collaboration in the UK aimed to support companies in the 
UK healthcare technology sector to assess the value of medical devices from 
concept through to mature product.  The collaboration extended the concept of 
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iterative economic evaluation described in the late 1990s and 2000 (Sculpher et 
al, 1997; Annemans et al, 2000) to develop methods and tools (for example, 
Cosh et al, 2007; McAteer et al, 2007; Vallejo-Torres et al, 2008; Girling et al, 
2010; Chapman, 2013) for SMEs.  The SMEs were often working in resource-
constrained environments and had little in-house knowledge or experience of 
HTA (Craven et al, 2012).  Other groups, particularly translational research 
bodies such as ProHTA (Kolominsky-Rabas et al, 2015) and the Center for 
Translational Molecular Medicine (Steuten, 2016), built upon the MATCH work 
and published further methodological and applied papers (for example, Ijzerman 
and Steuten, 2011; Markiewicz et al, 2014; de Graaf et al, 2018).  This form of 
HTA, initially described as ‘supply-side’ HTA by McAteer et al of the MATCH 
collaboration (McAteer et al, 2008), has more recently been described as ‘early 
HTA’ (Pietzsch and Paté-Cornell, 2008; Ijzerman and Steuten, 2011).   
The term “early HTA” as a term to describe HTA undertaken to inform 
developers is somewhat vague and unhelpful.  It might be taken to imply that 
methods and approaches for development-focused HTA are essentially similar to 
those of the more commonly reported use-focused HTA, only undertaken at an 
earlier point in time.  This problem is compounded by the fact that many early 
health economic modelling studies in the published literature take the normative 
structure of use-focused HTA and apply it at an earlier point in time.  However, 
there are fundamental differences between development- and use-focused HTA 
that arise as a consequence of the differences in the target audience and the 
decisions that the analysis is intended to inform and these are more important 
than the timing of the analysis.   
This chapter aimed to produce a characterisation of DF-HTA that is useful to 
analysts new to working in this field as the first element of a framework of DF-
HTA.  The characterisation, in the form of a list of features and accompanying 
questions, was intended as an aide-memoire for analysts more familiar with use-
focused HTA.  The list and questions could be used at the outset of a project to 
prompt reflection on the nature of the assessment and to help structure 
discussions with developers.  It could also be used at the reporting stage of a 
project, whether published or not, to ensure transparency.  The suggested list of 
features may also form the starting point for a debate in the wider academic 
58 
 
community about the nature of HTA undertaken to inform developers of health 
technologies. 
4.2 Features of DF-HTA 
4.2.1 Methods  
An iterative process similar to framework analysis was undertaken (Spencer and 
Ritchie, 2002; Oliver et al, 2008) to develop the list of features.  This was 
informed by selected papers from the literature review described in Chapter 3.  
An initial list of features was developed, informed by two explicit frameworks 
identified in the literature (Ijzerman and Steuten, 2011; Pietszch and Paté-
Cornell, 2008; see Appendix 3) and the prior experience of Professors Briggs and 
Hawkins, supervisors of this PhD thesis.  The initial list was refined and 
expanded using an iterative process informed by the content of articles 
identified as being particularly informative (see Appendix 4).  These papers were 
selected as they discussed DF-HTA in sufficient detail to allow additional 
features to be identified or provide new insight on previously identified 
features.  The list of features was compared against the identified applied 
papers (see Appendix 5). 
4.2.2 Results 
4.2.2.1 Features of DF-HTA 
Two studies set out explicit frameworks distinguishing between different 
perspectives of HTA and a further 11 discussed the distinction sufficiently for an 
implicit structure to be discerned.  These studies are set out in Appendices 3 and 
4.  The two studies with explicit frameworks (Pietzsch and Pate-Cornell, 2008 
and Ijzerman and Steuten, 2011) set out four features: perspective (user), 
timing, decisions informed and available evidence. A further four features were 
added after examination of the papers including implicit structures.  These 
were: underlying user objective; decision space; business model; and resources 
for analysis.  The final two features were added following discussion with PhD 
supervisors which were stance of analysis and burden of proof.  The ten features 
are presented in Table 4-1.  The identified features are not separate and 
independent but intimately linked.  For example, evidence is lacking because of 
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Table 4-1: Features of development-focused HTA  
Feature of DF-HTA Description 
Target audience Technology developers (both academic and commercial) and investors (both 
commercial and public sector) 
Underlying user objective Commercial developers and investors maximise long-term financial return on 
investment 
Public funders and non-commercial developers maximise societal return on 
investment, health or other goal, such as employment levels or financial growth  
Decisions HTA designed to inform Broad range including:  
Pre-clinical/preliminary market assessments 
First estimations of pricing/reimbursement scenarios 
Go/no go decisions 
Technology design 
Trial design/evidence generation strategy 
Research prioritisation 
 






Thresholds (test cut-off) 
Levels of test performance 
Positions in pathway 
Technologies (if a portfolio of research projects is being assessed) 
Available evidence Clinical studies tend to be small such that uncertainty is high 
Evidence specific to technology scarce early in the development process. 
Alternative methods of estimating parameters include: 
Expert opinion 
Evidence on comparators or previous generations of a technology 
Bench or animal studies 
Output from pharmacodynamic models 





Repeated on an iterative basis 




Fluid -not yet defined 
Various business models available including reimbursement-based models, direct 
marketing to patients, clinicians or health-care organisations 
 
Resources for analysis 
 
Often constrained at early stages due to conflicting demands on resources 
Less resource-intensive methods to establish and begin to quantify value 
proposition 
Stance of analysis Positive 
Which jurisdiction, position in pathway maximises return for developers? 
Burden of proof “Consumer-specific” methods and evidence credible to the development team 
Limitations made transparent 




1. Target audience 
The target audience for DF-HTA includes both the developers of technologies 
and the sponsors or funders of the development. These may include both 
commercial and academic institutions as well as private and public sectors 
funders (Pietzsch and Paté-Cornell, 2008).  Hereafter, the general term 
“developers” will be used.  The target audience of developers is the defining 
feature of this form of HTA.  DF-HTA differs from other forms of HTA because of 
the requirements of its target audience.  In published studies, the target 
audience is often not explicitly defined (e.g. Hjelmgren et al, 2006; van 
Nimwegen et al, 2017; Vilsbøll et al, 2018). In some cases, the analysts appear 
to adopt the perspective of a payer even when the HTA is undertaken to inform 
the developer.  For example, Latimer et al (2011) undertook an economic 
evaluation to inform developers about the feasibility of designing a collar for use 
by patients with motor neurone disease which would be cost-effective from the 
perspective of UK NHS.  Such an analysis fails to explicitly recognise that the 
technology might be marketable in multiple markets that apply differing criteria 
to determine reimbursement. 
2. Underlying user objective 
The primary objective for a commercial sector developer or investor is to 
maximise long-term financial return on investment ((Ijzerman and Steuten, 
2011; Hartz and John, 2008; Girling et al, 2015; Buisman et al, 2016b)). Other 
social objectives or motivations are typically subservient to this objective.  The 
primary objective of public sector developers (for example, academic 
developers funded by public bodies) is to maximise the societal return on 
investment. Societal return includes consideration of direct financial returns on 
development, industrial growth or employment and improvements in societal 
health (e.g. Innovate UK’s funding streams (Innovate UK, 2018)).  In order to 
maximise long-term financial return on investment, developers and investors 
need to consider the measures of value for money that payers use in their 
coverage decisions.  Thus, the underlying objective of the payer is relevant for 
developers to inform pre-clinical, preliminary market assessments and first 
estimations of pricing and reimbursement scenarios.  Although explicit 
thresholds, such as the £20,000 to £30,000 per quality adjusted life year in the 
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United Kingdom (NICE, 2013), are often used in DF-HTA to make a first estimate 
of the maximum price achievable for a technology in order for it to be 
considered cost-effective (McAteer et al, 2007; Chapman, 2013; Markiewicz et 
al, 2014) it is important for DF-HTA analysts to recognise that a range of 
approaches are used by different payers.  The underlying decision rules used by 
decision-makers should reflect their objectives.  Analysts undertaking DF-HTA 
should acknowledge that commercial developers and investors will use, either 
implicitly or explicitly, a decision rule based on the expected net present value 
of an investment.  This means that they will be interested in the expected 
revenues to be generated across relevant markets and the expected costs 
associated with delivering these sales as well as the timescales over which the 
revenues and costs occur.  In principle, the net present value of these potential 
inflows and outflows should be calculated using a discount rate which takes into 
account the company’s cost of borrowing reflecting the perceived risk of the 
project.   In practice, crude measures of the opportunity costs of a particular 
investment are likely to be used.  Public funders and non-commercial developers 
may base a decision to continue the development on a formal net value of 
information analysis based on the acceptable cost-effectiveness threshold (which 
itself should represent the opportunity cost of healthcare expenditure).  More 
informal analyses may simply try to estimate the likelihood or potential that a 
technology will be regarded as cost-effective.  In this situation, the decision rule 
used is to continue the development if the technology is likely to meet the 
appropriate thresholds for cost-effectiveness in the relevant jurisdiction.  
Commercial developers and investors may also be interested in the outcome of 
this analysis as it would provide some indication of the likelihood of sales in the 
relevant jurisdiction and provide guidance as to acceptable pricing.  It should be 
recognised that explicit thresholds are not used by all payers, they vary between 
jurisdictions, they are not the only determinant of reimbursement, and they are 
subject to change.  Commercial developers and investors may also take into 
account other aspects of value not typically included in formal cost-
effectiveness analyses, such as patient convenience or comfort and the value of 
knowing a diagnosis for patients and their families, if these are likely to 




3. Decisions HTA designed to inform 
DF-HTA potentially informs a wide range of decisions and considerations 
including: preliminary market assessment; estimation of pricing; review of 
reimbursement scenarios; individual go/no go decisions; technology design; 
evidence generation strategy including study design; and research and 
development portfolio prioritisation (Pietzsch and Paté-Cornell, 2008; Hartz and 
John, 2008).  As DF-HTA is undertaken before the development process 
concludes, developers can respond to the assessment by changing the design of 
the technology, its target indication(s) and position in the clinical pathway 
(Pietzsch and Paté-Cornell, 2008).  The assessment process itself may highlight 
gaps in the evidence for the new technology which can drive the evidence 
generation strategy at the next phase of development.  This can also facilitate 
discussions with regulators or reimbursement agencies that increasingly offer to 
engage with developers during the development process.  If assessment is 
undertaken simultaneously for a number of technologies, the results can be used 
to identify the most promising technologies facilitating the prioritisation of 
research effort and expenditure.  For example, de Graaf et al (2018) assessed 
the potential of biomarker tests in four roles in the prevention of Type 2 
Diabetes Mellitus to prioritise research effort and expenditure within a 
translational research organisation. 
4. Decision space 
Decision space means the range of different ways and places in which a 
technology may be used, for example, clinical indication, target population, and 
placement in the treatment pathway.  In DF-HTA, the decision space is often 
wide and poorly defined.  As DF-HTA is generally undertaken prior to licensing, 
the potential indications and positions in the clinical pathway are not yet 
constrained by licensing restrictions and multiple options may need to be 
assessed (Annemans et al, 2000).  Other aspects of decision space include 
multiple versions of the technology (including optimisation of test characteristics 
for diagnostics) (Buisman et al, 2016b), patient populations (Hartz and John, 
2008; Buisman et al, 2016b), jurisdictions, comparators, dosages, modes of 
delivery, pricing structures (Annemans et al, 2000) and diffusion scenarios 
(Rogowski et al, 2016).  Furthermore, these may vary across different potential 
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markets.  If a portfolio is being assessed decision space will include multiple 
technologies or potential research projects. 
5. Available evidence 
In DF-HTA, evidence specific to the technology is typically scarce early in the 
development process.  As direct evidence of clinical effectiveness is lacking 
there is more reliance on elicited expert opinion (Cosh et al, 2007, Vallejo-
Torres et al, 2008), evidence relating to comparator technologies (Vallejo-Torres 
et al, 2008), bench or animal studies, previous generations of a technology and 
extrapolations from pharmacodynamic models (Annemans et al, 2000).  Where 
direct clinical evidence is available, studies are often small so that uncertainty 
around any estimates is high.  Methods of expert elicitation have been 
developed to improve the reliability of experts’ estimates of plausible ranges.  
Evidence may also be required about usability or the impact of a technology on 
clinical pathways (Abel et al, 2019).  Qualitative methods (Davey et al, 2011; 
Kluytmans et al, 2019) and multi-criteria decision analysis (Hummel et al, 2000a) 
have been used to address this need.  Shortage of evidence is not unique to DF-
HTA, as uncertainty is inherent in all HTA.  However, the shortage is likely to be 
more pronounced earlier in a development process. 
6. Timing 
DF-HTA is an ongoing activity facilitating a continuous discussion around the 
technology development process rather than a discrete event with a specific 
output.  The majority of DF-HTA will be undertaken before a technology is 
approved by a regulatory body.  The starting point for the DF-HTA may be the 
identification of a clinical need preceding the product development process 
(Yock et al, 2015).  In this case, the DF-HTA would assess the potential for the 
technology proposed.  An example of this approach is provided by Brandes et al 
(2015), who assessed a hypothetical vascular closure device and found only a 
single sub-group where the technology had potential.  Alternatively, the starting 
point for DF-HTA may be the evaluation of a technology already in development.  
Kluytmans et al (2019) evaluated a surgical device at prototype stage and found 
that there was little potential for the device in meniscus surgery, which was the 
developers’ suggested indication.  DF-HTA is particularly suited to an iterative 
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approach with discussions with developers continuing alongside the development 
process and analysis undertaken prior to significant investments, such as Phase II 
or Phase III trials for pharmaceuticals (Vallejo-Torres et al, 2008; Girling et al, 
2010).  Vallejo-Torres et al (2011), presented an iterative economic evaluation 
of absorbable pins for hallux valgus at three different stages of development.  
The authors used retrospective data for this analysis to recreate the dynamic 
process of DF-HTA occurring in real-time alongside the development process.  It 
should also be noted that use-focused HTA may also use an iterative approach 
(rather than the discrete event with a specific output described above), as 
products are arriving to market with greater levels of uncertainty.  
7. Business model 
In this context the term ‘business model’ broadly refers to how a technology and 
the customer are brought together, which determines how the revenue stream is 
generated and what barriers there may be to entry (Yock et al, 2015).  In DF-
HTA, the business model may not be fixed.  Developers have the option to offer 
their technology (subject to local regulatory constraints) wherever the potential 
is greatest and to target patients and/or clinicians directly or to sell via national 
health services.  For example, van Nimwegen et al (2017) used parents’ 
willingness to pay for a diagnosis to calculate ‘headroom’ (valuing an estimated 
extension in life and/or improvement in quality of life at a given threshold value 
with an adjustment for the cost impact of the technology) rather than an 
explicit threshold for reimbursement as it was felt that the technology would be 
best suited to the private payer market.  The business model adopted by the 
commercial developer or investor may differ across jurisdictions.  Non-
commercial developers may also need to consider commercial means of bringing 
their technology to market, as established biotech companies maybe best-placed 
to maximise the technology’s potential. 
8. Resources for analysis 
In the early stages of development, in large companies, there may be a set of 
candidate technologies which could potentially be assessed using DF-HTA.  As 
many of these potential technologies will fail (Annemans et al, 2000; Vallejo-
Torres et al, 2008) resource-intensive approaches to HTA themselves may not 
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have a positive expected net present value.  DF-HTA must compete for scarce 
resources, potentially displacing aspects of the research and development 
process.  In addition, many medical devices, including tests, are developed by 
small and medium-sized enterprises and may be the sole product of that 
company (Craven et al, 2012).  Such companies may have limited HTA 
experience and resources.  This means that DF-HTA must deliver value within 
significant resource constraints.  At the earliest stages of development, it is 
suggested that effort is focused on articulating and quantifying a value 
proposition (Vallejo-Torres et al, 2008; Rogowski et al, 2016).  This could 
potentially be done using qualitative interaction with clinicians and users (Davey 
et al, 2011; Kluytmans et al, 2019) and simple quantitative methods such as 
headroom analysis (Chapman, 2013).  This prima facie case can then be 
developed further as the development progresses when more resources may be 
available (Vallejo-Torres et al, 2008; Buisman et al, 2016b, Rogowski et al, 
2016). 
9. Stance of analysis 
In this context, stance of analysis means the mindset adopted by the analyst in 
undertaking the assessment.  The adoption of a positive rather than a normative 
economic stance of analysis is one of the fundamental features of DF-HTA, which 
has not previously been widely discussed.  DF-HTA for commercial developers 
adopts a positive stance, as no value judgements are required (Culyer, 2010) and 
the analysis is focused on the maximisation of the developers’ return on 
investment.  For example, Hummel et al (2012) mentioned that the aim of their 
analysis was to ‘support the future development’ of the technology.  Similarly, 
Kluytmans et al (2019) commented that much early HTA ‘has a strong 
technology-focused or supply-driven character’.  Developers start with the 
technology and part of the role of DF-HTA is to find a place where it can be 
successful.  In this sense, DF-HTA has the character of a formative assessment 
i.e. an assessment to further the development.  By way of contrast, use-focused 
HTA has the character of a summative assessment against a pre-determined set 
of criteria.  Use-focused HTA adopts a normative stance; it involves judgements 




10. Burden of proof   
There are no guidelines about either methods to be adopted or the acceptable 
level of evidence required for DF-HTA, nor would such guidelines be appropriate.  
The process of DF-HTA is iterative; initial stages use whatever evidence is 
available and methods deemed appropriate by the analyst.  The output from the 
HTA process informs the discussion between the developer and the analyst and 
takes any limitations in evidence and methods of assessment into account.  For 
use-focused HTA, in many jurisdictions, there are clear guidelines as to what 
level and form of evidence the reimbursement agency or payer deems 
acceptable as well as how the assessment should be undertaken. For example, 
the National Institute for Health and Care Excellence, the reimbursement agency 
for England and Wales, prefers the evidence of health effects to come from 
randomised controlled trials directly comparing the intervention with one or 
more relevant comparators and has a comprehensive guide to methods (NICE, 
2013). 
4.2.2.2 How the list of features may be used 
This first element of the framework, the list features of DF-HTA, could be used 
as an aide-memoire at the planning stage of a project, in initial discussions with 
developers.  This would help to clarify essential features of the analysis in the 
mind of the analyst and ensure transparency between the developers and the 
analyst.  Certain features of the framework may encourage discussions about 
features which would be unlikely to be discussed otherwise, such as the 
developers’ underlying objective.  It may also encourage a consideration of the 
wider decision space or alternative business models.  Additionally, the list and 
questions could be used as a checklist for reporting to developers or in a 
published article to ensure that the characteristics of the analysis are 






Table 4-2: Questions for consideration in DF-HTA 
Feature of DF-HTA  Questions for consideration 
Target audience  Who is the analysis designed to inform? 
Underlying user objective  What are the developers ultimately trying to achieve through investment in 
development of a technology? 
On what basis will the developers decide whether and how it is worth continuing 
with the development of this technology? 
 
Decisions HTA designed to 
inform   
What decisions can the analysis inform? 
Decision space  What are the possible uses of the technology? 
What are the most promising uses of the technology? 
Which of the potential use(s) should be targeted first? 
 
Available evidence  What evidence is available? 




What is the most appropriate form of analysis (if any) to do now? 
 
Business model  
  
What alternative business models are possible for this technology in target 
jurisdictions/indications?  
 
Resources for analysis  
  
What resources are available for analysis? 
What would be the most appropriate use of the resources? 
Stance of analysis  How does the analyst ensure the study meets the needs of the developers? 
 
Burden of proof  Are the methods and sources of parameter estimates appropriate for this level of 
resources and this stage of development? 
Has the analyst communicated any limitations of the approach with the 
developers? 
 
DF-HTA – development-focused HTA, HTA – Health Technology Assessment 
4.2.3 Conclusions 
This chapter set out to provide a characterisation of HTA undertaken to inform 
developers.  Ten features of DF-HTA are set out which can be used as an aide-
memoire for analysts new to this work and as a checklist for reporting.  Four of 
the features (target audience, decisions to inform, available evidence and 
timing) had been included in previous frameworks distinguishing early and 
mainstream HTA (Ijzerman and Steuten, 2011) or classical HTA (Pietzsch and 
Paté-Cornell, 2008).  The remaining features (underlying user objective, decision 
space, business model, resources available for analysis, stance of analysis and 
burden of proof) were identified from the literature (see Appendices 3-5) with 
input and discussion with PhD supervisors. 
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Although previous authors have gone some way towards characterising DF-HTA 
(as part of “Early HTA”) (Ijzerman and Steuten, 2011; Markiewicz et al, 2014; 
Pietzsch and Paté-Cornell, 2008), it was often conflated with other activities 
where evidence was scarce such as horizon-scanning (Ijzerman and Steuten, 
2011) and the assessment of process or innovation from the perspective of the 
health service provider (Markiewicz et al, 2014; Dong and Buxton, 2006).  
Although these related activities may share some features with DF-HTA such as 
the timing and the lack of evidence, they differ significantly in important 
aspects of the work.  In particular, the target audience for health service 
perspective work is healthcare decision-makers and the stance of analysis may 
be normative in nature.  Authors associated with the MATCH collaboration in the 
UK set out a methodology for DF-HTA (Cosh et al, 2007; McAteer et al, 2007; 
Chapman, 2013) but did not attempt a comprehensive characterisation of this 
form of HTA.  There was a recognition from this research group that this work, 
undertaken primarily for small and medium enterprises in the assessment of 
devices, was “a different animal” from use-focused HTA.  For example, McAteer 
et al used the term “supply-side” HTA (McAteer et al, 2007).  However, this is 
the first comprehensive attempt to set out the features of HTA to inform 
developers. 
Formal validation of the list of features is hampered by the, understandably, 
limited number of published examples of DF-HTA, especially commercial 
examples. There is little incentive for developers to publish HTA studies and the 
need for commercial confidentiality creates a disincentive.  This means that the 
body of published literature is skewed towards work funded by a public body 
and/or supported by translational research bodies.  A recent useful article by 
Grutters et al (2019) highlighted this bias.  It summarised 32 assessments of 30 
non-drug technologies undertaken by their academic group in the Netherlands.  
Of the 32 studies, 30 were designed to inform developers and all but two were 
unpublished.  All the developers were small or medium sized enterprises.  The 
features described by Grutters et al (2019) supported the identified list of 
features characterising DF-HTA in the range of decisions to be informed and 
broad decision space.  Timing of the assessments in this study ranged from idea 
screening, through concept development, pre-market and market access.  50% of 
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the technologies assessed were already available on the market so the timing is 
potentially a little later than was envisaged in the characterisation of DF-HTA.   
For analysts outside of large device or drug companies, new to this work, this 
first element of the framework of DF-HTA provides a clear introduction to the 
features of DF-HTA and will guide their discussions with developers to ensure 
both parties are clear on the distinct nature of this work.  It should also improve 
the transparency of any published DF-HTA if the features of each study are 
reported.  For the wider academic community, this initial characterization of 
HTA to inform developers may provoke debate among practitioners about the 
nature of this work and the accuracy of the characterisation of DF-HTA.  Further 
research which would be of use include studies examining the features of DF-
HTA in the commercial context and empirical studies applying this element of 
the framework.  The different features of DF-HTA also necessarily impact on 
methods adopted.  This has been explored for Early HTA in the academic 
literature (Markiewicz et al, 2014) but the boundaries of DF-HTA were not 
clearly established. 
4.3 Contribution of this chapter 
The main contribution of this chapter is to develop a characterisation of DF-HTA 
in ten features.  Only four of these features had previously been identified 
explicitly.  The characterisation may help analysts new to working with 
technology developers to understand the different requirements of 
development-focused projects compared to use-focused work, with which they 
are generally more familiar.     
The features of DF-HTA set out in the framework drive important differences in 
the methods of analysis used.  The process and analytical methods used in DF-




5 Developing a framework of HTA to inform 
developers: part two - process and methods  
5.1 Introduction 
Chapter 5 addresses research questions 2 and 3: 
2. What is the process of HTA undertaken to inform developers? 
3. What are appropriate methods of HTA to inform developers of health 
technologies and how do these methods link with the particular features 
of HTA to inform developers? 
The previous chapter proposed that HTA undertaken to inform developers (DF-
HTA) has ten distinct features.  This chapter builds on that contention and looks 
at the process and methods of DF-HTA.  The chapter has three elements: 
• the development of a generic process of DF-HTA (Section 5.3.1).  This 
focuses on high level activities of DF-HTA and the information flows 
connected with those activities. 
• the identification and categorisation of analytic methods of DF-HTA used 
to generate the information flowing between activities (Section 5.3.2). 
• a description of analytic methods together with examples and critique of 
the methods (Section 5.3.3). 
5.2 Methods 
The full body of papers identified in the literature review described in Chapter 3 
was reviewed to identify frameworks for HTA to support developers of medical 
technologies (Section 5.3.1).  Inclusion criteria were that the authors of the 
study explicitly set out a framework and that it included more than one activity 
of DF-HTA.  Aspects of the identified frameworks were reviewed and discussed 
with thesis supervisors and a generic process of DF-HTA was suggested and 
justified.  The full body of development-focused papers identified in the 
literature review informed the second and third elements of this chapter: 
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identifying and categorising methods of DF-HTA (section 5.3.2).  The methods 
described or applied in included papers were extracted along with the aspect of 
the information flow they were supporting.  Terminology was streamlined where 
similar terms were describing essentially the same method.  For the third 
element, the link between the features of DF-HTA and the method of DF-HTA, 
authors of the papers generally made no reference to the features of DF-HTA so 
the connection between the feature and the approach taken had to be deduced.  
The one feature which was referred to by some authors was resource constraint. 
5.3 Results 
5.3.1 Developing a generic process of DF-HTA 
5.3.1.1 Frameworks of DF-HTA from the literature 
From the body of papers identified in the literature review described in Chapter 
3, eight papers presented frameworks of HTA to support developers of medical 
technologies (Cosh et al, 2007; Retel et al, 2008; Davey et al, 2011; Ijzerman 
and Steuten, 2011; Rogowski et al, 2016; Markiewicz et al, 2017; Borsci et al, 
2017; de Graaf et al, 2018).  These are set out in Table 5-1.  All frameworks 
included clinical and economic value assessment.  The frameworks varied in the 
extent to which they included other components, such as market/business case, 
the explicit involvement of users/other stakeholders and post-market 
considerations.  A key consideration is the extent to which these other 
components form part of DF-HTA or whether DF-HTA is focused on the properties 
and evidence related to the technology itself.  The different components 
included in each framework are discussed in the remainder of this section.  In 
section 5.3.1.2 a proposed generic process of DF-HTA is set out and justified. 
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Table 5-1: Identified frameworks of DF-HTA  
First author Cosh Retel Davey Ijzerman Rogowski Borsci Markiewicz De Graaf 
Date 2007 2008 2011 2011 2016 2017 2017a 2018 



































related juridical aspects 
   Stakeholders 
analysis 
 











     Space of 
adjustments – 
scenarios of use 
  
Headroom Economic - Cost-
effectiveness 
Headroom Headroom  Device definition 



























 Scenario/Roadmap – 
Diffusion scenario 
  Challenges of 
information and 
motivation 
   
74 
 
One framework included just clinical and economic aspects (de Graaf et al, 
2018). The aim of de Graaf et al’s study was to demonstrate an approach to the 
very early assessment of potential biomarker technologies without extensive 
modelling being required so economic analysis was restricted to the estimation 
of commercial headroom using a simple formulaic approach.   
Four of the frameworks included an aspect of strategic analysis (Cosh et al, 
2007; Davey et al, 2011; Ijzerman and Steuten, 2011; Markiewicz et al, 2017a).  
For example, the first stage of the framework put forward by Cosh et al (2007) 
included strategic considerations (such as the fit of the new technology with the 
developer’s competencies and assessment of the competitive environment) prior 
to the definition of the clinical problem.  Ijzerman and Steuten (2011) and 
Markiewicz et al (2017a) also included strategic activities in their frameworks 
but described them as ‘business case analysis’ and ‘market assessment’ 
respectively.  Davey et al’s (2011) framework saw clinical problem definition and 
early health economic analysis feeding into the development of a six-part 
business model (taken from Chesbrough, 2006) comprising value proposition, 
market segment, value chain required to create and distribute the technology, 
revenue generating mechanisms and profit potential, position of firm within 
value network including complementors and competitors and formulating 
competitive strategy. 
Two frameworks (Retel et al, 2008; Borsci et al, 2017) had a particularly strong 
focus on the inclusion of user and other stakeholder perspectives.  Retel et al 
(2008) set out a framework for the evaluation of innovations in nanotechnology 
in oncology based on the Constructive Technology Assessment (CTA) approach 
(Douma et al, 2007), which has primarily been utilised in the Netherlands for the 
assessment of non-pharmaceutical technologies (Bartelmes et al, 2009).  This 
approach sees health economic considerations embedded in a comprehensive 
research and development methodology.  There is a strong emphasis on patient-
related factors such as ethics, acceptability and psychosocial reactions and 
organisational factors such as what changes in skills, routines and logistics would 
be required for the technology to be successful (Retel et al; 2008). For example, 
a constructive technology assessment conducted alongside a clinical trial of a 
prognostic signature in breast cancer investigated patient acceptability of the 
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test.  It found that patient satisfaction with the test was lower when the results 
of the test (i.e. low or high risk of progression) were given on a separate 
occasion to risk of progression according to previous standard of care based on 
clinical and pathological factors.  This was particularly the case when results 
were discordant.  The same assessment included analysis of the impact on 
diffusion of physician resistance to the test due to uncertainty in the evidence 
base.  This scenario was considered unlikely at the outset of the assessment but 
proved to be realistic as the validity of a test based only on retrospective 
validation was called into question by Dutch physicians.  This approach would 
appear to be particularly useful in co-development situations where the 
developer and a healthcare organisation are working collaboratively to evaluate 
and potentially modify a technology in the later stages of development.  Borsci 
et al (2017) presented a framework which combined health economics and 
human factors approaches (Carayon et al, 2014).  Human Factors or ergonomics 
is defined by the International Ergonomics Association (undated) as: 
‘the scientific discipline concerned with the understanding of 
interactions among humans and other elements of a system’. 
Borsci et al’s framework was developed at one of the UK National Institute for 
Health Research (NIHR), Diagnostic Evidence Co-operative (DEC) centres, now 
replaced by Medtech and In vitro diagnostics Co-operatives (MICs) (NIHR, 2019).  
The framework suggested that human factors be incorporated into health 
economic modelling.  For example, workflow analysis using task analysis, 
observation and interview could feed into both design of the technology and 
provide contextual information for the health economic analysis (Borsci et al, 
2017).  
Retel et al (2008) and Rogowski et al (2016) both included components which 
considered post-market aspects of a technology’s life cycle.  Retel et al (2008) 
included scenario analysis or road-mapping of different diffusion scenarios as a 
final component and Rogowski et al (2016) included challenges of information 
and motivation as the final component in their three-stage framework.  These 
challenges primarily refer to the misalignment of incentives in technology 
innovation and diffusion.  The initial and continued success of a technology 
depends upon the extent of its diffusion. 
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5.3.1.2 A proposed generic process of DF-HTA 
The proposed generic process (Figure 5-1) adopts as its core the two key aspects 
of DF-HTA identified in all the frameworks found in the literature – clinical value 
assessment and economic value assessment.  DF-HTA is restricted to activities 
which involve the assessment of the technology.  These core activities are 
shown in orange in Figure 5-1.  The clinical value assessment considers what 
impact the technology might have on clinical practice and ultimately upon 
health (and wider social) outcomes. The economic value assessment builds on 
the clinical value assessment to consider the economic impact of changes in 
healthcare resource use and other economic value drivers such as productivity 
effects.  The clinical value assessment must always precede the economic value 
assessment as the latter is dependent upon the former.  The arrows connecting 
the clinical and economic value assessment indicate the iterative nature of the 
assessments with both aspects revisited numerous times during the course of the 
development.  For the purposes of this thesis these core aspects comprise DF-
HTA. 
The remaining components of Figure 5-1 are the research and development 
process and other commercial activities, both shown in blue.  These two 
components are not considered to form part of DF-HTA although they are closely 
associated with it.  The research and development process includes the 
generation of the concept for and the design of the technology, as well as the 
generation of evidence of its safety and clinical effectiveness.  Other 
commercial activities includes the consideration of potential markets, pricing, 
volume of sales, fixed and variable costs of production, estimates of net margin 
and ultimately whether the continuing development is likely to deliver a positive 
financial or societal return on investment.  It may also involve consideration of 
portfolios of candidate technologies.  
Along with the two core aspects of DF-HTA shown in orange in Figure 5-1, some 
of the frameworks discussed in 5.3.1.1 included consideration of 
strategic/market issues, stakeholder/user interaction and post-market issues.  
Consideration of all these issues forms part of the proposed generic process 
although not necessarily as development-focused HTA.  Strategic/market issues 
would form part of other commercial activities.  Stakeholder/user interaction 
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may form part of any of the components depending on what the interaction is 
seeking to achieve.  It would be part of the research and development process 
where it seeks to inform technology design.  It would be part of the clinical or 
economic value assessments if input from clinicians and patients was sought, for 
example, in order to map clinical pathways.  It would be part of other 
commercial activities if stakeholders were consulted in an attempt to estimate 
the size of the market.  Post-market issues, particularly around encouraging 
adoption of the technology, would form part of other commercial activities but 




Figure 5-1: Proposed generic process of development-focused HTA 
 
Core activities of development-focused HTA are shown in orange, related activities are 
shown in blue.  Arrows indicate the information flows between the different activities. 
A – Evidence of clinical effectiveness.   
B – Evidence of clinical effectiveness for technology and comparator, contextual 
information to allow pathway modelling and diffusion information to inform modelling 
and/or scenario analysis.   
C – Commercial headroom, pricing thresholds, evidence gaps, insight on potential impact of 
diffusion related parameters.   
D – Cost profile of technology.   
E – Potential market size.   
F – Potential indications to target.   
G - Target markets and indications for scenario selection.   
H – Markets/indications with most economic potential.   
I – Evidence gaps, threshold technology performance to improve clinical effectiveness, 
insights into contextual aspects requiring consideration in design. 
J – Target markets and indications. 
K – Threshold technology performance for cost effectiveness, evidence gaps.   




The presentation of Figure 5-1 suggests a time element to the framework.  This 
is true only to the extent that the clinical value assessment must necessarily 
precede an economic value assessment as the change in clinical pathways forms 
the basis of any decision model.  The research and development process has 
been put first as in practice, the technology (i.e. research and development) 
often precedes any DF-HTA (Kluytmans et al, 2019).  In some situations, 
commercial considerations or an identified clinical need will drive the research 
and development process.  The arrows and caption to Figure 5-1 demonstrate 
the complexity of the links between each of the components and the iterative 




5.3.2 Categorising methods by development-focused HTA activity 
5.3.2.1 Classification of methods from the literature 
The starting point for the classification of methods was the literature identified 
in the review.  As described in Section 3.2.4, methods identified in the search 
included many which contribute to the research and development process or to 
other commercial activities rather than to either the clinical or economic value 
assessments.  For the sake of completeness, all methods were classified into one 
of the four components of the generic process (see Appendix 6).  Detailed 
discussion is reserved for the methods which contribute to the components of 
DF-HTA (i.e. clinical value assessment and economic value assessment) including 
methods of providing estimates to feed into either the clinical or the economic 
value assessment.  It should be noted that Table 5-2 does not aim to set out a 
comprehensive list of methods for any of the components as this was not the 
purpose of the literature review.  It only includes methods identified previously 
as methods of early HTA including HTA to inform developers. 
The literature review identified methodological studies describing methods of 
development-focused HTA (n=43), studies applying methods of DF-HTA (n=25) 
and studies which involved a combination of the above factors (n=20).  Six 
studies listed and described a selected group of methods (Miller, 2005; Hartz and 
John, 2008; Bartlemes et al,2009; Ijzerman and Steuten, 2011; Mikudina and 
Redekop, 2014; Markiewicz et al, 2014).  A seventh source, (Graziadio et al, 
2020) was added at a late stage of thesis drafting as the methods described were 
relevant.  The categorisation process is shown in detail in Appendix 6 and the 
resulting parsimonious list of analytical methods which may be useful for DF-HTA 
is set out in Table 5-2.  Definitions of the methods are given in Table 5-3.  The 
paragraphs following the tables explain the methods and provide examples of 




5.3.2.2 Overview of methods of DF HTA  
Table 5-2: Analytic methods of DF-HTA 
Analytic methods  
(Sub-types) 





Information provided Adaptations to the method for the purposes of DF-
HTA 
Care pathway analysis 
 
Mapping of existing and 






Visual representation of existing and potential care 
pathway 
Market size  
Technology positioning 
Potential market gaps 
Identification of comparators 
Literature review less rigorous (reliance on small range 
of authoritative sources such as guidelines/HTA 
reports) 
Less formal methods of expert elicitation 
 
Qualitative methods of 
stakeholder consultation 
(e.g. interviews, focus 
groups and surveys) 
Consulting clinical experts, 







Articulation of value propositions 
Evidence of clinical effectiveness for technology 
and comparator 
Insight into contextual aspects requiring 
consideration in design. 
Barriers and facilitators for diffusion to inform 
economic model structure and/or scenarios for 
analysis.   
Less formal methods used 
Smaller numbers consulted 




Literature review Review of publicly 
available information and 






Existing care pathways 
Evidence of clinical effectiveness for technology 
and comparator 
Evidence of costs and utilities for comparator and 
potentially for technology 
Identification of current and potential comparators 
Barriers and facilitators for diffusion to inform 
economic model structure and/or scenarios for 
analysis. 
Less rigorous methods than systematic review. 
Reliance on small range of authoritative sources such 











Evidence of clinical effectiveness for technology 
and comparator 
Pricing  
Preferences of decision makers/users for attributes 
of a new technology 
Use of simple, transparent sub-type of multi-criteria 




Pairwise comparisons to 




Evidence of clinical effectiveness for technology 
Preferences of decision makers/users for attributes 
of a new technology 




Analytic methods  
(Sub-types) 











(e.g. Delphi Panel) 
Consulting experts using 
qualitative methods.  
Delphi panels involve two 






Identification of comparators 
Existing and potential care pathways 
Barriers and facilitators for diffusion to inform 
economic model structure and/or scenarios for 
analysis.   
Less formal methods used 
Smaller numbers consulted 
Limited number of settings 
 
Expert elicitation Consulting experts using 
quantitative methods to 
derive point estimates 







Estimates of clinical effectiveness for technology 
and comparator 
Estimates of costs and utilities for comparator and 
potentially for technology 
  
Less formal methods used 
Smaller numbers consulted 





(cost utility analysis 
cost consequence 
analysis 
cost benefit analysis 
cost minimisation 
analysis 
estimation of headroom, 
budget impact analysis) 
 
Comparing the costs and 
health outcomes of 






Target thresholds for development costs, pricing 
and clinical effectiveness/test performance  
Evidence gaps 
Reimbursement potential 




Shorter time horizons 
Intermediate outcomes  
Use of cost minimisation and cost consequence 
analysis  
One-way sensitivity analysis 
Value of information 
analysis 
(Expected value of 
perfect information, 
expected value of partial 
parameter information, 
expected value of 
sampling information) 
Estimating the value of 
further research to society 
or a commercial developer 
using a probabilistic 




Estimates of the societal or commercial value of 
further research 
Identification of influential parameters for 
reducing uncertainty in cost-effectiveness 
Estimate of optimum sample sizes 
Too complex for use in DF-HTA unless well resourced.  
 




Table 5-3: Definitions of analytic methods of development-focused HTA  
Method Definition Source of definition 
Care pathway analysis 
 
“Care pathway analysis is the method of modelling a care pathway in a healthcare system. It is a 
type of systems or process analysis. The resulting model is shown graphically as a systems diagram 
or map of the services provided to a typical patient” 
Graziadio et al, 
2020 
Qualitative methods of 
stakeholder consultation (e.g. 
interviews, focus groups and 
surveys) 
Focus groups – “Method based on asking questions in an interactive group setting where participants are free to talk with 
other group members, in order to gather the information about perceptions, opinions, beliefs, and attitudes towards a 
topic/product of interest.” 
Markiewicz et al 
2014 
Workshops – “a method based on creating a setting where participants can benefit from focused interaction with each 
other.  The goal is to discuss and to exchange experiences on a range of relevant topics in medical devices development, 
during facilitated sessions.” 
Markiewicz et al 
2014 
Interviews – “The qualitative research interview is performed to describe and understand the meanings of central themes 
in the medical devices development.” 
Markiewicz et al 
2014 
Survey research – “The broad area of survey research encompasses any measurement procedures that involve asking 
questions of respondents (e.g. a short paper and pencil feedback form to an intensive one-on-one in-depth interview) to 
get the user involvement in the development process.” 
Markiewicz et al 
2014 
Literature review “Reviewing a body of text to come up with the critical points of current knowledge including substantive findings as well as 
theoretical and methodological contributions to a particular topic of interest in the medical device’s development.” “Topic, 
product or field of interest may refer to different parts of analysis and actions performed during the development of the 
medical devices, in the fields like: applications, patient populations, patients preferences, usability, cost-effectiveness, etc” 
Markiewicz et al 
2014 
Multi-criteria decision analysis “A series of techniques aimed at supporting decision makers faced with making numerous and sometimes conflicting 
evaluations.  Multi-criteria decision analysis aims at highlighting these conflicts and deriving a way to come to a 
compromise in a transparent process.”  
Ijzerman and Steuten, 
2011 
 
Discrete choice experiments Choice-based conjoint analysis (Discrete Choice Modelling) – “Method based on the choice experiments: a test person is 
confronted with a small number of options sampled from a parameterized space, and has to choose his preferred option.”  
Markiewicz et al 
2014 
Expert opinion Expert opinion – “studies that aim to draw forth the opinions or beliefs of experts expressed in a qualitative format” Iglesias et al 
2016 
Expert elicitation Expert panels/elicitation (e.g. Delphi method) – “A highly structured technique in which selected experts provide their 
assessment of likely future outcomes of implementing new medical device by responding to several rounds of questions.” 
Markiewicz et al 
2014 
Cost-effectiveness analysis  
(cost utility analysis 
cost consequence analysis 
cost benefit analysis 
cost minimisation analysis 
estimation of headroom, budget 
impact analysis) 
 
Cost-effectiveness analysis “compares the relative costs and outcomes (effects) of two or more courses of action to find the 
best alternative activity, process or intervention that minimises resource use to achieve the desired result”. 
Markiewicz et al 
2014 
Cost-utility analysis – “a method aimed to estimate the ratio between the cost of a health-related intervention and the 
benefit it produces in terms of the number of years lived in full health by the beneficiaries.” 
Markiewicz et al 
2014 
Cost-consequence analysis – “is a form of economic evaluation where disaggregated costs and a range of outcomes are 
presented to allow readers to form their own opinion on relevance and relative importance to their decision-making 
context”  
Drummond et al 
2015 
Cost-benefit analysis – “a systematic process for calculating if a medical device development project is a sound 
investment/decision, and to provide a basis for comparing projects.” 




Method Definition Source of definition 
Cost-minimisation analysis – “compares interventions based solely on their net cost” Hunink et al 
2014 
Headroom “is a relatively simple threshold approach … that estimates the maximum amount that a technology could cost 
and yet still be considered cost-effective.”  
Redekop and Mikudina, 
2013 
A budget impact analysis provides a measure of the affordability of adopting a medical device by 
quantifying the effects on the budget of a healthcare provider. 
 
Graziadio et al, 
2020 
Value of information analysis 
(Expected value of perfect 
information, expected value of 
partial parameter information, 
expected value of sampling 
information) 
Value of Information analysis (VOI) – “an analysis aimed at presenting the amount a decision maker would be willing to pay 
for information prior to making a decision during the medical device development to avoid uncertainty.”  
Markiewicz et al 
2014 
Expected Value of Perfect Information (EVPI)... “reflects the discrepancy between the current information position and a 
position of no perfect information (no uncertainty)” “population EVPI can provide a measure of the maximum return of 
future research, placing an upper limit on the societal costs of it”.   
Steuten et al 
2013 
Expected Value of Partial Parameter Information (EVPPI) – “informs us for which specific consequences of the technology 
(e.g. impact on utilities, costs or health status) more information is needed to make a less uncertain decision in the future, 
again offset by the costs of collecting that further information.” 
Steuten et al 
2013 
Expected Value of Sample Information (EVSI) – “estimates the expected VOI that could be gathered from a sample of a 
given size n within a particular study design, over a specified time period”.   





5.3.3 Methods of DF-HTA 
5.3.3.1 Care pathway analysis 
Often development of health technologies is ‘technology driven’ (Martin et al, 
2008; Weiser, 2013).  An example of technology-driven development would be 
where engineers at a university develop a new imaging modality without having 
a single clinical application in mind.  The starting point for any DF-HTA then 
involves positioning the technology in the relevant care pathway in order to 
determine whether it is likely to add value.  Care pathway analysis involves the 
representation of clinical care pathways, often in a visual format, although a 
narrative representation may supplement the process diagrams (Graziadio et al, 
2020).  Information to populate the care pathway analysis can be derived from 
literature review and qualitative methods of stakeholder consultation such as 
interviews, surveys or focus groups.  Care pathway analysis is the necessary first 
step of an economic evaluation as the existing and potential care pathways form 
the alternative strategies to be modelled.  Multiple care pathways may need to 
be modelled as existing care pathways may vary within and across jurisdictions 
and the technology may be able to be used at multiple positions in the pathway. 
Figure 5-2 illustrates a visual representation from a generic care pathway 
analysis for a new test technology which Graziadio et al (2020) have named Test 
Rx.  Ovals represent inputs and outputs, lines with arrows represent paths and 
directions, rectangles represent processes and diamonds decisions.  The brown 
shapes in the proposed care pathway indicate where the new technology 
changes the clinical pathway.  The new test replaces clinical decision making 
and allows patients testing positive to be managed at home rather than 
admitted to hospital.  Although the ultimate outcomes remain the same 
(recovery or progression) the new technology may change the proportions of 
patients with these outcomes.  These changes form the basis of the value 





Figure 5-2: Graphic representation of existing and potential care pathways.   
 
Reproduced from Graziadio et al, 2020 (no permission required)
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Although the authors do not offer a step by step guide to care pathway analysis 
they provide the eleven recommendations set out in Table 5-4. 
Table 5-4: Recommendations for care pathway analysis  
1 Work with the manufacturer to articulate opportunities for improvement in the clinical pathway using the 
technology 
2 Work collaboratively with a team of stakeholders including manufacturers, healthcare payers, providers and 
patients 
3 Review national and local guidelines  
4 Obtain frequent feedback from clinicians and patients (consider ethics in patient interaction, use surveys, 
interviews and focus groups) 
5 Summarise current clinical evidence (consider analytic validity, clinical validity and clinical utility) 
6 Articulate the current clinical scenario (problem, setting, recommended management) 
7 Describe the technology, indications for use, strengths and limitations, who will use it and where? 
8 Describe how the information produced by the product will guide management decisions 
9 Obtain comments on usability and potential utility from stakeholders 
10 Describe outcomes (clinical and economic) that are expected 
11 Visit the places (preferably with an example of the technology) where the device and the information 
produced will be used and talk to potential users of the technology or the information it produces. 
Adapted from Graziadio et al, 2020 
Examples of care pathway analysis 
No examples of care pathway analysis were identified in the literature review.  
Graziadio et al (2020) refer to one example of a similar methodology ‘patient-
pathway analysis’ (Hanson et al, 2017).  Rather than assessing how a new 
technology may impact existing care pathways, patient pathway analysis aims to 
to understand the alignment between how patients access clinical services and 
how services are provided.  The context in Hanson et al (2017) was planning of 
tuberculosis services using survey data.  The outcome of the analysis illustrates 
gaps in services and may indicate useful starting points for technology 
innovation. 
Strengths of care pathway analysis 
• Undertaking care pathway analysis involves a consideration of the 
placement of the technology in an existing clinical pathway which 
requires developers to explicitly consider the clinical utility of their 
technology compared to existing and emerging comparator technologies. 
• Early engagement with potential payers, clinicians and patients may 




• Visual representation of pathways allows shared understanding between 
different groups of stakeholders, facilitating discussion and consensus-
building.   
• Care pathway analysis facilitates the articulation of value propositions 
which can feed into marketing strategies, business plans and evidence 
generation strategies.   
• Multiple pathways can be represented and the analysis can be updated on 
an iterative basis as the development progresses. 
• The existing and potential clinical pathways identified form the basis of 
the health economic analysis. 
Limitations of care pathway analysis 
• There is a lack of uniform terminology or methodology for care pathway 
analysis (Graziadio et al, 2020).  Although there are few explicit examples 
of care pathway analysis, the approaches described under qualitative 
stakeholder consultation have many common features with the care 
pathway analysis.  
• Diagrammatic representations of care pathways may not capture all 
aspects of a technology’s value such as more rapid diagnosis or improved 
quality of life for a patient.  Providing these elements are captured in 
narrative form they can be incorporated into the health economic analysis 
and used in marketing and business plans.   
• The proportions of patients taking different paths are not captured by 
care pathway analysis nor are the proportions of patients experiencing the 




5.3.3.2 Qualitative methods of stakeholder consultation 
Several applied studies identified in the review have described clinical value 
assessment using qualitative methods of stakeholder interaction although there 
is no consistency in the terminology used.  For example, Davey et al (2011) 
referred to ‘field research’ to determine ‘the value proposition’, Markiewicz 
(2017b) referred to a ‘stakeholder consultation exercise’ and ‘iterative 
stakeholder involvement’, Kluytmans et al (2019) referred to ‘early assessment 
of a proof of problem’, Wieser (2013) referred to a ‘health needs assessment’, 
Wissing (2012), a ‘clinical case scenario analysis’ and Graziadio et al (2020) to 
‘care pathway analysis’.  Despite the difference in terminology, these methods 
seem to share a common approach, although this is not always explicit and not 
all steps are undertaken in all studies.  The approach involves up to five steps.  
The five-step approach is set out in Table 5-5 and two examples follow the table 
to exemplify the approach.  Following the examples, the strengths and 
limitations of this approach are discussed. 
Table 5-5: Five-step approach to CVA using qualitative stakeholder interaction 
Step Description 
1 Identify the most favourable potential application/s for the technology using information from the 
literature, developers and in some studies stakeholder input 
 
2 Identify the claims about the new technology.   
What are its advantages over existing and emerging technologies?  Informants are generally the 
developers.  Discussions could be structured using strategic tools such as PEST or SWOT (Chapman, 2013).   
 
3 Identify the stakeholders.  Generally, the potential users of the new technology and/or decision-makers 
involved in the purchasing decision.  Often limited in number and/or range of settings. 
 
4 Elicit stakeholders’ views about current clinical pathways and the claims made for the new technology.  
Various methods may be used to elicit views including interviews, focus groups and surveys. 
 
5 Develop implementation scenarios.  Note barriers and facilitators for implementation.  
 
CVA – clinical value assessment, PEST – political, economic, social, technological 
(Sammut-Bonnici and Galea, 2015), SWOT – strengths, weaknesses, opportunities, threats 
(Madsen et al, 2016) 
Examples of qualitative stakeholder interaction 
Davey et al (2011) is an example of a study covering steps two to four of the five 
step approach.  The study aimed to set out the value proposition of a flexible 
stent in order to encourage funders to invest in clinical trials.  The authors 
identified target clinicians likely to use the new technology who were leading 
consultants from the vascular surgery and interventional radiology departments 
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in two different centres in the UK.  They held meetings in which the consultants 
were asked about clinical treatment routes, disease context, current treatments 
and challenges with current stent designs.  In this study, the developers’ claims 
for the technology were clarified by the stakeholder consultation allowing a 
three-part value proposition to be developed.  No information was provided in 
the study about the number of stakeholders involved or about the precise 
methods of developing the value proposition.  It was reported as having been a 
useful exercise for the developers as ‘it confirmed the potential for an 
innovative device in the treatment of peripheral arterial disease and the 
requirement for investment in this area’.  The authors also felt that the exercise 
allowed the developers to ‘enhance marketing of the attributes of the 
technology that are likely to provide the greatest clinical benefit’ and ‘improve 
linkages in the value chain and value network by strengthening the relationships 
an organisation has with the users of the technology.’ 
Markiewicz (2017b) is a further example of a purely qualitative method covering 
all the steps in Table 5-5.  This was a complex user consultation exercise over 
two stages of development, using a range of methods to consult a range of 
informants about an evolving point of care (POC) test of kidney function.  In the 
first stage of the study, at ‘targeting product’ stage, a brainstorming session 
with the developers elicited the ‘claims’ for the technology and potential uses.  
The test was designed to detect sodium in urine and potassium, phosphate and 
calcium in blood and was aimed at patients at risk of kidney failure and their 
clinicians.  The test was portable and had a quick turnaround time so would be 
suitable for daily screening.  The developers claimed the test could result in 
reduced hospitalisation from more frequent testing and that the test was more 
accurate than current standard.  Three potential implementation areas were 
identified 1) at home as a self-monitoring tool, 2) as a POC test in a GP’s office, 
or 3) as a POC test in the hospital.  A literature search had identified four 
populations at increased risk of developing kidney disease and the developers 
selected patients with diabetes mellitus type 2 as the most promising group to 
target due to the prevalence of kidney disease in that population and the size of 
the population.   
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40 people (22 patients, seven GPs, five radiologists and six radiographers) were 
recruited using snowball sampling across the Netherlands and took part in semi-
structured interviews and completed questionnaires to elicit current practice in 
screening and monitoring and satisfaction with current care.  The proposition of 
the new test was outlined and the needs and wants with such a test were 
elicited along with perceived clinical and ease of use benefits for both the 
specialist and the patient.  Patients were asked about preferences for 
frequency, way of contact with GP, responsibility for acting on results, cost to 
the patient and health benefits, influence of the test on relationship with doctor 
and whether they felt capable and motivated to manage their disease.  Patients 
indicated that they would prefer testing in the GP’s office but GPs rejected 
frequent testing in this population as kidney disease develops slowly and current 
testing was adequate.  GPs also indicated that any POC test would need to 
measure creatinine as this was the most important pathological sign of kidney 
failure.  Radiographers and radiologists identified two groups who may benefit 
from rapid testing in hospital and six implementation scenarios were developed 
in different locations, populations and indications.  These scenarios were 
explored in a larger sample of radiologists and radiographers and one was 
considered useful.  This single scenario was rejected by the developers as the 
market was not sufficiently large and it would not be feasible to price the new 
device to compete with hospital laboratories. 
In the second stage, the ‘early proof of concept stage’, the focus of the 
development had changed at this point to target patients with existing kidney 
disease who were either pre-dialysis or in dialysis and the detection of 
creatinine had been added to the functionality of the test.  The developers felt 
the most potential for the test was in home monitoring.  To explore the 
potential for home monitoring in this population, semi-structured interviews 
were held with seven key informants – one GP, one nephrologist, one pre-dialysis 
nurse, two patient representatives, one insurance company representative and 
one scientific researcher with experience of tele-health.  Two scenarios 
discussed: patients monitoring at home and GPs monitoring in their offices.  
Following the key informant interviews, four scenarios were developed with 
manufacturers in a brainstorming session.  Scenarios differed with the levels of 
self-monitoring responsibility, amount of contact with doctors and 
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reimbursement schemes.  These scenarios were evaluated by 17 patients through 
a web-based questionnaire.  The final preferred scenario was self-monitoring by 
the patient who then contacts the specialist if results deviate from expected 
levels. 
Strengths of qualitative stakeholder interaction 
• Where development is technology driven, developers may not have 
adequately considered whether a clinical need exists or precisely where 
the need is and how the technology must perform to meet the need.  
These consultation exercises explicitly explore where the need is and 
whether the technology is likely to fulfil it. 
• Stakeholder interaction helps developers to be explicit about their value 
proposition which may help to raise finance and enhance marketing 
efforts (Davey et al, 2011). 
• Negative findings can be used to redirect design effort at a relatively 
early stage of development to avoid costly late changes.  For example, 
developers of a POC test in kidney disease were able to include detection 
of creatinine in order to improve the probability that the test could be 
used for screening (Markiewicz et al, 2017b).  Developers of a surgical 
instrument were able to redirect attention to another application when 
stakeholder interaction revealed that there was little room for 
improvement in meniscus surgery (Kluytmans et al, 2019).   
• Scenario development is useful for subsequent modelling exercises as it 
focuses modelling on areas where there is a realistic need.  Stakeholder 
consultation may also provide insight into other aspects to be taken 
account of in clinical and/or cost effectiveness modelling such as the 
inclusion of patient and clinician preferences and behaviours.   
• Stakeholder interaction may be a useful precursor to economic methods 
as unless a technology is likely to be cheaper than the current standard of 
care there may be no point continuing to economic assessment unless 
clinical value can be demonstrated. 
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Limitations of qualitative stakeholder interaction 
• In the applied examples identified in the literature review, the number of 
stakeholders involved was limited to a small number and settings were 
generally single country.  It is possible that stakeholders in other settings 
would have differing views, particularly if healthcare systems are 
differently organised or resourced.  It is important, therefore, to see 
limited exercises in stakeholder interaction as informative but not 
conclusive.  Negative findings may require an extension of the settings or 
indications explored rather than a decision to stop developing the 
technology.  Positive findings should also be seen as informative rather 
than conclusive as more detailed evidence of clinical benefit is likely to 
be needed to persuade some decision-makers to adopt the technology. 
• Many small developers would not have the capacity to undertake 
extensive user consultation exercises and developers may have difficulty 
gaining access to clinicians and other user groups (Weiser, 2013).   
• It is difficult to distinguish between stakeholder consultation to inform 
design and consultation to inform assessment of the technology (see 
section 3.2.4).  Indeed, Borsci et al (2017) presented a framework 
(discussed in section 5.3.1.1) which links health economic assessment and 
human factors/ergonomics as the assessment considers whether there is a 
clinical need and human factors/ergonomics considers what the 
characteristics of the technology needs to be in order to fulfil the need. 
• Markiewicz et al (2017b) found that negative evidence from stakeholder 
interaction was not sufficient to influence the developers’ decision about 
how to target the technology.  In addition, the potentially useful scenario 
which was identified was rejected by the developers as there was 
insufficient potential for sales volume at feasible prices.  These factors 
suggest that the analysis may not be considered useful by the developers.  
It should be remembered that DF-HTA is not intended to provide a one-off 
assessment of a binary decision but to inform developers on an ongoing 
basis (see Table 4-1).  Developers need to weigh a range of different 
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considerations in their decisions about how and whether to develop the 
technology, the role of DF-HTA is to provide input into these decisions. 
5.3.3.3 Literature review 
Literature review is a key method in DF-HTA where evidence is limited.  
Information from the literature such as national and local guidelines can inform 
clinical pathway analysis thus providing the decision model which is the basis for 
the economic model.  Literature review may identify current and potential 
comparators (effectively a form of horizon scanning).  A literature review may 
also directly inform the economic model, providing parameter estimates for 
clinical effectiveness and costs. 
Systematic literature reviews may be appropriate for some forms of DF-HTA 
where time and resources are not limited.  Even the briefest systematic review 
using automated tools has been estimated to require over 60 man hours (Clark et 
al, 2020) and a typical review takes over 800 man hours estimate (Ba’ Pham et 
al, 2018).  In situations where resource and time are constrained which is likely 
to be the case for much DF-HTA, adaptations to literature review methods are 
required.  Abel et al (2019) recommend a ‘targeted’ approach where searches 
are conducted on a flexible, iterative basis and are interspersed with expert 
elicitation and stakeholder consultation.  Clinical experts may be able to 
identify key literature sources such as relevant recent trials, guidelines or 
comprehensive HTA reports.  Chapman (2013) recommends using a limited 
number of authoritative sources.  Others have relied on particularly relevant 
single sources (Dranitsaris et al, 2004; Brandes et al, 2015).  In all cases where 
parameter estimates were taken from a limited range of sources, the estimates 
should be confirmed with clinical experts and varied widely in sensitivity analysis 
(Grutters et al. 2019).  
5.3.3.4 Multi-criteria decision analysis  
Multi-criteria decision analysis was defined by Ijzerman and Steuten (2011) as ‘a 
series of techniques aimed at supporting decision-makers faced with making 
numerous and sometimes conflicting evaluations.  Multi-criteria decision analysis 
aims at highlighting these conflicts and deriving a way to come to a compromise 
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in a transparent process.’  There are different variations of the method including 
the ‘budget pie’ method (Ryan et al, 2001), Simple Multi-Attribute Rating 
Technique (SMART) and Analytic Hierarchy Process (AHP)(Goodwin and Wright, 
2014).  They all follow the same basic structure set out in Table 5-6 but differ in 
the mathematical sophistication of the weighting process.  The ‘budget pie’ 
method is the simplest in that it asks participants to allocate a set number of 
points over the attributes according to their importance to determine weights.  
SMART uses swing weights to elicit weights (Goodwin and Wright, 2014).  This 
involves asking respondents to compare a change from the least preferred to the 
most preferred value on one attribute with a similar change (swing weight) in 
another attribute.  AHP involves identifying top level criteria and grouping other 
criteria under these (Wissing, 2012).  Weighting and scoring are determined 
using pairwise comparisons of sets of two (sub) criteria.  The relative importance 
of one criterion in comparison to the other is appointed on a nine-point ordinal 
scale in which one reflects equal importance or preference and nine extremely 
higher importance or preference.  These varieties of MCDA vary in complexity 
and transparency with budget pie being the least complex and most transparent.  
Steps one to four in Table 5-6 require informants who may be a combination of 
the developers themselves, clinicians and patients and a difficulty of any form of 
MCDA is in choosing or having access to informants who accurately represent the 
ultimate decision makers.  Methods of eliciting the decision context and 
attributes draw on the qualitative methods previously described. 
Table 5-6: Steps involved in multi-criteria decision analysis 
Step Description 
1 Set out the decision context and the alternatives (i.e. the technology in development and current 
standard/s of care) 
 
2 Identify the relevant attributes (i.e. the characteristics of the technology and comparators which are 
relevant to the decision) 
 
3 Weight the attributes (i.e. the relative importance of the attributes) 
4 Score the alternatives (How well do the new technology and the comparators perform on each of the 
attributes?) 
5 Rank the alternatives using the weighted scores  
 
Examples of the use of multi-criteria decision analysis 
Wissing (2012) used AHP as part of a mixed methods study described as a 
‘clinical case scenario analysis’.  This study assessed the potential clinical value 
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of a bioartificial pancreas (BAP) compared to conventional islet and pancreas 
transplantation in patients with type 1 diabetes mellitus.  Literature searches, 
semi-structured interviews and focus groups were used to complete steps one 
and two set out in Table 5-6.  Relevant attributes were: the site of BAP implant; 
the type of intervention necessary for placement of the BAP; the amount of 
donor material required; and the dose of immunosuppressive agents necessary 
for a successful transplant.  In this example, three scenarios were constructed 
for BAP, a positive, a negative and a likely scenario in order that the preferences 
for the new technology over the current alternatives were assessed at different 
performance levels.  To develop the weights, 12 endocrinologists and 27 patients 
completed a questionnaire.  The three scenarios for BAP and the current 
alternative methods were scored by a clinician familiar with all the methods 
then these scores were weighted using the results from the AHP.  The most 
important attributes were effectiveness, patient safety and technique for 
placement.  Endocrinologists rated patient safety first whereas patient ranked 
effectiveness ahead of safety.  The new technology was preferred by 
endocrinologists providing it reached most likely performance.  Patients 
preferred conventional pancreas transplant in all performance scenarios. 
Hummel et al (2012) assessed a new treatment for adolescent idiopathic scoliosis 
(AIS).  The current standard of care involved bracing then posterior fusion 
surgery for severe cases.  Posterior fusion surgery stops growth in adolescents as 
vertebrae are fused and there is a relatively high rate of complications including 
pain and post-surgery infections.  The new treatment, non-fusion surgery (NFS), 
would allow surgery at an earlier age as there would be no restriction of growth 
and may prevent progression of disease.  There was no clinical effectiveness 
data for the new treatment.  A panel of four biomedical engineers and two 
orthopaedic surgeons estimated the missing data on a decision tree comparing 
new and existing technologies on costs (materials and treatment) and 
effectiveness (quality of life, pain, back function, self-esteem, medical and 
technical complications).  In this study, the decision tree provided no absolute 
estimate of clinical effectiveness, utilities or costs but the branch with the 
highest relative priority indicated the best decision alternative.  The study found 
that the new technology was the preferred option for patients with severe AIS 
because of its impact on spine function and patient esteem.  Further work was 
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required to reduce cost and improve prediction of those patients likely to 
progress to severe disease to improve clinical acceptance of the method.  
Assuming data was available for the existing treatment absolute values may have 
been calculable. 
Koning (2012) used SMART to assess the potential for a POC test (μDtect, an 
electronic nose) for the diagnosis of infectious disease.  Interviews with a multi-
disciplinary group of informants identified relevant attributes for the comparison 
of the new technology and standard of care.  The most promising indication had 
been previously identified in some qualitative work.  13 attributes were 
identified across three main categories – cost (capital cost, implementation cost, 
initial training cost , maintenance cost, cost of consumables , ongoing training 
cost, cost of labour ongoing), clinical performance (accuracy, time to 
identification, chance of contamination) and impact on workflow (ease of use, 
integration with other systems).  Clinical performance received the highest 
weighting at 0.56 with accuracy comprising 0.274 of that weighting.  Cost was 
weighted 0.2 and impact on workflow 0.24.  μDtect scored well in both cost and 
impact on workflow categories but it was not sufficiently accurate or rapid to 
offer advantages in well-resourced settings.  
More examples of MCDA from applied studies identified in the review are 
provided in Appendix 9.   
Strengths of multi-criteria decision analysis 
• MCDA extends the qualitative clinical case assessment providing some 
quantification of informants’ preferences for the new technology 
compared to the existing alternatives. 
• MCDA methodology may encourage more explicit consideration of all 
relevant criteria.  For example, if MCDA is used as an alternative to cost-
effectiveness analysis to perform an economic evaluation, more criteria 
can be explicitly considered in the decision-making process and cost can 
be weighted appropriately for the decision context. 
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• The ability to assess different scenarios provides an indication of the 
importance of achieving certain performance criteria across different 
stakeholder groups. 
Limitations of multi-criteria decision analysis 
• The initial steps of MCDA involve the same narrowing down of the 
potential indication for a new technology as qualitative methods of 
stakeholder interaction.  A negative result does not, therefore, indicate 
that the development of the technology should be stopped but may 
indicate that a new indication, application or setting may be more 
promising for the technology. 
• Undertaking the simplest form of MCDA (e.g. budget pie) is not technically 
challenging and may be achieved without significant commitment of 
resource.  Other forms of MCDA may require the use of specialist software 
or access to expertise that is not available for many developers of medical 
technologies at early stages of development. 
• The quantification of preferences using methodology such as SMART and 
AHP may result in a lack of transparency.  Moreover, the presentation of 
detailed quantitative results may be a case of ‘false precision’ (Pirie, 
2015) given the lack of evidence early in development and a potentially 
limited range of settings and informants.   
• Informants may not be representative of the real decision-makers. 
5.3.3.5 Discrete choice experiment 
A discrete choice experiment (DCE) is ‘a quantitative method increasingly used 
in healthcare to elicit preferences from participants (patients, payers, 
commissioners) without directly asking them to state their preferred options’ 
(York Health Economics Consortium, 2016).  Participants are presented with a 
choice between hypothetical scenarios which include a number of attributes 
thus indirectly revealing their preferences for each of the attributes. 
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Example of discrete choice experiment 
Groosthius-Oudshoorn et al (2014) used a discrete-choice experiment to estimate 
the clinical value in terms of increased test uptake for a variety of methods of 
screening for colorectal cancer (CRC) including a potential nanopill with 2,225 
respondents from the UK and Netherlands recruited by random sampling among a 
population 50-75 years of age.  Characteristics were identified from previous 
preference studies in CRC.  The six attributes included in the DCE were 
preparation, technique, sensitivity, specificity, complication rate and required 
frequency of testing.  The DCE revealed that participants preferred no 
preparation, 100% sensitivity and the nanopill compared to other techniques.  
The study also found that switching to a nanopill would result in an increase of 
3% in uptake of screening, from 76% to 79%. 
Latimer et al (2011) is an example of a brief time-trade off exercise being used 
to estimate utilities for an economic model. 
Strengths of discrete choice experiments 
A well-conducted DCE can provide evidence to developers of whether a new 
technology has the potential to outperform the existing standard of care.  It also 
provides evidence about the relative importance of the different attributes and 
information to inform modelling. 
Limitations of discrete choice experiments  
It requires expertise and resources to conduct a DCE and these may not be 
available to SME developers of medical technologies. 
5.3.3.6 Expert opinion and expert elicitation 
An expert is defined by Morgan (2014) as an individual ‘whose knowledge can 
support informed judgement and prediction about the issues of interest’.  
Iglesias et al (2016) distinguish expert opinion and expert elicitation on the basis 
that expert opinion involves qualitative information and expert elicitation 
quantitative information.  Although both are considered weak evidence (Evans et 
al, 2003), they are useful for DF-HTA as stronger evidence is often limited.  
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Expert opinion may be used to provide background information on the disease 
area, current and potential clinical pathways, to help interpret evidence, to 
define the decision problem (including relevant comparators and populations 
most likely to benefit from a new technology) and to sense check a model 
structure, data inputs and results (Peel et al, 2018).  Expert elicitation uses 
quantitative methods of elicitation and estimates may include probability 
distributions or ranges (Girling et al, 2007).  Such estimates may be used to 
populate decision models for cost-effectiveness analysis. 
Methods for eliciting expert opinion include qualitative stakeholder interaction 
methods discussed above.  A more formal process is a Delphi panel which 
includes two rounds of consultation with a view to establishing consensus.  Best 
practices for the reporting of Delphi processes to collect expert opinion and 
structured expert elicitation are presented by Iglesias et al (2016).  A recent 
methodological report put forward a framework for expert elicitation with 20 
recommendations across aspects such as selection of experts, avoiding bias, 
weighting judgements and reporting (Bojke et al, 2019).  The report included an 
empirical evaluation of this framework and found that a total of five months of 
full-time equivalent researcher time was required to undertake the elicitation 
exercise.  Even in the relatively well-resourced environment of NICE, time and 
resource constraints often lead to expert elicitation being conducted informally 
with individual experts (Peel et al, 2018).   
For well-resourced DF-HTA, quantitative expert elicitation may be possible using 
available tools such as the Sheffield Elicitation Framework (SHELF) (Oakley and 
O’Hagan, 2010) and MATCH uncertainty elicitation (Morris et al, 2014).  A 
number of applied examples were identified from the literature and are set out 
in Appendix 8.  Where resources were limited expert elicitation would need to 




Examples of expert elicitation 
Two of the studies identified in the literature review applied expert elicitation 
techniques in clinical value assessment, Breteler (2012) and Haakma et al, 
(2014).  Breteler (2012) used structured expert elicitation with 18 neurologists to 
narrow down the potential indications for a home-based brain monitoring system 
for patients with suspected epilepsy and to assess their probabilities for success.  
She used interviews with two neurologists to map the diagnostic pathway, 
identify uncertainties in the pathway and several places where the technology 
may impact.  She then defined five potential scenarios for use over three 
different populations.  She elicited the mode and range for a beta distribution of 
the probability that the neurologist would order the home-based monitoring at 
that particular point for a particular patient.  She also included a weighting of 
clinician estimates according to their years of experience, the number of 
electroencephalograms done each week and their ability to make long term 
recordings.  Haakma et al (2014) used structured expert elicitation to elicit 
radiologists’ beliefs about a range of test performance parameters in order to 
assess the clinical value of a novel imaging technology.  The study compared 
photo-acoustic mammography (PAM) to magnetic resonance imaging (MRI) in 
suspected breast cancer after an inconclusive xray or mammogram.  20 
radiologists from academic and non-academic hospitals in Netherlands were 
asked to estimate the number of true positives and true negatives likely to result 
from examination of a range of images.  First, the experts were asked to rate 
the importance of seven tumour characteristics in the examination of images by 
allocating 100 points across the characteristics.  Then they were asked to grade 
each imaging modality with its ability to visualise those characteristics, again 
giving a score between 0 and 100.  A questionnaire and spreadsheet-based 
exercise was used to elicit the probability distribution of true positives and true 
negatives during a face to face interview with individual radiologists.  They 
estimated TP and TN compared to pooled data for MRI by estimating the mode 
and the 95% credible intervals with the support of a graphical display of the 
probability density function.   
Structured expert elicitation can also provide quantitative estimates of 
parameters for use in economic evaluations before clinical evidence is available.  
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Probability distributions can be elicited as well as point estimates, which can 
enable the development of models using PSA and VOI.  Kip et al (2016) elicited 
the effect of a new biomarker on hospital discharge rates and interventions 
performed.  The elicitation involved the administration of a questionnaire to ten 
cardiologists.  The discharge and intervention rates provided parameter 
estimates for a cost-effectiveness model.  
Strengths of expert elicitation 
• The use of expert judgement may be the only way to source information, 
whether qualitative or quantitative, about the likely performance of a 
new technology.  However, there is concern that experts are often over-
optimistic about the likely performance of a technology and 
underestimate uncertainty, particularly if the experts are also involved in 
the development of the technology (Gosling, 2014).  More structured 
methods of expert elicitation try to ensure that heterogeneity and 
uncertainty are fully represented (Gosling, 2014).   
• Expert elicitation of probability distributions as well as point estimates 
enables the use of probabilistic analysis in models. 
Limitations of expert elicitation 
• Structured expert elicitation requires some resource and expertise to 
undertake and contacts with experts which may be difficult for SME 
developers.  The estimation aspects of structured expert elicitation may 
sometimes be difficult for experts to operationalise.  For example, six out 
of the 20 radiologists who undertook the initial elicitation exercise in 
Haakma et al (2014) felt unable to complete the elicitation of true 
positives and negatives.   
 
5.3.3.7 Cost-effectiveness analysis  
As shown in Figure 5-1, in the generic process of DF-HTA, economic value 
assessment follows clinical value assessment.  It accounts for healthcare and 
other resource usage.  It may also include productivity and other wider impacts.  
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In reimbursement-focused HTA, economic evaluation is typically undertaken to 
determine whether the technology, at a given price and given current evidence, 
represents a cost-effective use of healthcare resources. In development-focused 
HTA, economic evaluation using health economic modelling is also the mainstay, 
but it plays a different role.  It may be used to support a range of decisions 
including whether further development should be funded (go/no-go decision), 
placement of the technology (setting, indication and position in clinical care 
pathway), and threshold performances required or prices achievable for the 
technology. 
Economic value assessment in DF-HTA may include a formal cost-effectiveness 
analysis.  The umbrella term, cost-effectiveness analysis, includes cost-benefit, 
cost-utility, cost-effectiveness, cost-consequence and cost-minimisation analysis 
(Drummond et al, 2015).  All these methods compare the difference in outcomes 
brought by a new technology to the difference in costs.  All methods calculate 
costs in the same way, but they measure outcomes differently.  In a cost-benefit 
analysis, outcomes are measured in monetary terms.  In a cost-utility analysis, 
outcomes are expressed using a generic measure such as quality adjusted life 
years (QALYs).  This is because the generic outcome measures used in cost-utility 
analysis facilitate comparisons across technologies and disease areas.  In cost-
effectiveness analysis, outcomes are expressed as disease-specific measures, for 
example, cost per infection avoided.  In cost-consequence analysis, outcomes 
are expressed across multiple measures such as cost and cancer cases missed.  A 
particular challenge with both cost-effectiveness and cost-consequence analysis 
is the difficulty in making comparisons between indications and determining an 
acceptable threshold for willingness to pay.  Finally, in cost-minimisation 
analysis it is assumed that outcomes are either equal or superior for the new 
technology, hence it is sufficient to simply compare costs.  The challenge with 
this analysis is that it is only appropriate when it is safe to assume that 
outcomes are either equal or superior with the new technology.  
In some jurisdictions (for example: Australia, Canada, Netherlands, UK) there is 
a strong emphasis on cost-effectiveness analysis in reimbursement programmes 
and methods are well established (PBAC, 2016; CADTH, 2017; National Health 
Care Institute, Netherlands. 2016; NICE, 2013).  Where the target audience for 
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DF-HTA is not a publicly accountable body (such as a reimbursement agency) 
there is not the requirement for methods to be uniform and pre-prescribed.  
Commercial developers are investing their own (or their shareholders’) money 
and ultimately their success will be measured on whether the investment proved 
worthwhile rather than the quality and transparency of the process supporting 
the decision.  Commercial developers are more likely to take a pragmatic view 
of the methods used as they need to balance the expenditure of effort and funds 
between numerous aspects of the development.  This means that analysts of DF-
HTA can also take a more pragmatic stance of analysis as the methods to be used 
are not standardised.  They can apply methods which are appropriate for the 
developers’ needs and meet a burden of proof acceptable to them.  Public 
sector funders of research may require more structured methods to be applied 
as they may have to demonstrate consistency and transparency of their decision-
making process. 
As a result of these features (see also Section 4.2.2.1) some adaptations to these 
established methods might be expected when the analysis is being undertaken as 
part of DF-HTA.  A suggestion of such adaptations is set out in   
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Table 5-7 and discussed in the paragraphs that follow.  The comparison is made 
against the reference cases put forward by the technology appraisal and 





Table 5-7: Adaptations in economic evaluation for development-focused HTA 
Aspects of economic 
evaluation 
Economic evaluation for coverage 
decisions (based on NICE TAP and DAP 
methods guides) 






Market access stage Pre and during development 
Ideally an iterative approach 
Less evidence 
More uncertainty about positioning and 
performance of the technology 
Source of decision  
problem 
NICE scoping exercise Context dependent  
Expert opinion 
Less rigorous methodology 
Perspective UK NHS and PSS Multiple markets including public and/or 
private payers 
Type of economic 
evaluation 
Cost-utility analysis for TAP 
More flexible for DAP 
Focus on cost minimisation/ health 
outcomes other than QALYs 
Less focus on CUA 
Time horizon As required for health and cost outcome 
differences 
Shorter time horizons – may not capture all 
differences 
Discount rate applied 3.5% discount on costs and health outcomes Multiple discount rates 
Discount rates not applied 
Evidence for health 
effects 
Systematic review. 
RCT preferred for TAP 
More flexible for DAP 
Literature review not systematic 
Small clinical studies 
Expert opinion or assumptions 
Evidence of quality of 
life 
Health state reported by patients, valued by 
UK population 
Literature review not systematic 
Expert opinion or assumptions 
Evidence for costs Systematic review for TAP 
More flexible for DAP  
Comparator information  
Expert opinion or assumptions 
Modelling method Unspecified but should be fit for purpose Simpler modelling methods (headroom 
calculations, decision trees, markov models) 
Estimand ICER, NMB 
Budget impact 
Wider range including headroom and 
threshold costs, performance, health 
outcomes.  Budget impact. 
Dealing with 
uncertainty 
Probabilistic sensitivity analysis for 
parameter uncertainty 
Sensitivity analysis including alternative 
data sources 
Scenario analysis for structural uncertainty  
Multiple scenarios to reflect uncertainty 
about positioning of technology  
One-way sensitivity analysis for parameter 
uncertainty in earliest stages with 
probabilistic sensitivity analysis when some 
clinical evidence is available. 
CUA – cost-utility analysis, DAP – Diagnostic Assessment Programme, EE – Economic 
evaluation, HTA – Health Technology Assessment, ICER – Incremental Cost Effectiveness 
Ratio, N/A – not applicable, NHS – National Health Service, NICE – National Institute for 
Health and Care Excellence, NMB – Net monetary benefit, PSS – Personal Social Services, 
QALY – Quality Adjusted Life Year, RCT – Randomized controlled trial, TAP – Technology 
Assessment Programme, UK – United Kingdom 
 
1. Timing 
NICE assessments are typically done at the market access stage.  Economic 
evaluation as part of DF-HTA is generally undertaken before and/or during the 
development of a technology on an iterative basis although it can continue 
throughout the lifecycle.  In the 32 examples of economic evaluation for 
developers described by Grutters et al (2019), one was an idea not yet being 
developed, 16 were in development, eight had finished development and seven 
were on the market.  Although an iterative approach is recommended in the 
107 
 
literature (Grutters et al, 2019; Drummond, 2019) only one of the examples 
identified in the literature review presented an iterative approach and this was 
reconstructed on a retrospective basis as an illustration (Vallejo-Torres et al, 
2011). 
As economic evaluation in DF-HTA is often carried out before there is extensive 
clinical evidence specific to the technology.  This impacts on the source of 
estimates for populating models.  Uncertainty is greatest at the earliest stage in 
product development when the best placement for the technology may not yet 
have been determined.  At this earliest time, it may be appropriate to undertake 
a less resource intensive form of economic evaluation alongside the articulation 
of the initial value proposition for the technology (Graziadio et al, 2020).  Later 
in the development process, when the positioning of the technology is likely to 
be more concrete and there may be some clinical evidence specific to the 
technology a more developed form of cost-effectiveness may be appropriate 
(Graziadio et al, 2020). 
2. Source of decision problem 
For NICE assessments the scope of the decision problem is a collaborative, 
systematic and resource-intensive process (NICE, 2013, 2020a).  For economic 
evaluation in DF-HTA, the initial decision problem may be defined in 
consultation with the developers, depending on where they see the technology 
being used and what advantages it is thought to have over the current standard 
of care (Grutters et al, 2019).  Interviews with clinical experts may then be used 
to determine the current, and alternative, clinical pathways in sufficient detail 
to permit modelling (Grutters et al, 2019).  In order to keep the modelling 
exercise manageable, expert input may also be required to narrow down the 
alternative strategies to the most plausible ones although this approach is not 
always taken (Faria et al, 2018).   
3. Perspective 
A UK national health service and personal social services (NHS and PSS) 
perspective is required by NICE guidance.  This means that, generally, the only 
costs included are those incurred by the NHS or for adult social care.  Costs 
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incurred by the patient and productivity losses are excluded.  In economic 
evaluation as part of DF-HTA, multiple markets may be considered or a wider 
consideration of costs and benefits may be appropriate in a study, as 
technologies may be offered to private payers as well as to healthcare systems 
or to healthcare systems which do not place the same emphasis on cost-
effectiveness analysis as the UK.  In the applied studies identified in the review 
there was little evidence of the consideration of multiple jurisdictions (see 
Appendix 7).   
4. Type of economic evaluation 
NICE requires a cost utility analysis to be undertaken and may also require a 
budget impact analysis.  Cost-utility analysis uses the generic metric, the quality 
adjusted life year (QALY) as health outcome.  This allows NICE to compare 
across different disease categories on an equivalent basis.  A budget impact 
analysis is required when the anticipated budget impact is high.  In economic 
evaluation as part of DF-HTA, outcomes other than the QALY may be used as 
developers seek to demonstrate wider views of value than those captured in a 
QALY or lack the evidence translating clinical effectiveness into QALY values.  
There may also be a focus on cost saving or overall budget impact as this may be 
the easiest way for developers to demonstrate the value of their technology to a 
decision-maker.   
A type of cost-utility analysis suited to DF-HTA because of its simplicity is what 
has been termed ‘headroom analysis’ (Ijzerman and Steuten, 2011; Chapman, 
2013; and Girling et al, 2015).  In fact, headroom is simply an estimand from any 
form of cost-effectiveness analysis.  ‘Headroom’ is an indication of the maximum 
price which could be charged for a new technology.  It is calculated by 
multiplying the increase in utility (or other relevant effectiveness metric) 
expected to be generated by the introduction of the new technology by a 
willingness to pay threshold (for the relevant metric) for a given jurisdiction 
then adjusting for cost savings/additional costs included in the calculation.  In 
the UK, there is an explicit willingness to pay threshold of £20,000 to £30,000 
per QALY (NICE, 2013).  For example, if a new technology was expected to 
generate an incremental QALY of 0.1 and save £500 in further diagnostic 
procedures the headroom would be calculated as 0.1 x £20,000 (representing the 
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willingness to pay for 1 QALY in the UK) + £500.  A total headroom of £2,500.  
The headroom estimate represents the maximum price achievable for the 
technology if it is to be considered cost-effective in the UK.  Threshold analysis 
is a similar formulaic approach, which assumes a price for the technology then 
investigates what values the other parameters need to take in order for the 
technology to remain cost-effective.  Both headroom and threshold analysis are 
simple and quick to perform and can be based on expert opinions or 
assumptions, so they are ideal for undertaking extensive scenario or sensitivity 
analysis and when resources are constrained (Chapman, 2013; Vallejo-Torres et 
al, 2008).  The analysis may focus only on cost savings rather than valuing health 
outcomes (Markiewicz et al, 2016) and may even be limited to the analysis to a 
single category of savings (McAteer et al, 2007).  Craven et al (2009) developed 
the MATCH headroom tool, available on-line (Match.ac.uk, 2018), which can be 
used to undertake a headroom analysis.   
Cost-minimisation (Frappier et al, 2014; Steuten et al, 2009) or cost-
consequence analysis (Brandes et al, 2015) should theoretically be useful where 
resources are constrained although not many examples exist in the literature 
(Hunter and Shearer, undated).  The methods are useful because they avoid the 
evaluation of health outcomes in terms of utilities (required for cost-utility 
analysis) which may be complex.  Cost-effectiveness analysis where the outcome 
of interest is a clinical measure, may also be useful in DF-HTA as it avoids the 
use of a utility measure like the QALY.  Applied studies were identified in the 
review which used outcomes including complications avoided, cancer cases 
prevented, correct diagnoses, time to treatment and patients correctly 
discharged.  Budget-impact analysis goes beyond cost-consequences analysis in 
that it takes account of the scale and timing of revenues and expenditure 
associated with the new technology. It is particularly important to make budget 
impact transparent where spending in one area is offset by savings in another 
(Graziadio et al, 2020).   
5. Time horizon used 
The time horizon required by the NICE methods guides is a period sufficient to 
allow all differences between health outcomes and costs for the alternative 
technologies to be fully explored.  For many technologies this is equivalent to a 
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lifetime horizon.  As modelling to a lifetime horizon is often technically 
challenging and resource intensive, economic evaluations in DF-HTA may use 
shorter time horizons particularly in the earliest stages of development (Brandes 
et al, 2015; Chapman, 2013).   
6. Approach to discounting 
NICE requires that both costs and health outcomes are discounted by 3.5% per 
annum.  In economic evaluation for DF-HTA, due to a desire to simplify analysis 
and shorter time horizons adopted, analysts may not apply a discount rate.  
7. Evidence for health effects 
NICE requires evidence of health effects to be derived from a synthesis of the 
evidence from the literature extracted by systematic review.  In the TAP 
programme, evidence would generally from randomised controlled trials.  The 
DAP programme is more flexible and will accept other forms of high-quality 
evidence specific to the technologies under evaluation.  Due to the timing of 
economic evaluation in DF-HTA, robust clinical evidence specific to the 
technology may not be available.  Alternative sources of parameter estimates 
may be literature (see Section 5.3.3.3), outputs from clinical trial simulation, 
expert opinion or assumptions.  The analyst may also choose to make 
assumptions.  This is often done for the price of a technology at concept stage.  
In all these cases estimates would be varied over a wide range in sensitivity 
analysis and limitations of the data reported transparently (Chapman, 2013; 
Vallejo-Torres, 2011).   
8. Evidence for quality of life 
For quality of life estimates, NICE requires patient reported health conditions to 
be valued by the UK population using preference-based methodology.  In 
economic evaluation for DF-HTA, directly obtained estimates are often not 
available and estimates may be required for more than one jurisdiction.  Quality 
of life estimates may be derived from the literature in a non-systematic way or 
provided by experts.  Chapman (2013) described an approach for adapting 
utilities from the literature termed the ‘utility ladder’.  This approach (based on 
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solutions adopted when few utility studies were available) (McAteer, 2011) 
involved deriving utilities by placing the unknown condition among a range of 
conditions for which utilities were available.  Other analysts have used simple 
elicitation exercises to estimate utilities (Dranitsaris et al, 2004; Latimer et al, 
2011; McAteer et al, 2007; Vallejo-Torres et al, 2011).   
9. Evidence for costs 
In the technology appraisal programme, NICE requires that evidence for costs is 
derived using systematic review methodology although this is a little more 
flexible in the DAP.  For economic evaluation in DF-HTA, similar to the position 
with other categories of evidence, resource constraints and the timing of the 
analysis means that evidence on costs is more likely to come from less rigorous 
literature searches, relate to comparator technologies or be based on expert 
opinion or micro-costing exercises.  Different cost levels may be assumed or the 
analysis may work backwards to determine what the threshold cost may be for 
the technology to be considered cost-effective in a particular jurisdiction. 
10. Modelling method used 
NICE do not specify which modelling method is preferred providing that it is fit 
for purpose.  Decision trees, Markov models and simulation models are all 
regularly used.  A decision tree is a ‘visual representation of all the possible 
options and the consequences that may follow each option’ (Hunink et al, 2014).  
The initial line of a decision tree is labelled with the population or problem you 
are considering then a square indicates a decision node at which one of the 
alternative options, represented by subsequent lines, must be chosen (Hunink et 
al, 2014).  The circles (or chance nodes) represent time points at which there 
are two or more possible consequences of a decision.  These consequences are 
assigned probabilities which must sum to 1.  If cost and health outcomes are 
attached to each branch of the tree, the overall expected values for costs and 
outcomes can be calculated for each strategy.   
One practical difficulty with decision trees is that they can become unwieldy 
quickly particularly if longer time horizons need to be considered and/or if the 
disease is of a remitting/relapsing type (Briggs et al, 2006).  As a consequence, 
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decision trees generally represent a relatively short time horizon, often the 
acute treatment phase of an intervention.  The Markov framework is often used 
to extend the short time horizon covered by a decision tree.  Markov models are 
structured around mutually exclusive disease states.  Rather than representing 
different possibilities over time as pathways in a decision-tree they are modelled 
as possibilities of transitioning between different disease states during a discrete 
time period known as a cycle (Briggs et al, 2006).  Costs and health outcomes 
are attached to each of the disease states and they accumulate based on the 
number of individuals from a notional cohort in any one state during a given 
period.  Markov models often include a death disease state and include 
sufficient time periods to allow the analysis to extend until all members of the 
modelled cohort have transitioned to the death state. 
A significant limitation of Markov models is that they are said to be ‘memoryless’ 
(Briggs et al, 2006).  This means that the model type, in its simplest form does 
not take account of how long an individual in a particular disease state has been 
in that state.  This can limit the ability of the Markov model to accurately 
represent some disease processes.  For example, in many types of cancer the 
probability of progressing to more severe forms of the disease may depend upon 
how long the patient has been in remission following the first treatment.  This 
aspect would be difficult to capture in a simpler Markov model.  Although 
adjustments to the Markov model have been put forward, they may result in 
unwieldy models which are difficult to operationalise (Briggs et al, 2006).   
Simulation models, where patients pass through the stages of the model on an 
individual basis, are a possible solution to this limitation.  They allow the 
accumulating patient history to impact upon transition probabilities, costs and 
health outcomes (Briggs et al, 2006).  Simulation models may require more data, 
which are generally not available in development-focused HTA.  However, if a 
large dataset (of observational data, for example) were available, this could be 
developed into a generic decision model which could then be available to 
address a range of decision problems in the disease area as they emerge (Briggs 
et al, 2006). 
Conceptual models are a means of representing an understanding of the nature 
of the problem under consideration, the objective of a decision model and its 
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scope prior to the development of the decision model (Roberts et al, 2012).  
They generally precede a quantitative decision model although in theory the 
elucidation of the conceptual model, in itself, may be sufficient to inform a 
negative go/no go decision where there is no clear mechanism for the new 
technology to deliver incremental benefit or cost savings compared to the 
current standard of care. 
In economic evaluation for DF-HTA, simpler models may be preferred as they are 
easier to construct and are more transparent (Grutters et al, 2019).  For 
example, Craven and Morgan (2011) were able to develop a simple Markov model 
in two weeks.  Headroom and decision trees are easy to understand and thus 
good to aid communication between the analyst and non-expert.  Complex 
methods used in the early stages of development when there is uncertainty over 
the positioning of the technology and no clinical evidence may risk false 
precision (Grutters et al, 2019).  Simple models are not universally preferred.  
Annemans et al (2000) argued that it was more useful and efficient to produce a 
model of the same quality required at reimbursement stage earlier in 
development.  This ensured that the full complexity of the clinical and disease 
pathways were captured and identified all evidence gaps to aid evidence 
generation strategy.  This point of view is also taken by two recent studies 
setting out the experience of two of the Diagnostic Evidence Cooperatives, 
public-funded bodies in the UK, set up with aim of helping developers of 
diagnostic tests to generate evidence (Abel et al, 2019; Graziadio et al, 2020).  
Abel et al (2019) recommend the development of flexible models which can be 
updated iteratively as new clinical evidence becomes available.  The authors do 
recognise that such models are not necessarily faster, easier to implement or 
less complex than models developed at late stages of development so that 
resourcing is a challenge, particularly if more than one scenario needs to be 
modelled. 
11. Estimand 
NICE generally require the estimation of an incremental cost-effectiveness ratio 
(ICER) or Net Monetary Benefit (NMB) and budget impact where this is likely to 
be over £20 million per annum (NICE, 2020b). Broader considerations such as 
equity are considered in decision-making committees.  In many jurisdictions 
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cost-effectiveness is not considered as part of the choice of treatments and even 
in jurisdictions where it is considered, it is not used in all situations.  In 
economic evaluation for DF-HTA, both developers and decision-makers may be 
interested in wider considerations than those captured in an ICER.  
Considerations for developers include whether to continue to invest, where to 
position the new technology, how to price it, what the performance of the 
technology needs to be to justify a given price and what the most important 
drivers of cost-effectiveness may be to inform evidence generation strategies.  
Both developers and decision-makers may also be interested in implementation 
issues such as budget impact including timing of cash flows, how well the 
technology fits into the existing clinical pathways and workforce configurations.   
An ICER or NMB can be estimated in DF-HTA.  Grutters et al (2019) estimated an 
ICER when there was data for both costs and effects.  This is useful to 
developers as an indication that, on the basis of existing evidence, the 
technology would be considered cost-effective in a given jurisdiction and may be 
recommended or reimbursed in that jurisdiction.  All 30 technologies considered 
by Grutters et al (2019) could potentially have been cost-effective using the 
threshold willingness to pay in the Netherlands.  This led Love-Koh (2019) to 
comment that potential cost-effectiveness is a ‘low bar’ and not a very useful 
finding for developers.  However, Grutters et al (2019) make the point that their 
sample may be biased towards technologies with more potential as the 
developers have had the confidence to commission a health economic model.  
Two of the studies identified in the literature review had negative findings 
(Markiewicz, 2017b; Kluytmans et al, 2019) which would seem to indicate that 
health economic modelling can be useful to inform decisions about whether to 
continue to invest in the technology.  Negative findings in the indication, setting 
or position in a clinical pathway suggested by the developer may also help to 
inform decisions about where to position a technology.  For example, Kluytmans 
et al (2019) found that a surgical instrument believed to be of benefit in 
meniscus surgery would not add much value in that indication but there was 
potential in other surgical applications.   
Applied studies identified in the literature review estimated the ‘headroom’ of a 
technology in development (for example Chapman, 2013; Markiewicz et al, 2016; 
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Vilsboll et al, 2018).  Headroom indicates the maximum price which can be 
charged for a technology at given performance levels assuming the developer 
‘captures’ the full added value of the technology.  This can be useful to 
developers if the headroom is much lower than their price expectations they 
have the ability to reconsider the chosen market, change the design of the 
technology (for example, aiming to improve test performance) (Drummond, 
2019).  The price estimate may also be used as an input to a return on 
investment (ROI) calculation where the developer compares the likely 
discounted cash flows generated by the new technology to the future costs of 
development in order to estimate the likely profit arising (Singh, 2010; 
Markiewicz et al, 2016).  Threshold technology performance may be estimated if 
a price or set of prices are assumed (Grutters et al, 2019).  In diagnostics, for 
example, modelling a number of scenarios with the new technology used in 
different positions in the clinical pathway may help to identify the threshold 
sensitivity and specificity required for the new test to be considered cost-
effective in the given jurisdiction (Miquel-Cases et al, 2017).   
Although not a quantitative estimand, Grutters et al (2019) included aspects 
relating to the implementation of the technology to the developers who had 
commissioned the health economic modelling.  Lehoux and Silva (2019) suggest 
that ‘risks, competing upcoming innovations and logistical issues’ be more 
explicitly considered in order to reduce failure rates and inefficiency in research 
and development.  Although implementation and adoption may be considered 
beyond the scope of DF-HTA, the modelling process may make evident some 
barriers to or facilitators of adoption that are of interest to developers in making 
decisions during the development process.   
12. Methods of dealing with uncertainty 
The NICE TAP and DAP methods guides require different approaches to deal with 
the various sources of uncertainty inherent in economic evaluation.  For 
structural uncertainty and uncertainty around which data source to use, 
sensitivity analysis is recommended (NICE, 2013, 2020a). For parameter 
uncertainty, probabilistic sensitivity analysis (PSA) is recommended.  PSA deals 
with uncertainty in all parameters simultaneously compared to one-way 
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sensitivity analysis, which varies one parameter at a time whilst holding the 
other parameters constant.   
In addition to the three forms of uncertainty referred to above economic 
evaluation for DF-HTA may have a further source of uncertainty due to the wide 
decision space available to the developers.  Until the positioning of the 
technology is decided there may be many combinations of setting, indication and 
position in clinical pathway which require investigation.  Parameter uncertainty 
is also high in DF-HTA as there is often no clinical evidence specific to the 
technology and little information on how the technology may be priced.  
Grutters et al (2019) reported the use of deterministic models and one-way 
sensitivity analysis (OWSA) because they are simpler, less resource intensive and 
are easier for non-experts to understand.  Deterministic models are those which 
assume a single value for a parameter.  OWSA allows decision-makers to 
understand the impact of individual parameters on the results of the analysis, 
particularly when presented visually, for example using a tornado diagram.  
Grutters et al (2019) were sceptical of PSA as they felt it may give an impression 
of ‘pseudo-certainty’ when there is so little data.  The use of simpler models 
allows the exploration of multiple scenarios at a time when resources may be 
scarce.  Scenario building is an approach originating in management science 
(Retel et al, 2012). It is similar to sensitivity analysis in that input parameters 
are varied in order to determine the impact on outcomes of interest.  However, 
it involves the imagining of a number of potential future scenarios, for example, 
concerning the future diffusion of a health technology or its relative 
performance compared to current standard treatment.  The parameters are 
varied in accordance with the imagined scenario, resulting in a number of 
parameters being varied at one time. 
The approach described by Grutters et al (2019) and reflected in some of the 
studies identified in the literature review (for example, Craven et al, 2011; 
Hummel et al, 2012; Latimer et al, 2011) of simple deterministic models and 
OWSA has been criticised by some commentators (Love-Koh, 2019; Abel et al, 
2019; Federici and Torbica, 2020; Kim et al, 2020).  Love-Koh (2019) commented 
that the methods adopted ‘fall short of the methodological standard of 
probabilistic sensitivity analysis and value of information uniformly 
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recommended in the literature for early models’.  In support of this argument, 
he cites Annemans et al (2000) who argue for models alongside pharmaceutical 
development to include all the complexity of the final reimbursement focused 
model so that the model can be used throughout the life-cycle of the drug.  
Graziadio et al (2020) also support this line of argument claiming that it is more 
efficient to create a model which is sufficiently flexible to allow iterative 
updating as more information becomes available.  They do, however, recognise 
that this may be challenging due to restrictions on resource.  Vallejo-Torres et al 
(2008) suggest a two-stage process where at the earliest stage simple models 
and OWSA are used but when some clinical evidence is available a more complex 
model is built including PSA to allow value of information analysis.  As simple 
methods do not require much resource and many technologies will fail, this 
approach may be equally efficient to producing a complex, flexible model at an 
early stage. 
Strengths of cost-effectiveness analysis 
• Simple, deterministic models provide a low resource method to explore 
potential technology positioning across wide decision space.  Such models 
are useful as aids in communication, to guide developers about price and 
technology performance thresholds and to identify parameters likely to 
impact most on cost-effectiveness. 
• Once the positioning of the technology is more certain and there is some 
clinical evidence, more complex models, potentially incorporating 
probabilistic sensitivity analysis and value of information analysis, may be 
developed which would help inform evidence generation strategies.  Such 
a model could be updated on an iterative basis as more evidence became 
available and be used to support early engagement with a reimbursement 
agency, if that was relevant. 
Limitations of cost-effectiveness analysis 
• Cost-effectiveness analysis has been described as reductive (Grutters et 
al, 2019; Lehoux and Silva, 2019) in the sense that it only considers the 
cost and clinical effectiveness of a technology when other issues are of 
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importance to decision makers.  However, although the quantitative 
analysis may be reductive, the process of constructing the model may 
provide insights into aspects which may help or hinder the technology and 
these can be communicated qualitatively to the developers alongside the 
results of the cost-effectiveness analysis (Chapman, 2013; Grutters et al, 
2019).   
• More developed forms of cost-effectiveness analysis may be resource and 
expertise intensive and is competing for funds at a time when many 
developers do not have unlimited resource.  Cost-effectiveness analysis 
itself must deliver value for money for the developer.  This value could be 
in terms of improving the chances of success of the technology, perhaps 
by demonstrating the levels of test performance required in a given 
position.  The analysis may reduce overall development costs if 
technologies with little chance of success were identified at an early 
stage of development.  
5.3.3.8 Value of information analysis 
If probabilistic sensitivity analysis is undertaken alongside cost-effectiveness 
analysis the characterisation of parameter uncertainty can be used to provide 
estimates of the potential value of additional information from further research.  
Value of Information (VOI) analysis can be conducted from a commercial or a 
societal perspective.  When conducted from a societal perspective the analysis 
can be used to estimate the net impact on health benefit arising from an 
increase in the probability of selecting the optimal treatment resulting from 
further research reducing uncertainty.  Expected value of perfect information 
(EVPI) is the basic form of VOI and it values the resolution of uncertainty across 
all parameters simultaneously.  A development of EVPI is expected value of 
partial perfect information (EVPPI) which values reduction in uncertainty of 
individual or groups of parameters.  This is useful to identify the parameters 
which most influence the cost-effectiveness estimate so should be the focus of 
evidence generating activities.  Expected value of sample information (EVSI) 
values the reduction in uncertainty to be expected from a specific trial with a 
given sample size.  Expected net benefit of sampling (ENBS) is the difference 
between EVSI and the cost of the trial (Steuten et al, 2013).  Undertaken from a 
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commercial perspective, the value of the reduction in uncertainty can inform 
pricing decisions and allow developers to balance the cost of a future clinical 
trial to the improvement in prices which may be available if there is greater 
certainty of cost-effectiveness (Drummond, 2019).   
VOI uses the uncertainty estimates from PSA and may be difficult to 
operationalise and of questionable worth when there is limited data specific to a 
technology.  However, as the evidence base starts to develop, VOI may be useful 
to determine whether further research is worthwhile and if so, what the 
optimum design for a trial would be.  Vallejo-Torres et al (2011) illustrated how 
VOI can aid study design and investment decisions for commercial technology 
developers.  Both expected value of perfect information (EVPI) and expected 
value of perfect parameter information (EVPPI) were estimated in the study.  
VOI may be particularly useful in situations where a technology is approved with 
further research and research is being funded by a public payer.  For example, 
Miquel-Cases et al (2016b) used EVPI, EVSI and ENBS to inform decisions about 
the design of future studies and to prioritise research and Boyd (2012) used EVSI 
to determine appropriate sample sizes for future research studies. 
There is some overlap between VOI and both clinical trial simulation (CTS) and 
assurance calculations.  VOI builds on the output of cost effectiveness analysis to 
estimate the value of future research in terms of a reduction in uncertainty.  
CTS is a form of modelling and simulation used generally within pharmaceutical 
companies in order to model biological systems and the pharmacology of 
treatments acting on these systems (Holford et al, 2010).  Assurance calculations 
are an alternative to statistical power calculations (O’Hagan et al, 2005).  Both 
CTS and assurance calculations are techniques designed to inform the efficiency 
of clinical trials thus having a role in the research and development process.  
Neither method is concerned with the assessment of either clinical or cost 
effectiveness of a technology in development although both may use similar 
inputs and similar modelling techniques. 
5.4 Summary and contributions of this chapter 
This chapter set out a generic process for development-focused HTA (DF-HTA) 
comprising two linked activities, clinical and economic value assessment.  It 
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distinguished these assessment activities from the linked activities of research 
and development and other commercial activities.  Clinical and economic value 
assessment are both iterative and may be revisited a number of times during 
development.  As much technology development could be described as 
‘technology-driven’, assessment work in the earliest stages may involve 
‘positioning’ the technology.  At this point there may be no evidence specific to 
the technology available.  Many methods share the approach of testing the 
developers’ ideas about technology positioning with clinical experts who inform 
the analyst about the current clinical pathway and potential pathway if the new 
technology were adopted.  The methods vary in terms of how they interact with 
the clinical experts and how they present their results.  Qualitative methods of 
user interaction and headroom appear to be particularly appropriate at this 
earliest stage.  Kluytmans et al (2019) provides a good example of the approach.  
This assessment in the earliest stage can confirm the potential (or otherwise) of 
the technology in the particular position, provide insights about potential 
barriers or facilitators to implementation and guidance on attributes of the 
technology which require modification in order to increase chances of success.  
The earliest stage of assessment can assist the developers to articulate the value 
proposition for the technology.  As the development progresses, the positioning 
of the technology may be more certain and there may be some clinical evidence 
specific to the technology.  At this point, developers and investors may be more 
confident of the potential of the technology and more willing to invest in more 
formal analyses.  It may be appropriate at this stage to develop a cost-
effectiveness model.  Although there is some debate about whether simple or 
complex methods are appropriate, more formal methods of expert elicitation to 
populate the model are an option and these would allow the inclusion of 
probability distributions to enable probabilistic sensitivity analysis and value of 
information analysis.  This form of model may form the basis of early dialogue 
with a reimbursement agency and/or a discussion around managed entry or risk 
sharing.  Alternatively, if cost-effectiveness analysis is considered reductive, a 
formal multi-criteria decision analysis may provide evidence of the potential of 
the technology. 
This chapter has two main contributions.  Firstly, it presents a generic process 
for DF-HTA as a second element of a framework of DF-HTA.  The generic process 
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builds upon the work of the MATCH UK collaboration and Professor Ijzerman’s 
group including work undertaken at CTMM.  Of relevance was the work of Cosh 
et al (2007), Davey et al (2011), Markiewicz et al (2014) and Rogowski et al 
(2016).  The generic process comprises core assessments of clinical value and 
economic value which are linked to the parallel activities of business case 
development and research and development.  The second contribution builds 
upon the work of Markiewicz et al (2014) to identify HTA methods used in each 
of these activity groups and to explain their appropriateness with reference to 
the features of development-focused HTA identified in chapter 4.  This simplifies 
the existing literature where business case development and research and 
development were not clearly distinguished from assessment activities and 
methods of each had become conflated.  It also distinguishes the earliest stages 
of assessment when less formal methods may be appropriate to confirm the 
positioning of the technology and later stages when more formal methods could 
be of use.  This simplification and clarification is consistent with the recent 
addition to the literature from Graziadio et al (2020) and may be of assistance as 
a point of reference to analysts undertaking development-focused HTA.    
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6 Approach to case studies in development-
focused HTA  
6.1 Introduction 
Chapter 6 provides a link between the methodological parts of the thesis and the 
empirical sections.  It addresses research question 4: 
4. To what extent do the case studies demonstrate the suggested features, 
process and methods of HTA to inform developers of health technologies? 
Chapters 4 and 5 set out a framework of features, process and methods of 
development-focused HTA.  After briefly introducing the case studies, this 
chapter draws on the outputs of the previous chapters and applies them to the 
case studies.  First, the case studies are used to illustrate the list of features 
developed in Chapter 4 then activities and methods for the case studies are 
selected from those set out in Chapter 5. 
The initial concept for this thesis was to undertake a prioritisation exercise in 
the context of the project base of Glasgow Molecular Pathology Node.  For 
practical reasons this was not possible and the case studies eventually formed a 
convenience sample sourced partly from the GMP Node.  Three case studies, all 
concerned with tests predicting treatment response were node projects (Case 
studies 2 and 3) or suggested by node participants (Case study 1).  A further two 
case studies (4 and 5) were sourced through personal contacts and selected as 
they were useful illustrations of methods of development-focused HTA.  A 
summary of the case studies is provided in Table 6-1.  For the purposes of this 
thesis acute means ‘severe and sudden in onset’ and chronic means a condition 




Table 6-1: Summary of case studies included in thesis 
Case study 
number 
1 2 3 4 5 
Chapter 7 8 9 10 11 









Acute Chronic Acute Acute Acute 
Technology type 






















(see Figure 2-2) 





In clinical use Targeting 
imaging 
modality 















GMP – Glasgow Molecular Pathology  
6.2 Illustration of features of DF-HTA 
6.2.1 Introduction 
Table 4-1 set out a list of ten features of DF-HTA and Table 4-2 set out questions 
which the analyst may wish to discuss with developers prior to undertaking an 
assessment.  In this section, the features of each of the case studies are 
assessed against the features in the table in order to illustrate this element of 
the framework of DF-HTA.  The questions are considered in relation to each case 
study. As the case studies were completed before the questions were answered, 
this exercise is less valuable than it may have been but may provide some insight 
into the usefulness of the questions. This section includes a table setting out the 
features of each case study.  Section 6.2.2 to Section 6.2.7 discuss both the 
features and responses to questions for each case study in turn.  Section 6.2.8 
concludes on the extent to which the case studies demonstrate the features of 






Table 6-2: Comparison of features of case studies with features of DF-HTA 
Feature of 
development-
focused HTA  
Feature of Development-focused HTA Case study 1 
Test to predict 
response to 
treatment in ovarian 
cancer 
Case study 2 




Case study 3 
Extension of 
molecular testing in 
colorectal cancer 
Case study 4 
Diagnostic test in 
malignant 
melanoma 
Case study 5 
Diagnostic test in 
prostate cancer 
Target audience of  Technology developers (both academic 
and commercial) Investors (both 
commercial and public sector) 
Academic and clinical 
development team 
Public funders 















Maximise long-term financial return on 
investment (if commercial) or societal 
return on investment, health or other 
goal (if public funder or non-commercial) 
Maximise health Maximise financial 
and societal return 
on investment  
Maximise health  Maximise financial 
return on investment  
Maximise health  
Decisions HTA 
designed to inform 
Broad range including:  
• Pre-clinical/preliminary market 
assessments 
• First estimations of 
pricing/reimbursement scenarios 
• Go/no go decisions 
• Technology design 
• Trial design/evidence generation 
strategy 
• Research prioritisation 
 




Go/no go decision  
Value proposition 




Whether to extend 
testing 
Evidence required 
Go/no go decision 
Value proposition 
















• User groups 
• Thresholds (test cut-off) 
• Levels of test performance 
• Positions in pathway 
Multiple: 
jurisdictions 






position in pathway 
Multiple: 
jurisdictions 













positions in pathway  


















Available evidence Clinical studies tend to be small such 
that uncertainty is high 
Evidence specific to technology scarce 
early in the development process. 
Alternative methods of estimating 
parameters include: 
• Expert opinion 
• Evidence on comparators or 
previous generations of a 
technology 
• Bench or animal studies 
• Output from pharmacodynamic 
models 
Evidence required about usability and 
clinical pathways 
 
No evidence specific 
to technology. 
Evidence from single 
retrospective study 
Evidence base 
limited, specific to 
context 
Evidence base 
limited, specific to 




limited, specific to 






Repeated on an iterative basis 
Pre and during development 
Pre-development.  
The test is 
hypothetical. 
During development.  
Prototype existed 
and was undergoing 
analytical validity 
testing.  
Molecular tests are 
established 
laboratory tests.  
New technology is 
hypothetical 
pathway with more 
extensive testing. 
During development.  
Prototype exists – 
undergoing trials in a 
number of contexts.   
Test is commercially 




incorporating test.   
   
Business model Fluid -not yet defined 
Various business models available 
including reimbursement-based models, 
direct marketing to patients, clinicians or 
health-care organisations 
 
Not considered as 





may impact upon 
diffusion and use of 
technology 
Extension to testing 
would be funded out 





may impact upon 
diffusion and use of 
technology 
Likely fee per test – 




Often constrained at early stages due to 
conflicting demands on resources 
Less resource-intensive methods to 
establish and begin to quantify value 
proposition 
Constrained.  12-





context of GMP 
Node 














Stance of analysis Positive 
Which jurisdiction, position in 
pathway maximises return for 
developers? 
 
Positive Positive Normative Positive Normative 
Burden of proof Evidence credible to the development 
team 
 








Evidence credible to 
audience and the 
development team 
 
Evidence needs to be 
credible to the 
development team 
Evidence needs to be 
credible to the 
decision-maker 
BRAF – B-Raf Proto-Oncogene, CRC – colorectal cancer, GMP – Glasgow Molecular Pathology, HTA – Health Technology Assessment, KRAS – Kirsten Rat 






6.2.2 Case study 1 - Test to predict response to treatment in 
ovarian cancer 
The empirical example which motivated this case study was a question from a 
clinician about whether a test to predict response to hormone treatment could 
be clinically/cost effective.  It is interesting as it is an example of an analysis 
undertaken at concept stage (i.e. no research work had been undertaken) and 
because it is needs-driven rather than technology-driven.  As ovarian cancer is 
an acute condition with poor prognosis, treatment is generally aggressive.  A 
test to predict response to hormone treatment could spare some patients the 
burden of additional chemotherapy.  The implications of a wrong test result are 
serious as a patient may be denied the opportunity of an effective treatment.  
The case study demonstrates that a simple model with limited inputs can be 
used to determine that investment in developing a test is not likely to be 
worthwhile. 
6.2.2.1 Features of DF-HTA 
This case study exhibits all the features of DF-HTA.  The audience was an 
academic clinician who potentially may have started to develop the technology. 
The underlying objective was to maximise health.  In this case the decision to be 
informed was whether to invest researcher resource in initiating a project and 
seeking funding.  Technology design considerations, particularly the required 
sensitivity and specificity of a potential test in order to clinical value, were also 
of interest.  Timing, resources, stance of analysis and burden of proof were all 
typical of DF-HTA.  Business model was not relevant at this stage as the 
assessment only explored potential clinical value.  Decision space was more 
limited than in many DF-HTA assessments as the development was needs-driven 
rather than technology-driven, so indication and position in the pathway were 




6.2.2.2 Questions for consideration in DF-HTA 
Table 6-3: Questions for consideration – case study 1 
Feature of DF-HTA  Questions for consideration 
Target audience  Who is the analysis designed to inform? 
An academic clinician considering the research portfolio of his department 
at the University of Glasgow raised a number of possibilities where a test 
to predict treatment response may meet a clinical need.  One of these 
possibilities was a test to predict response to hormone treatment.  
 
Underlying user objective  What are the developers ultimately trying to achieve through investment 
in development of a technology? 
On what basis will the developers decide whether and how it is worth 
continuing with the development of this technology? 
The developers were trying to meet clinical need.   
No research had been undertaken but if the analysis showed that a test had 
potential then this may have encouraged the team to seek funds and pursue 
this line of research.  It is unclear what would constitute potential. 
 
Decisions HTA designed to 
inform   
What decisions can the analysis inform? 
Whether to pursue the research project. 
Decision space  What are the possible uses of the technology? 
What are the most promising uses of the technology? 
Which of the potential use(s) should be targeted first? 
These questions are appropriate in a technology-driven assessment.  In a 
needs-driven assessment the use is determined by the need. 
 
Available evidence  What evidence is available? 
What is the best approach to estimating parameters in the absence of 
evidence? 
No evidence specific to the technology is available. 
A rapid literature review can be used to identify appropriate estimates for 
the response rates to the treatments and this can be confirmed with a 




What is the most appropriate form of analysis (if any) to do now? 
As patients and clinicians would be most interested in whether a test would 
be likely to improve response rates, a simple model to explore this 
question is appropriate. 
 
Business model  
  
What alternative business models are possible for this technology in 
target jurisdictions/indications?  
Not relevant to this analysis. 
Resources for analysis  
  
What resources are available for analysis? 
What would be the most appropriate use of the resources? 
No specific resources were available for this analysis so a simple model 
using limited evidence sources was appropriate. 
Stance of analysis  How does the analyst ensure the study meets the needs of the 
developers? 
The analysis was presented back to a clinical expert. 
Burden of proof  Are the methods and sources of parameter estimates appropriate for 
this level of resources and this stage of development? 
Has the analyst communicated any limitations of the approach with 
the developers? 
The validity of the conclusion was highly dependent on the 
appropriateness of the single source of response rates to hormone 
treatment and chemotherapy.  This was communicated back to the clinical 





6.2.2.3 Does case study 1 demonstrate the features of DF-HTA? 
This case study demonstrates all the features of DF-HTA.  As the case study is 
needs-driven (i.e. the question was ‘would it be worth developing a technology 
in this particular indication and position in the pathway?’) decision space is 
somewhat narrower than would be envisaged in technology-driven analysis as the 
positioning of the technology is not being explored. 
6.2.3 Case study 2 - Test to predict response to treatment in 
rheumatoid arthritis 
The empirical example which motivated this case study was a research project 
at preclinical stage supported by the Glasgow Molecular Pathology Node.  The 
technology in development was a test predicting response to two biologic 
treatments in rheumatoid arthritis using an algorithm.  Unfortunately, the 
algorithm was not validated in the subsequent round of testing but the case 
study remains of interest from an academic perspective.  Rheumatoid arthritis 
is a chronic condition so clinicians have more opportunity to vary treatment in 
order to find a therapy which works for each patient.  Compared to an acute 
condition this may make a test less valuable as the consequences of treating 
with the wrong therapeutic are less severe.  As the results of a small 
retrospective study were available, this case study provided the option to 
undertake analyses at two points in time to illustrate the iterative nature of 
DF-HTA.  The case study found that continued investment was justified in the 
early-stage analysis but that cost-effectiveness in the mid-stage analysis was 
particularly sensitive to the relative price of the test, treatment and 
comparator.  This illustrates the difficulties of developing a cost-effective test 
in a fast-moving therapeutic and competitive environment.    
6.2.3.1 Features of DF-HTA 
This case study also exhibits many features typical of DF-HTA (see Table 4-1).  
Again, the audience was an academic clinician and the underlying objective was 
to maximise health.  The decision to be informed was whether to invest resource 
in the project and seek funding.  In this case study, both clinical and economic 
value were important and decisions to be informed involved the positioning of 
the technology and the level of test performance necessary to deliver value.  
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The timing of this assessment was just following the retrospective analysis of a 
clinical trial which provided evidence of the test performance of the technology.  
In order to mimic the iterative approach to DF-HTA, a retrospective clinical 
value assessment was undertaken to demonstrate that it could be shown that 
the test had potential to increase response rates even before the retrospective 
analysis of the clinical trial was undertaken.  Burden of proof and stance of 
analysis were both typical of DF-HTA.  In this case study, the reimbursement 
business model was used as the method of analysis was cost-utility analysis 
assuming UK thresholds but sale to private payers was considered in the 
discussion.  The decision space included multiple comparators, tests could be 
arranged in different orders in the clinical pathway and there were a variety of 
test outcomes which were possible.  As the project was supported by the 
Glasgow Molecular Pathology Node, it would have been possible to develop a 
more complex health economic model including probabilistic sensitivity analysis 
and value of information analysis.  It is, however, unclear how useful this would 




6.2.4 Questions for consideration in DF-HTA 
Table 6-4: Questions for consideration – case study 2 
Feature of DF-HTA  Questions for consideration 
Target audience  Who is the analysis designed to inform? 
A team of academics and clinicians with a technology in development 
supported by Glasgow Molecular Pathology Node.  
Underlying user objective  What are the developers ultimately trying to achieve through investment 
in development of a technology? 
On what basis will the developers decide whether and how it is worth 
continuing with the development of this technology? 
The developers were trying to meet clinical need but recognised that 
commercial involvement would be necessary to bring the test to market.  
Funding had been found to complete analytic validity testing and further 
funding was being sought to fund initial clinical studies.   
Decisions HTA designed to 
inform   
What decisions can the analysis inform? 
Whether to continue to invest.  Design of the technology in terms of 
required sensitivity and specificity.  Evidence required to support value 
proposition such as patient and physician preferences for test outcome and 
likely prescribing behaviour given test results. 
Decision space  What are the possible uses of the technology? 
What are the most promising uses of the technology? 
Which of the potential use(s) should be targeted first? 
The technology comprised three tests which could be used at different 
points in the clinical pathway and in different chronological order in 
different populations.  Rather than model all the alternatives the scenario 
with the most direct clinical relevance in the UK was assessed. 
Available evidence  What evidence is available? 
What is the best approach to estimating parameters in the absence of 
evidence? 
A retrospective analysis of a clinical trial was available to allow the 
performance of the test to be estimated. 
Guidelines and an HTA report were used to provide evidence about 




What is the most appropriate form of analysis (if any) to do now? 
As some clinical data was available a cost-utility analysis could be done.  
A retrospective analysis was also done following the simple modelling of 
clinical value as in case study one.  The developer was also encouraged to 
consult stakeholders (clinicians and patients) about essential design 
elements of the technology (which level of response it was better to 
predict, whether a prediction of response to either TNFi inhibitors or 
rituximab or both was more useful).   
 
Business model  
  
What alternative business models are possible for this technology in 
target jurisdictions/indications?  
A cost-utility analysis was undertaken to explore potential cost-
effectiveness assuming a reimbursement model with UK thresholds.  
Discussion included the potential of a private payer model. 
 
Resources for analysis  
  
What resources are available for analysis? 
What would be the most appropriate use of the resources? 
No specific resources were available, but analysis was possible as this was 
a Glasgow Molecular Pathology Node project.  A more complex 
modelling approach could have been adopted (confidence intervals were 
available for the estimates from the small clinical trial so PSA and VOI 
could have been undertaken) but it is unclear whether this would have 




Feature of DF-HTA  Questions for consideration 
Stance of analysis  How does the analyst ensure the study meets the needs of the 
developers? 
The analysis was presented back to the developers.   
Burden of proof  Are the methods and sources of parameter estimates appropriate for 
this level of resources and this stage of development? 
Has the analyst communicated any limitations of the approach with 
the developers? 
It was appropriate to use the results of the small clinical study to produce a 
cost-utility analysis.  Developers were aware of the limitations of the 
approach, in particular that all the options for ordering of tests were 
explored.  Other outcomes could not be explored as the data was not 
available but the bioinformatician was advised about the different analyses 
which would be useful and the developer advised to undertake stakeholder 
consultation to narrow down the preferred option.   
 
 
6.2.4.1 Does case study 2 demonstrate the features of DF-HTA? 
The features of this study conform to the features of DF-HTA set out in Table 
4-1.  Two points of interest are: the impact on decision space of whether the 
assessment started with the clinical need or with the technology; and the 
difficulty in determining whether the burden of proof is met. 
This study could be seen as hybrid needs-driven and technology-driven in the 
sense that the initial research was based on a need to identify responders to 
biologic drugs in rheumatoid arthritis but as the technology was in development 
it was clear that there were many options to position it in the clinical pathway.  
This has implications for decision space.  Here, the decision space is wider than 
study one, which was completely needs based but not as wide as the melanoma 
case study, where the technology in development could be used in multiple 
indications.   
The difficulty in determining whether the burden of proof is met derives from 
the fact that developers may not know what they want from the DF-HTA.  In this 
case study, the findings were reported back to the developers who concurred 
with the findings.  Most importantly, the developers accepted the need to 
engage stakeholders to assist with the design and positioning of the potential 
test.  The questions accompanying the framework may be of particular use in 




6.2.5 Case study 3 - Extension of molecular testing in colorectal 
cancer 
In contrast to the previous two case studies, this example looked at a 
technology which was well established in clinical practice – testing for 
KRAS/NRAS and BRAF testing prior to the use of cetuximab for patients with 
metastatic colorectal cancer.  The clinicians’ question concerned whether it 
would be cost-effective to extend the use of the existing companion diagnostic 
to a broader population earlier in the diagnostic pathway.  The case study is 
interesting as an illustration of the importance of the positioning of a 
diagnostic test in the existing clinical pathway to its cost-effectiveness.  It 
demonstrated that, as a result of the downstream consequences of delayed 
molecular testing, the extension of molecular testing to all patients diagnosed 
with colorectal cancer would be likely to be cost-effective in this local context.  
The use of an expert steering group to provide inputs to the modelling, advise 
on the existing and the adapted clinical pathway and validate the models is also 
of interest as a pragmatic approach for local evaluations where evidence and 
resources may be limited. 
6.2.5.1 Features of DF-HTA 
As the technology is not in development it would be expected that this case 
study would not exhibit features typical of DF-HTA (see Table 4-1).  Most 
features differed from those typical of DF-HTA.  The audience was the decision-
making body for molecular testing within NHS Scotland, the Molecular Pathology 
Evaluation Panel (MPEP).  The underlying objective was to maximise health.  The 
decisions to be informed were whether the extension to molecular testing was 
likely to be cost effective in the local context so whether the clinical team 
should continue to pursue the change in pathway and if they did what additional 
evidence may be required.  The decision space was limited as in an adoption 
decision, with indication, position in pathway and test performance known.  The 
clinicians sought to change the position in the pathway of an existing 
technology, so the timing was partway through the lifecycle of the technology.  
The stance of analysis was normative in that it was the cost-effectiveness 
thresholds set by the UK NHS which were the target.  The reimbursement 
business model was used as the method of analysis was cost-utility analysis 
135 
 
assuming UK thresholds.  In a number of respects, however, the features of this 
case study did resemble DF-HTA.  The burden of proof was not equivalent to a 
NICE process as this decision was being made by MPEP and they have no specific 
methodological guidance for health economic analysis.  Evidence was limited so 
simple modelling was undertaken with parameter estimates informed by an 
expert panel.  Finally, resources were constrained as the project had no specific 
funding.  It was supported through the Glasgow Molecular Pathology Node so 
that more complex modelling could have been undertaken but as with the 
previous case study, it is unclear whether a more complex approach would have 
provided any more value for either the clinicians looking to redevelop the 
pathway or MPEP as decision-makers. 
6.2.5.2 Questions for consideration in DF-HTA 
Table 6-5: Questions for consideration – case study 3 
Feature of DF-HTA  Questions for consideration 
Target audience  Who is the analysis designed to inform? 
The clinicians developing the pathway and the Molecular Pathology 
Evaluation Panel.  
Underlying user objective  What are the developers ultimately trying to achieve through investment 
in development of a technology? 
On what basis will the developers decide whether and how it is worth 
continuing with the development of this technology? 
The clinicians developing the pathway were trying to achieve an 
improvement in health outcomes and patient/clinician satisfaction with the 
pathway.  The ultimate decision-makers on the extension of testing also 
seek to maximise health but the testing budget is constrained and the 
impact on cost of the change in pathway is an important factor in their 
decision-making.  
Decisions HTA designed to 
inform   
What decisions can the analysis inform? 
The demonstration of the economic impact of the proposed change in the 
testing pathway informed the clinicians’ decisions about whether to 
continue to push for the change and what additional evidence may be 
necessary to evidence the impact.  
Decision space  What are the possible uses of the technology? 
What are the most promising uses of the technology? 
Which of the potential use(s) should be targeted first? 
The decision space in this case study was narrow as the indication and 
position in pathway for this technology was constrained by the aim of the 
study. 
Available evidence  What evidence is available? 
What is the best approach to estimating parameters in the absence of 
evidence? 
Local evidence was required.  Evidence was taken from national sources 
and local clinical audit.  Where required estimates for parameters were 




Feature of DF-HTA  Questions for consideration 
Timing  
  
What is the most appropriate form of analysis (if any) to do now? 
The most appropriate form of analysis was a cost-minimisation analysis.  It 
was important for the ultimate decision makers that this extension in 
testing should save costs overall and there was no likelihood of health 
outcomes being adversely affected by testing being extended to all patients 
with colorectal cancer rather than only those with metastatic disease. 
Business model  
  
What alternative business models are possible for this technology in 
target jurisdictions/indications?  
A reimbursement business model was appropriate as the setting was the 
NHS in Scotland. 
Resources for analysis  
  
What resources are available for analysis? 
What would be the most appropriate use of the resources? 
No specific resources were available, but analysis was possible as this was 
a Glasgow Molecular Pathology Node project.  A more complex 
modelling approach could have been adopted (but uncertainty would have 
had to be estimated through expert elicitation for many of the parameters). 
It is unclear whether a more complex modelling approach would have 
been more useful to developers. 
 
Stance of analysis  How does the analyst ensure the study meets the needs of the 
developers? 
The analysis was presented back to the developers and to MPEP, the 
ultimate decision makers.  The approach to modelling and evidence 
sources used appeared sufficient for the decision-maker.  However, 
circumstances around molecular testing for colorectal cancer changed as 
micro satellite instability testing was required earlier for some diagnosed 
patients so additional modelling would have been required before a 
definitive decision could be made.     
Burden of proof  Are the methods and sources of parameter estimates appropriate for 
this level of resources and this stage of development? 
Has the analyst communicated any limitations of the approach with 
the developers? 
The approach to modelling and evidence sources used appeared sufficient 
for the decision-maker.  However, circumstances around molecular testing 
for colorectal cancer changed as micro satellite instability testing was 
required for all diagnosed patients so additional modelling would have 
been required before a definitive decision could be made.   
 
 
6.2.5.3 Does case study 3 demonstrate the features of DF-HTA? 
This case study does not exhibit most of the features of DF-HTA identified in 
Table 4-1.  The ultimate audience for the assessment was a public payer and the 
main decision to be informed was whether to extend the testing given the 
estimated economic impact.  The decision space was narrow as the indication, 
jurisdiction and position in pathway were all fixed.  The timing of the 
assessment was when the technology was well established in clinical use.  The 
stance of analysis was normative, as the technology was assessed according to 
the decision-maker’s criteria.  This contrasts with the exploratory positive 
stance taken in DF-HTA when the analysis seeks the most beneficial positioning 
and design for the technology. 
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Initially, the justification for including this case study and the Prostate Health 
Index case study was that the clinicians were effectively developing a new 
pathway including an established technology.  Whilst this is undoubtably true, it 
is clear that this kind of HTA is different in most features from what has been 
termed DF-HTA.  The similarities between DF-HTA and this case study are that 
resources were somewhat limited and that evidence was lacking and needed to 
be supplemented with input from an expert panel.  These similarities were 
driven by the context-specific nature of the assessment, as although evidence 
was available on a national basis, it was the local pathway information which 
needed to be supplemented with clinical audit or expert input.  This difficulty in 
establishing relevant clinical pathways is discussed by Abel et al (2019) in 
connection with diagnostic technologies assessed by the DECs.  Resource 
limitation is also typical of local assessment as dedicated support is not available 
as it may be in a national assessment programme. 
Burden of proof is, again, a difficult feature to judge for this assessment.  MPEP 
have no reference case and applications for funding are generally not supported 
by a formal health economic analysis.  It is unclear what evidence the panel 
base their decisions on.  The panel accepted the evidence as presented but it 
did not lead immediately to a change of practice as an additional test was being 
assessed which impacted upon this clinical pathway.  A full scoping of the 
decision problem may have highlighted this additional test at an earlier stage, 
and it could have been incorporated into the analysis. 
6.2.6 Case study 4 - Diagnostic test in malignant melanoma 
Rather than looking at tests to predict treatment response as in the previous 
three case studies, this case study looks at an imaging test for the diagnosis of 
malignant melanoma.  There was a prototype of the technology in existence and 
the developers had completed one clinical study but had not finalised 
placement in the clinical pathway.  This case study concerns an acute condition 
which is the subject of government targets in that all patients with suspected 
skin cancer should be seen within two weeks.  This creates capacity constraints 
in the clinical pathway.  The case study found that costs could be saved by 
introducing a test to triage between referral for a suspicious mole and 
specialise dermatologist review.  These cost savings were limited as only the 
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cost of a consultation was saved.  The test needed to be highly sensitive as it 
was ruling out melanoma (Baeyens et al, 2019).  Of more interest, if capacity 
constraint of specialist dermatologists was built into the model, the triage test 
is able to ‘enrich’ the population (i.e. increase the prevalence of malignant 
melanoma in the population referred to the specialist dermatologist) so that 
more cases are diagnosed overall. 
6.2.6.1 Features of DF-HTA 
This case study exhibits many features typical of DF-HTA (see Table 4-1).  The 
audience is an SME commercial developer with this single technology in 
development.  The underlying objective was to maximise financial return on 
investment.  The decisions to be informed were whether it was worthwhile to 
continue to invest resource in the project given an optimal position in the 
clinical pathway, how the technology should be designed to maximise potential 
in this position, the evidence required to demonstrate value and which business 
model had the most potential.  The timing of this assessment was just following 
a small clinical trial which provided evidence of the test performance of the 
technology.  Burden of proof and stance of analysis were both typical of DF-HTA.  
In this case study, the threshold from the UK reimbursement business model was 
used as headroom calculations were undertaken.  Sale to private payers was 
considered in the discussion.  The decision space included multiple comparators 
depending on the position in the clinical pathway and the setting.  The 
developers were prepared to provide more resource for analysis, so it would 
have been possible to develop a more complex health economic model including 
probabilistic sensitivity analysis and value of information analysis.  However, 
given the uncertainty around positioning of the technology in the clinical 




6.2.6.2 Questions for consideration in DF-HTA 
Table 6-6: Questions for consideration – case study 4 
Feature of DF-HTA  Questions for consideration 
Target audience  Who is the analysis designed to inform? 
An SME commercial developer and investors.  
Underlying user objective  What are the developers ultimately trying to achieve through investment 
in development of a technology? 
On what basis will the developers decide whether and how it is worth 
continuing with the development of this technology? 
The developers were trying to bring the product to market and maximise 
financial return on investment.  Private investment had funded 
development and clinical testing to date, but further funding was required 
for ongoing development and further clinical testing.   
 
Decisions HTA designed to 
inform   
What decisions can the analysis inform? 
Whether to continue to invest.  Value proposition for the technology. 
Positioning of technology.  Design of the technology in terms of required 
sensitivity and specificity.  Evidence required to support value proposition. 
Decision space  What are the possible uses of the technology? 
What are the most promising uses of the technology? 
Which of the potential use(s) should be targeted first? 
The technology could be used in different settings and the cut-off levels 
could be set to detect different levels of skin abnormality.  At its most 
restrictive it would detect only malignant melanoma but there was also 
scope to detect other skin cancers and abnormalities.   
Available evidence  What evidence is available? 
What is the best approach to estimating parameters in the absence of 
evidence? 
A small clinical trial was available to provide estimates of test 
performance.  Guidelines and other literature sources provided information 
about clinical pathways.  Publicly available data was used to estimate 




What is the most appropriate form of analysis (if any) to do now? 
As positioning was uncertain, it was not appropriate to develop a detailed 
model.  Rather, a simple model which could demonstrate the costs and 
consequences of using the technology in different settings was developed.  
The developer was also encouraged to consult and potentially collaborate 
with a wide range of stakeholders (clinicians and commissioners) about 
essential design elements of the technology (which settings would be the 
most appropriate and what functionality would be required in those 
settings).   
 
Business model  
  
What alternative business models are possible for this technology in 
target jurisdictions/indications?  
A cost-consequence model assumed a UK setting.  Discussion included the 
potential of other models. 
 
Resources for analysis  
  
What resources are available for analysis? 
What would be the most appropriate use of the resources? 
No resource was provided but developers would have paid for a more 
extensive analysis.  The value of more complex health economic 
modelling was unclear given the stage of development.  More extensive 
stakeholder consultation and collaboration would likely have been a better 
investment of constrained development resources.  
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Feature of DF-HTA  Questions for consideration 
Stance of analysis  How does the analyst ensure the study meets the needs of the 
developers? 
The analysis was presented back to the developers.  They did not feel the 
analysis met their needs.  They were hoping for a more detailed analysis of 
the relevant epidemiology.  However, the granular level of 
epidemiological data which they required is not publicly available.  Hence, 
the recommendation to collaborate closely with a range of healthcare 
providers in developing context-specific value propositions.   
Burden of proof  Are the methods and sources of parameter estimates appropriate for 
this level of resources and this stage of development? 
Has the analyst communicated any limitations of the approach with 
the developers? 
It was appropriate to undertake a simple modelling study to link the costs 
avoided later in the clinical pathway to the cost and performance of the 
test.  A significant component of the value proposition for the technology 
in the UK is that it protects some specialist dermatologist capacity, which 
is constrained.  This aspect was built into the modelling to illustrate that 
even a test with relatively low performance can improve case detection by 
enriching the prevalence in the population accessing the specialist 
dermatologist.   
 
6.2.6.3 Does case study 4 demonstrate the features of DF-HTA? 
The features of this study align with all the features of DF-HTA identified in 
Table 4-1.  As the assessment was technology-driven positioning of the 
technology was important and decision space was wide.  Stance of analysis is of 
interest as it is difficult to determine whether this assessment met the needs of 
the developers.  The case studies were completed before the questions set out 
in Table 4-2 were drafted.  On completion of the assessment it became clear 
that the analysis did not meet the developers’ expectations even if it may have 
met their needs.  The developers’ expectation was that the study would produce 
a full cost-effectiveness analysis using detailed data on incidence and clinical 
pathways.  However, at the current stage of development, positioning was still 
sufficiently uncertain that such a model would have been of questionable value.  
At this stage, more focus on developing value propositions in collaboration with 
a range of stakeholders in a variety of settings was of more value to the 
developers.  There is evidence in the literature of developers’ expectations or 
actions not being aligned with analysts’ conclusions (Miquel-Cases, 2016a, 
Markiewicz, 2017b) thus highlighting the need for all parties to be clear about 
the purpose of the assessment and the appropriateness of different approaches 
at different points in the analysis.  Use of the questions in Table 4-2 may have 
made this misunderstanding explicit. 
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6.2.7 Case study 5 - Diagnostic test in prostate cancer 
The final case study looks at a second diagnostic test, this time in prostate 
cancer.  The technology was on the market and a number of clinical studies had 
been completed.  Again, this case study concerned an acute condition where the 
consequences of missing clinically significant cases could be severe.  The current 
diagnostic pathway had room for improvement as the Prostate Specific Antigen 
(PSA) blood test identified a large number of false positives so patients then 
underwent prostate biopsy, an invasive and expensive procedure.  The study 
quantified the cost savings and consequences ensuing from the introduction of 
Prostate Health Index (PHI) as a triage test after PSA before biopsy at different 
thresholds of sensitivity and specificity.  The case study showed that biopsy and 
its attendant complications are sufficiently costly that the introduction of a 
triage test which avoids some biopsies has the potential to be cost effective.  A 
high sensitivity test is required to rule out clinically significant disease, but it is 
specificity which drives cost savings through avoided biopsies.   
6.2.7.1 Features of DF-HTA 
As the technology was available on the commercial market, it would be 
expected that this case study would not exhibit features typical of DF-HTA (see 
Table 4-1).  Most features differed from those typical of DF-HTA.  The audience 
was the clinicians developing the potential care pathway as well as the ultimate 
decision-making body for Hong Kong.  The underlying objective was to maximise 
health.  The decision to be informed was whether the inclusion of PHI in the 
diagnostic pathway was likely to be cost effective in the local context.  The 
decision space was limited as in an adoption decision, with indication and 
position in pathway known.  The study explored the optimum thresholds for 
sensitivity and specificity to adopt using cost-consequence analysis.  The stance 
of analysis was normative in the sense that the criteria for adoption would be 
externally determined by the decision-making authority.  The reimbursement 
business model was assumed with costs and care pathways appropriate to the 
Hong Kong healthcare authority.  In a number of respects the features of this 
case study did resemble DF-HTA.  In terms of burden of proof, no specific 
methodological guidance for health economic analysis was available or followed.  
Evidence was limited to a single clinical study and deterministic modelling was 
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undertaken.  Finally, resources were constrained as the project had no specific 
funding. 
6.2.7.2 Questions for consideration in DF-HTA 
Table 6-7: Questions for consideration – case study 5 
Feature of DF-HTA  Questions for consideration 
Target audience  Who is the analysis designed to inform? 
The clinicians developing the pathway and Hong Kong Hospital Authority. 
Underlying user objective  What are the developers ultimately trying to achieve through investment 
in development of a technology? 
On what basis will the developers decide whether and how it is worth 
continuing with the development of this technology? 
The clinicians developing the pathway and the ultimate decision makers 
were trying to achieve an improvement in health outcomes and reduction 
in costs.  If similar health benefits could be achieved with the potential for 
reduced costs it would be worth continuing with the development of the 
technology. 
Decisions HTA designed to 
inform   
What decisions can the analysis inform? 
The demonstration of the economic impact of the proposed change in the 
testing pathway informed the clinicians’ decisions about whether to 
continue to push for the change and what additional evidence may be 
necessary to evidence the impact.   
Decision space  What are the possible uses of the technology? 
What are the most promising uses of the technology? 
Which of the potential use(s) should be targeted first? 
The decision space in this case study was narrow as the indication and 
position in pathway for this technology was constrained by the aim of the 
study.  However, there was still flexibility over the choice of test 
performance thresholds and this was explored in the analysis. 
Available evidence  What evidence is available? 
What is the best approach to estimating parameters in the absence of 
evidence? 
Local evidence was required.  Evidence was taken from a single clinical 
effectiveness trial and local cost data. 
Timing  
  
What is the most appropriate form of analysis (if any) to do now? 
The most appropriate form of analysis was a cost-consequence analysis.  It 
was important for the ultimate decision makers that costs savings should 
be made.  It was important to assess the level of cost savings available in 
light of the potential consequences, particularly in terms of missed cases. 
Business model  
  
What alternative business models are possible for this technology in 
target jurisdictions/indications?  
A reimbursement business model was appropriate as the setting was the 
Hong Kong Hospital Authority. 
Resources for analysis  
  
What resources are available for analysis? 
What would be the most appropriate use of the resources? 
No specific resources were available.  The analysis undertaken was 
relatively resource light and was a useful step in demonstrating to the 
clinicians and the ultimate decision maker the level of cost savings 
available and the potential consequences of different threshold choices. 
 
Stance of analysis  How does the analyst ensure the study meets the needs of the 
developers? 
The analysis was presented back to the developers.  The developers 
continued the research effort and have since produced a full cost-
effectiveness model comparing PSA and PHI as an initial test in 




Feature of DF-HTA  Questions for consideration 
Burden of proof  Are the methods and sources of parameter estimates appropriate for 
this level of resources and this stage of development? 
Has the analyst communicated any limitations of the approach with 
the developers? 
The approach to modelling and evidence sources used appeared sufficient 
for the decision-maker.     
 
 
6.2.7.3 Does case study 5 demonstrate the features of DF-HTA? 
As with the assessment of the extension to molecular testing in colorectal cancer 
(case study 3) this study differs from DF-HTA in most of the features.  The 
ultimate audience was a public payer and the main decision to be informed was 
whether to adopt a commercially available test.  As in case study 3, the features 
which were consistent with DF-HTA were evidence limitations and resource 
constraint.  Again, both these features were driven in this case study by the 
local nature of the assessment.  Evidence at the granular level and care 
pathways were very specific to this setting and were derived from a single 
clinical study.  Resource for the study was not provided through an evaluation 
body.  For burden of proof, it was not clear what level of evidence decision-
makers required to make a decision.  The analysis was useful to demonstrate the 
likely cost-effectiveness of the introduction of PHI and may have encouraged 
further research into the cost-effectiveness of the test in other positions in the 
pathway by the Hong Kong based clinical team (Teoh et al, 2020).   
6.2.8 Do the case studies demonstrate the features set out in the 
framework? 
Three of the case studies exhibit all the features of DF-HTA as identified in 
Table 4-1.  The remaining two case studies exhibit few of the features (including 
limited evidence and restrained resources) but these case studies are quite 
different as they assess existing technologies for public payer audiences.  The 
framework of features does seem to describe DF-HTA adequately.  The questions 
presented in Table 4-2 appear to identify useful aspects of the assessment and 
may have been helpful to make explicit features of the analysis at the outset of 
each of the case studies.  In particular, questions about the stance of analysis 
and burden of proof may help to make explicit the nature of the assessment and 
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ensure that both the developer and the analyst were clear about the goals of the 
analysis. 
6.3 Activities and methods used in the case studies 
The generic process of development-focused HTA presented in Figure 5-1 
includes the core activities of clinical and economic value assessment.  These 
assessments take place in an iterative process and each activity is likely to be 
revisited on more than one occasion.  Table 6-8 sets out the activities and 
methods of DF-HTA selected in the case studies.  The first step in all case 
studies was to undertake a clinical value assessment using a simple modelling 
approach to map clinical pathways with and without the new technology.  In 
cases where the clinical value assessment was positive the next step was to 
undertake an economic value assessment, again using simple decision tree 
models to undertake cost minimisation, cost consequence or cost utility analysis 
to estimate headroom. 
Table 6-8: Activities and methods of DF-HTA used in case studies 
 Case study 1 
Test of response 
to treatment in 
ovarian cancer 
Case study 2 
Test of response 
to treatment in 
rheumatoid 
arthritis 































































7 Case study 1 - Test and Treat Superiority Plot: a 
simple tool for developers of tests for treatment 
response. 
7.1.1 Introduction 
Tests, such as companion diagnostics, that attempt to predict an individual’s 
response to a specific treatment are likely to be an important component of 
precision medicine.  For developers of medical technologies, it is useful to 
articulate a value proposition at an early stage of development (Rogowski et al, 
2016) and at this stage developers often do not have the time or funds to fully 
evaluate the potential impact of the test in development (Vallejo-Torres et al, 
2008).  However, patients, physicians, and by extension, developers of 
diagnostic technologies are most likely to be interested in those tests that 
improve clinical outcomes, so a decision model that predicts net clinical benefit 
may be sufficient for decision-making during early development.  The objectives 
of this chapter are to develop a generic decision analytic model, predicting 
probability of response, comparing ‘test and treat’ and ‘treat all’ strategies for 
a test that predicts individual response to a given treatment and to introduce 
the Test and Treat Superiority Plot which visually presents the combinations of 
sensitivity and specificity at which a test and treat strategy would improve 
expected treatment response when compared with a treat all strategy.   
The generic approach is presented then applied in a case study of response to 
hormone treatment or chemotherapy in ovarian cancer. 
This chapter is based upon an MSc dissertation submitted Dmitry Ponomarev and 
co-supervised by Janet Bouttell and Neil Hawkins.  The chapter forms the basis 
of an article (using a different case study) in preparation. 
7.1.2 Method 
A decision-tree model was developed comparing the two ‘treat all’ strategies 
with either treatment A or treatment B with a test and treat strategy where 
patients are tested for response to treatment A and are treated with A if the 
test is positive (and B if test negative).  It is assumed that the test is not 
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predictive of response to treatment B.  Extensions to this model are considered 
in the discussion.   
The model is shown in Figure 7-1.  The first strategy is the test and treat 
strategy where all patients are tested.  The patients with a positive test result 
(which indicates that they are likely to be responders to treatment A) are 
treated with treatment A.  A proportion of patients treated with treatment A 
respond (determined by the positive predictive value of the test and the 
response rate to treatment A - pA) and the remainder do not respond.  Those 
that are predicted not to respond are treated with Treatment B with response 
rate pB (this response rate is assumed to be independent of the test result).  The 
other two branches of the decision tree show treat all strategies using either 
treatment A with response rate pA or treatment B with response rate pB.  
Response rates to the two treatments are known.   
Figure 7-1: Structure of generic model 
 
+ve – test positive (i.e. indicates likely responder to treatment A), Resp – 
responder/response, -ve – test negative (i.e. indicates likely non-responder to treatment A, E 
– estimate 
Based on this decision tree it can be shown that, for a given specificity, the 
threshold sensitivity at which the expected response of the ‘test and treat’ 
strategy  for a test predicting individual response to treatment A equals the 
optimal ‘treat all’ strategy can be estimated based solely on the odds ratio of 
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response comparing treatment A and B and is independent of the absolute 
probability of response. The equations estimating the threshold sensitivity are 
given below. 
If the Odds Ratio for treatment A compared with treatment B is >= 1: 
sensitivity = 1 − specificity/ORa.vs.b eqn. 1 
If the Odds Ratio for treatment A compared with treatment B is <= 1: 
sensitivity = (1 − specificity)/ORa.vs.b eqn. 2 
The mathematical proof is provided as Appendix 10.  
The threshold sensitivity is plotted as a function of specificity for a given odds 
ratio.  The plot has been termed a ‘Test and Treat Superiority’ Plot.  Specificity 
is plotted on the X axis in reverse (1 to 0) so that the plot is analogous to a 
Receiver Operator Characteristics (ROC) curve. It is also possible to chart the 
expected net clinical gain with the test and treat strategy compared with the 
optimal treatment strategy. This is a function of the expected responses to 
treatment A and treatment B.  The plot and chart of clinical gain are presented 
in the results to the case study.   
RShiny is a software package which allows users to use the statistical software R 
to build interactive web-based apps.  An RShiny app has been developed, based 
on the plot and table in this chapter, and it is available at 
https://nshpublicapps.shinyapps.io/test_and_treat_app/. 
7.1.3 Case study 
7.1.3.1 Background 
Ovarian cancer (OC) is the fourth most common cause of death due to cancer in 
women (Denny, 2013) with the majority of cases presenting at an advanced 
stage (SEER, 2014).  Epithelial OC, where the cancer starts from the cells 
covering the outer surface of the ovary, accounts for up to 90% of all OC 
(Granstrom et al, 2008; McCluggage, 2008).  Prognosis is generally poor, with 
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average 5-year survival below 40% (de Angelis et al, 2017; Usach et al, 2015) and 
relapse rates within three years of treatment around 70% (Ledermann et al, 
2013).  OC is generally treated aggressively following diagnosis.  For Stage 1, OC 
National Institute for Health and Care Excellence (NICE) guidelines in the UK 
include surgical staging with possible subsequent chemotherapy depending on 
the results of staging and other factors (NICE, 2011).  For advanced (stage II-IV) 
cancer primary debulking surgery, followed by chemotherapy (adjuvant therapy) 
is recommended (NICE, 2011).  Additionally, chemotherapy could precede 
surgery (neoadjuvant chemotherapy).  Standard chemotherapy regimens include 
platinum-based drugs (cisplatin or carboplatin) and/or cytotoxic drugs, such as 
paclitaxel, as first-line therapy. 
Response to treatment in OC is most commonly assessed using the response 
evaluation criteria in solid tumours (RECIST) version 1.1 (Eisenhauer et al, 2008).  
This guidance distinguishes complete response, partial response, stable disease 
or disease progression.  Either complete response or partial response may be 
considered best overall response (Eisenhauer et al, 2008).  The progression-free 
period after first-line treatment is considered to be one of the most important 
factors associated with probability of response to second-line therapy and 
subsequent rounds of treatment (Ledermann et al, 2013).  Patients are 
categorised as “platinum-refractory” if progression occurs during treatment or 
within four weeks of the last dose, “platinum-resistant” if progression occurs 
within six months or “platinum-sensitive” if progression occurs after more than 
six months.  Platinum-resistant and refractory patients generally receive 
palliative chemotherapy as their survival is unlikely to exceed 12 months 
(Ledermann et al, 2013).  Platinum-sensitive patients receive additional lines of 
platinum-based therapy in combination with cytotoxic drugs but eventually 
become resistant to any chemotherapeutic regimen (Ledermann et al, 2013).  
This drives the search for new agents and treatment strategies.  Hormone 
therapy (HT) is considered one such treatment strategy (Paleari et al, 2017). 
Hormone treatment is not routinely used to treat patients with refractory OC.  
Plausible biological mechanisms exist whereby gonadal steroids may impact upon 
OC and to date, a variety of hormonal agents have been used in clinical studies, 
(including anti-estrogen tamoxifen, aromatase inhibitors, anti-androgens, 
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progestins and luteinising hormone releasing agonists).  A recent comprehensive 
review and meta-analysis of clinical benefit and risk of death with endocrine 
therapy included 53 trials and 2,490 patients with OC (Paleari et al, 2017).  
Populations were a combination of platinum-resistant, not platinum resistant, a 
mixture of both or platinum-resistance was not reported. The summary clinical 
benefit rate (SCBR, defined as the proportion of patients who achieved complete 
response, partial response or stable disease or the proportion of patients with no 
disease progression within the study period) for any HT was 0.41 (95% confidence 
interval (CI), 0.34-0.48) (Paleari et al, 2017).  However, the authors 
acknowledged a high level of heterogeneity of studies within the analysis.  As 
well as the mix of platinum-resistance many treatments and comparators were 
included.  Only one single randomized control trial was identified which directly 
compared the two forms of treatment considered in the case study (Lindemann 
et al, 2017).  This was preferred as the source of the base case model estimates 
as it was a relatively recent trial which was specific to the population, 
technology and comparators in the case study.   A clinical expert confirmed that 
this trial was representative of expected response rates in this population. 
Given the high level of heterogeneity in the population of patients with OC, it is 
possible that there is a sub-population of patients who are likely to respond well 
to HT.  If a biomarker test could be developed to identify such patients this 
could improve overall response rates and overall survival. The aims of this case 
study were to explore the test performance necessary in order for a test and 
treat strategy to deliver improved clinical performance over strategies to treat 
all with either chemotherapy or hormone therapy in a population of platinum- 
refractory/resistant patients with OC.  This information would also form the 
basis of a go/no go decision, if the hypothetical test was unable to demonstrate 
sufficient clinical value to justify the costs of investment even with perfect test 
performance. 
7.1.3.2 Method 
The case study model is shown in Figure 7-2.  The first strategy is the test and 
treat strategy where all patients are tested for response to hormone treatment.  
Patients with a positive test result are treated with hormone therapy.  A 
proportion of patients treated with hormone therapy respond (determined by 
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the positive predictive value of the test and the response rate to hormone 
therapy - pA) and the remainder do not respond.  Those that are predicted not 
to respond are treated with chemotherapy with response rate pB.  This response 
rate is assumed to be independent of the test result.  The other two branches of 
the decision tree show treat all strategies using either hormone therapy with 
response rate pA or chemotherapy with response rate pB.   
Figure 7-2: Required test performance for test of response to HT 
 
+ve – test positive (i.e. indicates likely responder to treatment A), HT – hormone treatment, 
Resp – responder/response, -ve – test negative (i.e. indicates likely non-responder to 
treatment A, E – estimate, PPV – positive predictive value  
A single randomized control trial was used as the source of the model inputs as it 
was a recent trial directly comparing the two forms of treatment which are the 
subject of the case study (Lindemann et al, 2017).  It estimated response to 
hormone therapy in platinum-resistant patients (treatment A) at 5% and 
response to chemotherapy (treatment B) at 15%.  From these values an odds 
ratio can be calculated for treatment A compared to B of 0.31.  
A range of odds ratios (with both chemotherapy and hormone therapy having 
better response rates) were explored to illustrate the impact of this on the 
required test performance.  
PPV
Resp|Test+ve 4%




7% Resp|Test -ve 15%
Test - ve/treat B 31%
No resp 85%
Resp 5%
Treat all with A
E[Response]
5% No resp 95%
Resp 15%
Treat all with B
E[Response]
15% No resp 85%
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7.1.3.3 Results  
For a test and treat strategy to improve response rates in the base case scenario 
(response to CT - 15% and odds ratio 0.31) specificity must be above 69% at 100% 
sensitivity.  As specificity increases required sensitivity decreases until it equals  
0% at 100% specificity (see Figure 7-3). 
Figure 7-3: Test and Treat Superiority plot for HT compared to CT 
 
CT – chemotherapy, HT – hormone treatment 
As the response rate to HT is not high in the base case (5%) even a perfect test 
with 100% sensitivity and specificity would only deliver a 4% improvement in 
overall response rates (see Figure 7-4).  As the odds ratio increases beyond one 
(i.e. hormone treatment has higher response rate relative to chemotherapy) the 
proportion of responders overall increases but the benefit of the test and treat 
strategy is compared to a higher response rate so does not increase beyond that 




Figure 7-4: Gain from test and treat strategy 
 
Sens – sensitivity, Spec - specificity 
Figure 7-5 illustrates the threshold sensitivity and specificity required for a test 
and treat strategy to dominate the optimum treat all strategy for a range of 
odds ratios.  The area above and to the left of the line is the area where test 
and treat strategy improves overall response rate. 
Figure 7-5: Test and Treat Superiority Plot for a range of odds ratios 
 
OR – odds ratio.  Area above and to the left of the line is the area where test and treat 




This chapter has shown that based on only the odds ratio comparing two 
treatments, it is possible to identify the threshold at which a test and treat 
strategy for a test (predicting response for one of treatment) outperforms a 
treat all strategy using the optimum treatment.  This threshold varies only with 
the odds ratio between the treatments rather than with the level of treatment 
response per se.  The Test and Treat Superiority Plot illustrates the threshold 
above which a test and treat strategy will increase overall response rates and 
thus indicates the minimum levels that a test must achieve in order to begin to 
establish a value proposition for a potential diagnostic technology. 
Table 7-1 shows how sensitivity and specificity can be estimated for the form of 
test under consideration.  The proportion of patients meeting response criteria 
could be taken from empirical data and the test result determined 
retrospectively from data samples. 
Table 7-1: Estimation of sensitivity and specificity 
Prediction of Response to Hormone Treatment Test +ve Test -ve 
Patient meets response criteria post treatment A 0.25 0.05 
Patient does not meet response criteria post treatment A 0.25 0.45 
Sensitivity (0.25/0.3)  0.83 
Specificity (0.45/0.7)  0.64 
-ve – negative, +ve – positive 
A strength of this approach is that it is simple and easy to operationalise.  It is 
clear to developers the levels of test performance they must achieve in order for 
a testing strategy to be preferred to a treat all strategy.  The Test and Treat 
Superiority Plot is novel although it is similar to test-threshold graphs presented 
in Hunink et al (2014).   Hunink et al (2014) plotted the pre-test and post-test 
probabilities of disease for patients with positive and negative test results in 
order to derive a threshold for the pre-test probability of disease below which 
you would neither test or treat and a further threshold above which you would 
treat regardless of a test result.  Hunink et al’s plot involves test performance, 
disease prevalence and a previously derived treatment threshold (where an 
individual would be indifferent between the treat or no treat strategies) so is 
more complex that the Test and Treat Superiority plot.  
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A key limitation of this simple model is the assumption that expected probability 
of response to the second treatment is independent of the test result. The 
decision model could easily be extended to tests where the expected response 
to both treatments varies conditional on test results. It should be noted that the 
evidence requirements are more extensive in this situation. 
However, as the approach is intended as a first step in assessing potential 
clinical value the simple model may still be of value as it may allow the 
development of technologies that are unlikely to add value even with strong 
assumptions to be terminated at an early stage.  Although some forms of health 
technology assessment require a systematic approach to the identification of 
relevant literature and potentially meta-analysis to synthesise the evidence, this 
very early form of assessment of potential value requires less onerous forms of 
evidence collection.  Expert opinion could be used as could a very rapid review 
of the literature to identify an appropriate starting point for the analysis, as 
exemplified here.  Care must be taken to consider whether there is any 
limitation in the availability of the treat all strategies.  For example, many 
expensive cancer treatments are not available on a treat all basis.  In this case, 
the model may still be used but the comparison of the test and treat response 
rate should be against the treat all comparator which is available. 
Another limitation is the focus on response rates rather than quality of response, 
but again the same logic applies that this technique can be a useful first step in 
evaluation for developers or funders of health technologies rather than providing 
definitive guidance.  This technique would not be intended to replace any 
further clinical or cost-effectiveness modelling rather as a very early technique 
to assess whether the technology is likely to have clinical utility.   
This Test and Treat Superiority Plot offers a simple and quick first assessment 
tool for a test of response to a treatment.  The data requirement is low and the 
model is sufficiently flexible to allow numerous scenarios to be assessed in a 
short space of time.  The visual presentation of the plot facilitates discussion 




8 Case study 2 - Development-focused HTA of test 
to predict response to biologic treatments in 
rheumatoid arthritis 
8.1 Introduction 
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterised by 
progressive, irreversible joint damage, impaired joint function, and pain and 
tenderness caused by swelling of the synovial lining of joints (Stevenson et al, 
2016).  RA affects approximately 1% of the population (SIGN, 2011), is more 
prevalent in women than men and the typical age at onset is between 40 and 80 
with peak incidence in the 70s (Stevenson et al, 2016). Diagnosis of RA is based 
on guidelines known as the Rheumatoid Arthritis Classification Criteria jointly 
issued by the American College of Rheumatology (ACR) and the European League 
Against Rheumatism (EULAR) (Stevenson et al, 2016).  These guidelines focus on 
early signs of persistent and/or erosive disease such as joint involvement, 
duration of symptoms, serology (presence of certain antibodies in the serum) 
and acute-phase reactants (proteins which respond to the presence of 
inflammatory agents) (Stevenson et al, 2016) as well as the absence of an 
alternative diagnosis.  It is important to start treatment in response to early 
disease due to the irreversibility of the joint damage if RA is left untreated. 
In the UK, monitoring of disease-progression is often undertaken using the 
Disease Activity Score 28 joints (DAS28).  This assesses 28 joints in terms of 
swelling and tenderness, incorporates a measure of erythrocyte sedimentation 
rate (ESR – which measures how quickly red blood cells settle at the bottom of a 
test tube) and a patient-reported subjective assessment of disease activity.  
EULAR criteria use the individual change in DAS28 and the level of DAS28 
reached to classify patients as responders, good responders or non-responders 
(Stevenson et al, 2016).  Table 8-1 sets out the change and levels of DAS28 
corresponding to each response level.  Another outcome measure widely used in 
RA is the Health Assessment Questionnaire (HAQ).  This is a patient completed 
disability assessment comprising a score from 0-3 in increments of 0.125 where a 
higher score indicates higher disability.  In economic evaluations HAQ has been 
shown to correlate to utility scores such as those gathered using EQ-5D (Euroqol 
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5 dimensions - which is a standardized instrument for measuring generic health 
status) (Stevenson et al, 2016). 
Table 8-1: Determining EULAR response based on DAS28  
 Improvement in DAS28 
DAS28 at end point >1.2 >0.6 and <=1.2 <= 0.6 
<= 3.2 Good Moderate Non 
>3.2 and <=5.1  Moderate Moderate Non 
>5.1 Moderate Non Non 
DAS28 -disease activity score 28 joints.  EULAR – European League Against Rheumatism.  
From Stevenson et al, 2016. 
Traditional treatment for RA has been conventional disease-modifying anti-
rheumatic drugs (cDMARDs) which include sulfasalazine and methotrexate, as 
well as corticosteroids, analgesics and non-steroidal anti-inflammatory drugs.  
From the late 1990s, a group of drugs have been developed consisting of 
monoclonal antibodies and soluble receptors that specifically modify the disease 
process by blocking key protein messenger molecules such as cytokines or cells 
such as B-lymphocytes.  These drugs have been labelled biologic disease-
modifying anti-rheumatic drugs (bDMARDS) (Stevenson et al, 2016).  Tumour 
Necrosis Factor alpha inhibitors (TNFi) are a sub-set of bDMARDs.  At the time of 
writing five drugs were licensed in the UK for the treatment of patients with 
Rheumatoid Arthritis (RA) who do not show or maintain adequate response to 
non-biological (or conventional) disease modifying anti-rheumatic drugs 
(cDMARDs) (Stevenson et al, 2016).  Adalimumab (ADA) and Etanercept (ETN) are 
two of the five licensed TNFis.  They are the drugs which were used in the 
clinical trial from which the data was taken to develop the response signature 
subject of this study.  Rituximab (RTX) is an anti-CD20 monoclonal antibody that 
depletes various pathophysiological subsets within the B-cell population (Porter 
et al, 2016).  Rituximab is approved for use in patients who have not responded 
to TNFi drugs.  It was shown to be non-inferior to TNFi drugs (ADA and ETN) in 
the treatment of biologic-naïve, sero-positive patients (Porter et al, 2016). 
Figure 8-1 illustrates the position of bDMARDs within NICE recommendations for 
sequence of treatments for patients with severe RA (DAS28>5.1) (adapted from 
Stevenson et al, 2016, Figure 1).   
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Figure 8-1: Treatment sequence for patients with RA in the UK (DAS28>5.1) 
 
bDMARD – biologic disease modifying anti-rheumatic drugs; cDMARD – conventional 
disease modifying anti-rheumatic drugs; DAS28 – disease activity score 28 points, MTX – 
Methotrexate ; RTX – rituximab ; TCZ –tocilizumab (interleukin 6 inhibitor). Adapted from 
Stevenson et al, 2016. 
  
For newly diagnosed patients a combination of cDMARDs (generally methotrexate 
(MTX) plus another cDMARD) is recommended (NICE, 2018c).  If a patient has 
severe symptoms (DAS28>5.1) and has not responded to two cDMARDs then 
bDMARDs may be prescribed (usually TNF inhibitors).  If TNFi fail then rituximab 
and methotrexate would typically be prescribed (Stevenson et al, 2016, p3).  
Currently, in the UK, an empiric strategy of drug selection is used as patients try 
a sequence of drugs, trying another if they fail to respond or stop responding.   
There is potential for a test-based strategy to improve response rates if a test 
were able to identify which patients would respond to a specific bDMARD 
(Russell et al, 2018).  There is currently no such test available.  The technology 
in this case study (which is at an early prototype stage) is a series of three 
transcriptomic signatures to predict response to two types of biologic drugs in RA 
using a sample of the patient’s blood.  The signatures involve approximately 23 
genetic markers combined with either age or gender of the patient depending on 
the signature.  The signatures were developed using whole genome sequencing 
of samples collected during a clinical trial into the non-inferiority of the 
treatments.  Now the genetic markers have been identified the next step is to 
develop a panel testing only the identified markers and to explore whether the 












The objective of this case study is to assess the potential clinical and economic 
value of the signatures at different time points following the approach set out in 
Vallejo-Torres et al (2011).  A stage-gate is a term used in research and 
development to represent an important decision point when it is appropriate to 
assess the current position in the development and decide whether the project 
should proceed (Pietszch et al, 2009).  This study examines two stage-gates in 
the development process of the testing technology.  The early-stage analysis 
considers the evidence which was available prior to the whole genome 
sequencing (WGS) and analysis of the ORBIT trial data which identified the 
signatures.  The aim of this aspect of the study is to determine whether there 
appeared to be prima facie value in the potential test which would justify the 
research expenditure.  The mid-stage analysis includes the evidence from the 
WGS and subsequent analysis.  The aim of this aspect is to begin to evaluate the 
prima facie case for value set out in the early-stage analysis.  Output from this 
second stage can also begin to inform evidence generation strategy and 
technology design. 
8.2 Early-stage analysis 
8.2.1 Introduction 
The basic value proposition of this technology is that a test and treat strategy 
may lead to an increase in response rates to the relevant biologic drugs.  In 
order for the tests to add clinical value they have to improve response rates.  In 
order to add economic value they either have to improve response rates or 
provide savings through prescription of a lower cost drug which are sufficient to 
justify the cost of testing all patients in the population.  As the respective cost 
of drugs varies by jurisdiction and over time, this early-stage analysis focuses on 
the potential additional response rates generated by the tests. 
8.2.2 Method 
The early-stage assessment comprised a clinical value assessment.  The clinical 
value assessment used a decision tree to show the health impact of the tests in 
terms of potential improved response rate. 
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Population, Intervention, Comparator and Outcome measures (PICO) criteria for 
the decision problem are set out in Table 8-2.   
Table 8-2: PICO criteria for simple health impact assessment 
Population Adults with moderate to severe and severe RA who have not responded or stopped 
responding to cDMARDs so are eligible to commence biologic DMARDs. 
Intervention Test all for response to TNFi (treatment A) and treat according to result of the test.  
If not predicted to respond A treat with rituximab (treatment B). 
Comparators Treat all with TNFi or rituximab. 
Outcome measures Response rate at 6 months (good response and moderate/good response modelled 
separately) 
cDMARDs – conventional disease modifying anti-rheumatic drugs, RA – rheumatoid 
arthritis, TNFi – tumour necrosis factor inhibitors 
Decision trees with a time horizon of six months were developed to compare a 
strategy of testing all patients and prescribing treatment A (in this case TNFi) if 
the test predicts that a patient will respond.  Otherwise a patient is prescribed 
treatment B (in this case rituximab).  The second and third branches of the tree 
show strategies of treating all patients with either treatment A or treatment B 
(Figure 8-2 for good response and Figure 8-4 for moderate/good response).  The 
decision tree generates an expected response rate from all three strategies.  
The additional response generated by a test and treat strategy over the best of 
the empiric treatment strategies can be compared to determine the level of 
additional response at a range of levels of sensitivity and specificity.  The Test 
and Treat Superiority (TTS) Plot was produced from the odds ratio between the 
two treatments as explained in chapter 7.  The threshold plotted on the TTS plot 
showed the combinations of sensitivity and specificity at which the testing 
strategy outperforms the best treat all strategy.  Table 8-3 summarises the 
methods and data sources used in the early-stage assessment.  
Table 8-3: Methods and data sources used in early-stage assessment 
Method Data Source 
Epidemiological 
analysis and Health 
impact assessment 
Clinical pathway in UK 
Response rates to bDMARDs (see Table 8-4) 
NICE CG100 (NICE, 2018c) SIGN guideline 123 
(SIGN, 2011), Stevenson et al, 2016 
ORBIT trial (Porter et al, 2016)  
 
DMARDs – disease modifying anti-rheumatic drugs, HTA – health technology assessment, 
NICE – National Institute for Health and Care Excellence, SIGN – Scottish Intercollegiate 
Guidelines Network, TNFi – tumour necrosis factor inhibitors 
Table 8-4 sets out selected response rates from a recent HTA report meta-
analysis.  It is evident that there are a proportion of patients who do not respond 
to the various drugs prescribed.  Equivalent response rates for rituximab are 
given in the ORBIT trial as 0.29 for good response and 0.83 for moderate/good 
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response (Porter et al, 2016) although this is based on an intention to treat 
analysis so response rates will include patients who switch to the other 
treatment. 
Table 8-4: Selected response rates taken from meta-analysis  
Intervention At least moderate response (95% CrI) At least good response (95% CrI) 
cDMARDs 0.410 (0.344 to 0.479) 0.077 (0.048 to 0.117) 
ADA +MTX 0.664 (0.327 to 0.903) 0.220 (0.048 to 0.546) 
ADA 0.704 (0.321 to 0.948) 0.254 (0.047 to 0.669) 
ETN +MTX 0.871 (0.437 to 0.992) 0.473 (0.085 to 0.886) 
ETN 0.670 (0.132 to 0.973) 0.224 (0.010 to 0.772) 
Grouped 
biologics 
0.711 (0.217 to 0.967) 0.260 (0.023 to 0.743) 
ADA – Adalimumab, cDMARDs – conventional disease modifying anti-rheumatic drugs, CrI 
– credible interval - ETN – Etanercept, MTX – methotrexate. Taken from Stevenson et al, 
2016. 
Pathways and data sources were based on the UK.  This is because good quality 
evidence was readily available for the UK and the development was based here. 
8.2.3 Results 
8.2.3.1 Clinical value assessment 
Set out below are the decision trees, additional response tables and TTS plots 
for good response and moderate/good response.  Response rates are taken from 
Porter et al, 2016.  Treatment A in this case is TNFi (so the test is for response 
to TNFi).  The odds ratio of good response at six months, TNFi to rituximab was 1 
as both treatments had response rates of 29%.  For moderate and good response 
the odds ratio TNFi to rituximab was 0.65 - ((0.76/0.24)/(0.83/0.17)) reflecting 




Figure 8-2: Decision tree for good response at 6 months 
 
ErespA(B) – expected response from treatment A(B), ErespTest – expected response from 
test and treat strategy, resp – response, PPV – positive predictive value, Resp|Test+ve(-ve) 
– response rate conditional on positive (or negative) test result, Treat A – TNFi, Treat B, 
rituximab 
Figure 8-3: Test and treatment superiority plot for good response at 6 months 
 
Above and to the right of the threshold line (Figure 8-3) indicates the area of 
test performance where the test and treat strategy outperforms the best of the 
treat all strategies.  An odds ratio of 1 produces the threshold shown in Figure 
8-3 where, because the treatments have an equal response rate as long as the 
test has a better than 50/50 performance it will add value.   
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Table 8-5: Response for test and treat strategy – good response 
 
  
Figure 8-4: Decision tree for moderate/good response at 6 months 
 
ErespA(B) – expected response from treatment A(B), ErespTest – expected response from 
test and treat strategy, PPV – positive predictive value, resp – response, Resp|Test+ve(-ve) 




21% 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
Sensitivity 1 0% 2% 4% 6% 8% 10% 12% 14% 16% 19% 21%
0.9 0% 0% 2% 4% 6% 8% 10% 12% 14% 16% 19%
0.8 0% 0% 0% 2% 4% 6% 8% 10% 12% 14% 16%
0.7 0% 0% 0% 0% 2% 4% 6% 8% 10% 12% 14%
0.6 0% 0% 0% 0% 0% 2% 4% 6% 8% 10% 12%
0.5 0% 0% 0% 0% 0% 0% 2% 4% 6% 8% 10%
0.4 0% 0% 0% 0% 0% 0% 0% 2% 4% 6% 8%
0.3 0% 0% 0% 0% 0% 0% 0% 0% 2% 4% 6%
0.2 0% 0% 0% 0% 0% 0% 0% 0% 0% 2% 4%
0.1 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 2%
0 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
163 
 
Figure 8-5: TTS plot for moderate/good response at 6 months 
 
TTS – test and treat superiority  
Table 8-6: Response for test and treat strategy – mod/good response 
 
The above plots and tables demonstrate that a test and treat strategy could add 
clinical value provided that test performance exceeded the thresholds shown in 
Figure 8-3 for good response and   
Specificity
13% 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
Sensitivity 1 0% 0% 0% 0% 1% 3% 5% 7% 9% 11% 13%
0.9 0% 0% 0% 0% 0% 2% 4% 6% 8% 10% 12%
0.8 0% 0% 0% 0% 0% 0% 2% 4% 6% 8% 10%
0.7 0% 0% 0% 0% 0% 0% 1% 3% 5% 7% 9%
0.6 0% 0% 0% 0% 0% 0% 0% 2% 4% 6% 8%
0.5 0% 0% 0% 0% 0% 0% 0% 0% 2% 4% 6%
0.4 0% 0% 0% 0% 0% 0% 0% 0% 1% 3% 5%
0.3 0% 0% 0% 0% 0% 0% 0% 0% 0% 2% 4%
0.2 0% 0% 0% 0% 0% 0% 0% 0% 0% 1% 3%
0.1 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 1%
0 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
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Figure 8-5 for moderate and good response.  Additional good response of 21% 
(29% to 50%) and moderate to good response of 13% (83% to 96%) could be 
achieved.  The TTS Plot shows equanimity between sensitivity and specificity for 
good response when the treatment response rates are equal (OR=1)(Figure 8-3) 
but specificity maximised when looking at moderate and good response as RTX 
(treatment B) has higher rates of response (  
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Figure 8-5).  Three further points are worthy of note: 
• In the UK, rituximab (RTX) is licensed for use after the failure of a TNFi.  It 
is, therefore, clinically appropriate to test for response to TNFi rather than 
RTX.  If sensitivity of the test is maximised this will optimise the 
identification of non-responders to TNFi.  Clinicians may be more inclined to 
prescribe off-label if they had evidence that the patient would be unlikely to 
respond.  Outside of the UK, the licensing position and clinician attitudes 
may differ. 
• This simple modelling assumes that response rates are independent but this 
may not be the case.  If there is overlap in the sense that it is the same 
patients who would respond to both treatments then this model will over-
estimate the benefits of a test in increasing response rates.  However, the 
test may still have economic value if it allows a cheaper treatment to be 
prescribed where a patient is likely to respond to both. 
• The population in the ORBIT trial (Porter et al, 2016) were seropositive and 
their response rates may not be generalizable to the whole RA population. 
8.2.4 Conclusion of early-stage analysis 
The clinical value assessment demonstrates that a test of response to TNFi has 
the potential to increase response rates in the short term thus demonstrating 
potential clinical utility sufficient to justify initial investment in the 
development of the transcriptomic signatures from the ORBIT (Porter et al, 
2016) data.  Economic value of any test developed would derive partly from an 
ability to generate higher utilities in the period when response rates are higher 
than they would be under an empiric treatment selection strategy.  The other 
aspect of economic value would be context specific and would depend on an 
ability to prescribe a cheaper treatment than TNFi if the test indicated that a 
patient was unlikely to respond.  This aspect of value has not been calculated as 
the continued development of the test appears to be justified on the clinical 
value alone and this aspect is more generalizable. 
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A more detailed analysis follows which takes account of a greater variety of 
development scenarios and crucially incorporates the data generated from 
retrospective analysis of samples taken from responders and non-responders to 
both classes of drugs in the ORBIT trial (Porter et al, 2016).  This provides an 
opportunity to include test accuracy in the models as well as different levels of 
overlap in response to treatments.  
8.3 Mid-stage analysis 
8.3.1 Introduction 
The previous section set out how to articulate a basic value proposition for this 
technology in the absence of technology specific evidence.  The second iteration 
will begin to evaluate the value proposition using the first technology specific 
evidence (from the retrospective analysis of the ORBIT trial data).   
8.3.2 Method 
The additional evidence incorporated in this stage of analysis comprised a 
retrospective analysis (unpublished) of samples collected during the ORBIT trial 
(Porter et al, 2016).  The aim of the retrospective analysis was to identify 
transcriptomic signatures in the ORBIT cohort that can predict response/non-
response to biologic therapy.  The study comprised the Ribonucleic Acid (RNA) 
sequencing of 241 samples of which 70% (n=169) were used to develop models 
and 30% (n=72) used to validate the models.  Clinical response was defined as a 
fall in DAS28-ESR of >1.2 units between baseline and 3 months.  Multiple 
machine learning techniques were used to train models that predicted 1) general 
responsiveness to both TNFi and rituximab therapy and 2) differential response 
to TNFi or rituximab therapy.  Three gene sets were identified that predicted 
general responsiveness to both TNFi and rituximab therapy (8 genes), response 
to TNFi (23 genes) and response to rituximab (23 genes).  When tested on the 
validation set these models resulted in receiver operator curve (ROC) plots with 
an area under the curve of 91.6% for general responsiveness, 89.7% for TNFi and 
85.7% for rituximab response.  Patients who were predicted to respond at three 
months were also more likely to have a DAS28-good response (43% v 23%) or 
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DAS28 remission (23% v 10%) at 12 months (retrospective analysis of ORBIT data, 
unpublished). 
A one-year decision-tree structure was developed in Microsoft Excel to explore 
the potential impact on response rates, cost and utilities of a test and treat 
strategy.  The only costs included were assumed cost of test and the cost of drug 
treatment (including administration costs).  The PICO criteria for the decision 
problem are set out in Table 8-7. Discounting was not applied as this is not 
appropriate for a 12-month time horizon. 
Table 8-7: PICO criteria for cost-utility analysis 
Population Adults with moderate to severe and severe RA who have not responded or stopped 
responding to cDMARDs so are eligible to commence biologic DMARDs. 
Intervention Test all for response to TNFi and rituximab and treat according to result of the test.  
If predicted to respond to both or neither treat with TNFi.  
Comparator Treat all with TNFi. 
Outcome measures Response rates at 3 and 12 months.  Response is defined as a reduction in more than 
1.2 points on the Disease Activity Scale 28 (DAS28),  12-month costs and utilities and 
ICER. 
cDMARDs – conventional disease modifying anti-rheumatic drugs, ICER – incremental cost 
effectiveness ratio, RA – rheumatoid arthritis, TNFi – tumour necrosis factor inhibitors 
The decision-tree presented in Figure 8-6 compares a test and treat strategy 
with strategies of treating all patients initially with TNFi (treatment A) and 
rituximab (treatment B).  The test and treat strategy includes four options 
depending upon the result of the test.  Where the test indicates that the patient 
is likely to respond to treatment A but not treatment B (Test A +ve/Test B -ve) 
the patient receives treatment A for the first three months.  If the test indicates 
that the patient is likely to respond to treatment B but not treatment A (Test A -
-ve/Test B +ve) the patient receives treatment B for the first three months.  If 
the test indicates that the patient is likely to respond to both treatments the 
base case assumes treatment A is given (as this corresponds to clinical guidelines 
and current practice in the UK).  Where the test indicates that the patient is 
likely to respond to neither treatment the base case assumes that treatment A is 
still given.  This reflects the fact that there are a number of alternative biologic 
modes of action available and no biologic treatment is unlikely to be acceptable 
to either clinician or patient.  After the initial three months patients have 
responded or not.  If they respond to the treatment received they remain on the 
treatment until 12 months but a proportion of patients will stop responding.  If 
they do not respond they switch treatments at 3 months.  They may or may not 
respond to the new treatment by 12 months.  These periods were chosen as the 
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test is currently designed as a prediction of response overall (i.e. 
moderate/good response) at 3 months and 12 months is the latest data available 
in the dataset from the ORBIT trial.  In practice, patients with severe disease are 
likely to be assessed every three months.  The initial treatment may be retained 
longer than 3 months and treatment switching would occur between 3 and 12 
months. 
Inputs to the model and their sources are set out in Table 8-8.  The key 
difference between this analysis and the simpler analysis set out in Section 8.2 is 
the availability of the data from the unpublished retrospective analysis of the 
ORBIT trial.  In particular, this allowed for the estimation of test performance 
and the inclusion of estimated overlap of response to treatments.  The column 
headed ‘Range’ gives the lower and upper limits used in the one-way sensitivity 
analysis.  For response and test performance parameters these are the 95% 
confidence intervals.  The upper limit for response at 9 months for switchers to 
rituximab was capped at 75% in line with overall response.  This was necessary 
as confidence intervals were very wide due to small numbers and the calculated 
upper limit was over 90% response which was not consistent with the 3-month 
response rate.  Observed persistence reflects the number of patients who 
responded to either treatment at 3 months and were still responding at 12 
months.  This was derived using survival analysis in Stata and confidence 
intervals are provided within the output from the analysis.  The initial cost of 
testing was assumed to be £500.  Costs of testing were varied between £250 and 
£1,000 (half and double the base case).  Costs of treatment were 
increased/reduced by 35% as this is the estimated cost reduction associated with 
a biosimilar product (Manova et al, 2018).  The utility values were based on 
those given in Stevenson et al, 2016.  The HTA report gave values for responses 
for good, moderate and non-responders to TNFi.  The value for non-responders is 
taken directly from Stevenson et al, 2016.  The value for responders is a 
weighted average of good and moderate responders.  Utility values are assumed 
to be the same whether the response is to TNFi or rituximab. 
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Figure 8-6: Decision model comparing testing and treat-all strategies  
 
bDMARDs – biologic disease modifying anti-rheumatic drugs, No resp – no response to 
treatment, Resp A – respond to treatment A, RespB – respond to treatment B, TestA – test 
for response to TNFis, TestB – test for response to rituximab, +ve – positive result, patient 
likely to respond, -ve – negative result, patient unlikely to respond,  
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Table 8-8: Inputs to cost-utility model 
Input parameter Base case Range Source
Patients initiating biologic DMARDs annual - England and Walesc ses 6,000 Stevenson et al, 2016
Patients predicted to respond to TNFi and Rituximab predR_overlap 41% 34% -47% Reanalysis of ORBIT trial data (unpublished)
Sensitivity of test for response to TNFi sensA 89% 81%-94% Reanalysis of ORBIT trial data (unpublished)
Specificity of test for response to TNFi specA 89% 81%-94% Reanalysis of ORBIT trial data (unpublished)
Sensitivity of test for response to Rituximab sensB 98% 93%-100% Reanalysis of ORBIT trial data (unpublished)
Specificity of test for response to Rituximab specB 93% 86%-97% Reanalysis of ORBIT trial data (unpublished)
Response to TNFi at 3 months pA 63% 53%-72% Reanalysis of ORBIT trial data (unpublished)
Response to Rituximab at 3 months pB 75% 65%-83% Reanalysis of ORBIT trial data (unpublished)
Response for switchers to TNFi at 9 months pA_sw 64% 35%-87% Reanalysis of ORBIT trial data (unpublished)
Response for switchers to Rituximab at 9 months pB_sw 60% 15%-75% Reanalysis of ORBIT trial data (unpublished)
Observed persistence in TNFi response rate by 12 months OP_A 67% 56%-76% Reanalysis of ORBIT trial data (unpublished)
Observed persistence in Rituximab response rate by 12 monthsOP_B 62% 51%-71% Reanalysis of ORBIT trial data (unpublished)
Cost of test (£) cost_test 500 250-1,000 Assumed
Cost of treatment with TNFi (etanercept)- 6 months (£) cost_A 4,648 3,021-6,275 NICE Technology Assessment 195
Cost of treatment with Rituximab - 6 months (£) cost_B 3,492 2,270-4,714 NICE Technology Assessment 195
Annual utility for responder u_resp 0.52 0.42-0.61 Calculated based on Stevenson et al, 2016










Utility Costs (£) ICER (£) 
Test and treat  90% 65% 0.4581 8,867.01 n/a 
Treat all TNFi 63% 64% 0.4445 8,654.42 n/a 
Incremental test and 
treat vs treat all TNFi – 
base case analysis 
27% 0% 0.0136 212.59 15,613 
Treat all rituximab 75% 63% 0.4478 7,417.50 n/a 
Incremental test and 
treat vs treat all 
rituximab 
15% 2% 0.0103 1,449.51 140,393 
The results of the base-case analysis show an improvement in response rate at 3 
months of 27% from 63% response under a treat all with TNFi.  By 12 months no 
additional response is generated by the testing strategy as over this time-frame 
all patients will have had the opportunity to try both modes of action.  The 
difference in response in the first three months leads to an incremental utility of 
0.0136 at an incremental cost of £212.59.  The ICER at £15,613 is below the 
lower threshold set in the UK for reimbursement of health technologies of 
£20,000.  This demonstrates that, if the assumptions in the base case held 
(including, in particular the assumption that the developers were able to offer 
the test for £500) then the technology may be eligible for reimbursement in the 
UK. 
The ICER for the test and treat strategy compared to treat all with rituximab is 
considerably higher than when the test and treat strategy is compared with treat 
all with TNFi.  This is because the response rate to rituximab is higher in the 
first three months than the response to TNFi so the incremental gain of moving 
some patients to TNFi is not as high as moving patients in the other direction.  
Additionally, rituximab is cheaper than TNFi so any patients moved to TNFi will 
incur more cost.  The comparison against treat all with TNFi is given as the base 
case analysis as this more closely reflects clinical practice in the UK.  
One-way sensitivity analysis was undertaken to assess the impact of each input 
parameter on incremental clinical effectiveness, incremental costs and the ICER.  
The analysis shows that the effectiveness result (Figure 8-7) is most sensitive to 
utilities for response and non-response, rituximab response rates at 3 months 
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and at 9 months for switchers, predicted overlap in response between the 
treatments and observed persistence in response to rituximab at 12 months.  
The effectiveness results are less sensitive to test performance parameters 
although they are more sensitive to sensitivity than to specificity of tests for 
both treatments.  
The incremental cost results are most sensitive to the cost of the treatments and 
the cost of the test.  As the test cost is reduced to the lower bound (£250) the 
ICER is negative as the testing strategy reduces costs and improves clinical 
effectiveness.  These results reflect the cost of each treatment moving in 
isolation (i.e. the price of TNFi reducing but rituximab staying the same).  Where 
TNFi prices reduce this results in a lower saving so increases the ICER.  This is 
because part of the benefit of the testing strategy comes from moving patients 
onto a cheaper treatment.  The opposite is true for rituximab as the price 
decreases this improves the saving and results in a negative ICER due to an 
overall cost saving of the testing strategy.  Relative and absolute costs of the 
treatments vary depending upon the setting of use of the test and over time and 
will be a critical factor for the developers to consider when selecting markets to 
prioritise.  The introduction of biosimilars will also impact upon pricing - an issue 
that is addressed in Scenario 1.  The cost of the test is, as yet, unknown and 
costs are changing rapidly as platforms and processes develop.  Again, this will 




Figure 8-9 shows that the ICER is most sensitive to the cost parameters, cost of 
the test and the costs of both treatments.  The ICER is moderately sensitive to 
rituximab response parameters, the overlap of patients predicted to respond to 
both treatments and longer term (9 month) and utility parameters.  The ICER is 
not sensitive to any of the test performance parameters within the ranges 
tested.      
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Figure 8-7: One-way sensitivity analysis - effectiveness results 
 
Red effect of lower limit, blue effect of upper limit 
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Figure 8-8: One-way sensitivity analysis - costs results 
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-500 -400 -300 -200 -100 0 100 200 300 400 500 600
Annual utility for  responder
Annual utility for  non-responder
Response for switchers to TNFi at 9 months
Response for switchers to Rituximab at 9 months
Observed persistence in TNFi response rate by 12 months
Observed persistence in Rituximab response rate by 12 months
Specificity of test for response to Rituximab
Specificity of test for response to TNFi
Sensitivity of test for response to Rituximab
Response to TNFi at 3 months
Sensitivity of test for response to TNFi
Proportion of patients predicted to respond to TNFi and Rituximab
Response to Rituximab at 3 months
Cost of treatment with Rituximab - 6 months (£)
Cost of treatment with TNFi (etanercept)- 6 months (£)
Cost of test (£)
Change in incremental cost from base case (£)
176 
 
Figure 8-9: One-way sensitivity analysis – ICER 
 
Red effect of lower limit, blue effect of upper limit 
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Scenario analysis involves exploring alternative plausible scenarios which could 
impact on the value of the technology in development.  One scenario explores 
the impact of biosimilars, three concern response rates and the extent of the 
overlap between response to TNFi and rituximab and a final scenario addresses 
behavioural aspects of use of test results.   
The introduction of biosimilars will change the potential economic impact of a 
test and treat strategy.  Assuming that the tests in development were equally 
effective in identifying responders to biosimilars as in the drugs they are 
designed to copy, pricing is very different.  It is, therefore, appropriate to model 
scenarios where a biosimilar displaces either or both TNFi and rituximab.  The 
impact modelled will be confined to modelling price change (i.e. assuming that 
market penetration of the test would be unaffected by the market presence of 
biosimilars).  One-way sensitivity analysis in the cost-utility section models the 
impact of a change in the price of either drug – scenario 1 below models the 
impact of a change in the price of both drugs simultaneously. 
Another aspect of importance is the extent of the overlap between the 
responders to TNFi and rituximab.  This overlap can always only be estimated as 
by definition patients can only be prescribed one treatment as their initial 
biologic treatment.  The base case analysis takes the extent of the overlap in 
response rates from the predictions made using the transcriptomic signature in 
development.  Scenario 2 tests the impact of using equal response rates (the 
base case uses the response rates from the ORBIT trial (Porter et al, 2016) and 
takes the overlap from the retrospective analysis of the ORBIT trial data (as in 
the base case).  Scenarios 3 and 4 retain equal response rates but assume a 
complete overlap in responses and minimum overlap in responses, respectively 
(see Figure 8-10). 
A further risk is that clinicians and/or patients may be reluctant to apply the 
results of the diagnostic test (Thompson et al, 2014).  Scenario 5 models the 
impact of 25% of decisions not following the recommendation of the test.  In 
effect this means that 25% of patients are treated empirically under the test and 




Table 8-10: Results of scenario analysis 
Strategy Change in assumptions Incremental response rates at 3 months, 12 months, incremental utility, 
incremental costs and ICERs 




Utility Costs (£) ICER (£) 
Base case See Table 8-8 27% 0% 0.0136 212.59 15,613 
Scenario 1 Biosimilars replace TNFi 
and rituximab with 35% 
price reduction across 
the board 
27% 0% 0.0136 313.28 23,008 
Scenario 2 Equal response 
parameters to TNFi and 
rituximab and test 
performance – overlap 
in responders to TNFi 
and rituximab as in 
base case 
16% -1% 0.0035 336.89 97,395 
Scenario 3 As Scenario 2 but 
minimum overlap 
25% -1% 0.0097 251.45 25,931 
 
Scenario 4 As Scenario 2 but full 
overlap 
-2% 0% -0.0102 523.30 -51,550 
Scenario 5 25% of patients 
continue to be treated 
empirically under test 
and treat strategy 
17% 0% 0.0092 266.02 28,823 
 
Scenario 1 – price reduction for treatments 
As shown in Figure 8-10, one-way sensitivity analysis shows that If the cost of 
rituximab reduces by 35% with all other parameters held equal the overall test 
and treat strategy dominates the existing strategy as it is cheaper and more 
effective.  This is because a greater proportion of patients are treated with 
rituximab for longer using the test and treat strategy.  If the cost of rituximab 
goes up by 35% the test and treat strategy is no longer cost effective at UK 
threshold levels (ICER £37,925).  This is because, under base case assumptions, 
the cost of testing is partially offset by a greater proportion of patients being 
treated with the cheaper treatment.  With a 35% increase, rituximab is more 
expensive than TNFi and the improvement in utilities achieved through the 
improved response rates is not sufficient to justify the increased cost of 
universal testing.  If the price of TNFi reduces by 35%, while all other 
parameters remain fixed, including the price of rituximab, the test and treat 
strategy is no longer cost effective under UK thresholds as there are no 
treatment cost savings to offset the cost of testing.  If the cost of TNFi increases 
by 35% then the test and treat strategy is cost saving and dominates the treat all 
strategy (as when the cost of rituximab reduced).  It is clear that the relative 
pricing of the two drugs is key to the cost-effectiveness of the test in the United 
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Kingdom and other jurisdictions that use similar thresholds to determine 
whether the technology will be made available.   
Scenario 1 extends the one-way sensitivity analysis to show what the impact is of 
both treatments reducing by 35%.  This scenario is possible as biosimilars replace 
both TNFis and rituximab (Manova et al, 2018).  From, it can be seen that the 
ICER increases in the event that the prices of both treatments drop.  This 
somewhat counter-intuitive result is because the cost savings from treating a 
greater proportion of patients with the cheaper treatment are not so great in 
absolute terms.  As the cost of testing remains unchanged the test and treat 
strategy becomes less cost-effective.  
Scenario 2 – Equal response rates to TNFi and rituximab holding overlap 
constant at 41% 
The purpose of this scenario is to investigate the extent to which the base-case 
result depends on the higher response rate for rituximab suggested by the ORBIT 
trial reanalysis.  In this scenario, the proportion predicted to respond to both 
treatments is held constant at 41% (as in the base case) but the overall response 
rates are equalised at 65% (24% responding only to TNFi or rituximab and 41% to 
both).  This compares with overall response rates of 75% for rituximab and 63% 
for TNFi.  Similarly, test performance, observed persistence rates and response 
rates for switchers are also equalised at 90%, 60% and 60% respectively.  The 
results of this analysis show that the test and treat strategy still increases the 
overall response rate in the first 3 months by 16% (compared to 27% under the 
base case).  However, the impact of this reduced incremental response rate on 
the utility gain and higher costs due to a higher proportion of patients on TNFi 
results in an ICER of £83,191. 
Scenario 3 – Equal response rates – minimum overlap 
Retaining response rates for TNFi and rituximab equal at 65%, this scenario 
models the impact of the testing strategy if there is the least possible overlap in 
responders.  For response rates of 65% this minimum overlap is 30% (compared to 
the base case of 41%).  Scenario 3 results in the testing strategy increasing 
response rates at 3 months by 25% over the treat all strategy.  The gain in utility 
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is 0.0116 at an incremental cost of £338.56 resulting in an ICER of £29,074 
compared to the treat all strategy.  This improvement over the treat all strategy 
is possible because the testing strategy allows a greater proportion of patients to 
be prescribed their optimum treatment in the first three months.  It is not as 
favourable as the base case due to the equalisation of response rates closer to 
TNFi response rates. 
Scenario 4 -Equal response rates – full overlap  
Scenario 4 results in the testing strategy reducing response rates at 3 months by 
2% compared to a treat all strategy.  This is because the tests are not perfect 
and response rates to the two treatments are equal.  Thus, there is no 
opportunity to improve response rates by treating with one treatment compared 
to another.  This reduction in response rates results in reduced utility and 
testing increases costs over a treat all strategy so that the testing strategy is 
dominated by the strategy of treating all with TNFi.   
The model makes the assumption that patients who will respond to both 
treatments are prescribed TNFi in the first instance, as this follows licensing and 
clinical guidance in the UK.  However, where it is acceptable to prescribe either 
treatment, there is an opportunity for the cheaper treatment to be prescribed 
when responses overlap.  The bigger the overlap, the larger the likely cost 
savings to be made. 
Scenario 5 – 25% of patients continue to be treated empirically under test and 
treat strategy 
The purpose of this scenario is to evaluate the impact of behavioural aspects 
known to affect diagnostic technologies.  The scenario assumes that for 25% of 
patients who are tested the clinician and/or patient do not follow the result of 
the test but prescribe as if under the treat all strategy.  At 25% test and ignore, 
the response rate improvement at 3 months is reduced to 17% which results in an 
ICER just below the £30,000 upper threshold in the UK.  It will be key for the 
developers to investigate which factors may lead clinicians and/or patients to 
test but then disregard the results and prescribe empirically. 
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Figure 8-10: Scenario analysis - treatment response and overlap 
    
Scenario 2 – response rates equal, non-response rate and overlap equivalent to base case; Scenario 3 – response rates held at 65% but overlap reduced to 
minimum without overall response rate exceeding 100%; Scenario 4 – response rates held at 65% but complete overlap of responders assumed so that 
non-response rate increases to 35% 
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8.3.4 Conclusion of mid-stage analysis 
The updated clinical value assessment and the economic value assessment 
demonstrate that a test of response to TNFi has the potential to be cost-
effective in a UK setting but that the cost-effectiveness is particularly sensitive 
to the relative cost of the treatments under consideration.  The analysis 
supports the continuation of the development at this stage-gate subject to a 
number of considerations discussed in the general conclusions for the case study 
in section 8.4.2 
8.4 Discussion 
8.4.1 Strengths and limitations 
This case study demonstrates several strengths of the methods of development-
focused HTA.  Firstly, the simple modelling provides a means of communication 
between the development team and other stakeholders and facilitates discussion 
around the technology under development.  Rheumatoid arthritis is a complex 
disease to model and full models are both resource-intensive and difficult to 
interpret.  This model allows the development team and other stakeholders to 
see the impact on short term response rates of the different parameters – and 
the cost associated with achieving those increases.  The complex aspects are not 
ignored but are dealt with outside of the modelling.  As well as showing the 
impact of the different parameters on the response rates the model allows 
different scenarios to be assessed.  The case study also demonstrates the value 
of the wealth of information available from a rapid literature review of key 
sources such as HTA reports and NICE and SIGN guidelines for the mapping of the 
clinical pathways and potential health impact of the technology.  The iterative 
approach showed that analysis can be undertaken before any technology specific 
evidence is available thus providing a prima facie case of clinical value before 
any research cost has been incurred.   
Development-focused HTA incorporates methods with a wider remit than 
reimbursement-focused HTA and the inclusion of scenario analysis taking into 
account the dynamic therapeutic environment in RA ensures that issues such as 
the potential impact of biosimilars and JAK inhibitors are explicitly considered.  
183 
 
Furthermore, the modelling identified areas where clinician and patient output 
were required (such as preferred outcome measure and likelihood of adhering to 
result) suggesting that stakeholder consultation would be appropriate. 
The approach adopted in this case study also had a number of limitations.  The 
analysis assumed a class action for TNFi.  This may not be the case and 
Stevenson et al (2016) did not make a class action assumption in their multiple 
technology assessment of bDMARDs.  However, Stevenson et al (2016) did 
comment that there was little difference between most of their modelled 
strategies.  Whilst it may be an acceptable approach at this stage, the 
identification of a prediction signature for a particular drug is likely to be more 
acceptable to clinicians and patients as well as more helpful in deciding 
between the increasing number of drugs offered in this area.  Scenarios 
modelled to date all assume that TNFi is prescribed both for non-responders and 
for those patients predicted to respond to both TNFi and rituximab.  Although 
this may under-estimate the potential benefit of the test and treat strategy it is 
likely to be representative of clinical practice as rituximab is not licensed for 
use before a TNFi in the United Kingdom and other Western jurisdictions.  In 
markets where clinicians were prepared to prescribe rituximab before a TNFi 
and rituximab was cheaper, there may be potential to realise a cost-saving by 
prescribing rituximab to those who were predicted to respond to both although 
this is highly dependent upon the proliferation and pricing of the many 
biosimilars currently being introduced.  The population in the ORBIT trial were 
all sero-positive.  There is a possibility that estimates of response improvements 
are increased as response to rituximab is thought to be higher in sero-positive 
patients (Porter et al, 2016).  The model assumed that utilities were equivalent 
across responders to different treatments and for all levels of response.  An 
improvement to the model would be to consider other levels of response such as 
good response or remission over other time periods.  A final limitation is that the 
fact that the analysis uses a UK-centric approach.  Other jurisdictions have very 
different ways of assessing whether a technology is deemed cost-effective and 
there is potential to market directly to patients.  It is key that the development 
team take a broad view about which jurisdiction in which the technology may be 
most viable and valuable.   
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8.4.2 Conclusions, implications and next steps for the 
development team 
Conclusions from the development-focused HTA exercise in this case study can 
be linked back to the decisions that the exercise was seeking to inform which 
were technology design, evidence generation strategy and go/no go decision.  
Aspects of technology design that could be informed in this case study included 
required test performance, choice of outcome measure and placement of the 
tests in the diagnostic/treatment pathway.  The HTA has shown that test 
performance is not critical to the value proposition of the tests but that 
treatment response rates and the overlap between the response to the different 
treatments are important.  As more data are generated, some further 
investigation into alternative thresholds may be warranted to assess the impact 
of maximising sensitivity or specificity to either of the treatments.  This may be 
particularly important if different measures of outcome are being considered.   
Choice of outcome measure may be of key importance as the initial value 
proposition assessment demonstrated that if the odds ratio for the treatments is 
different for the quality of response, then this may result in a different value-
based price.  The data available meant that the prediction of response could 
only be modelled for response overall at three months, however, in later stages 
of development it would be informative to model different levels of response at 
different time points.  Patients and clinicians may also have preferences for 
particular outcome measures (both in terms of quality of response and time of 
response) so this aspect may impact upon uptake of the test.  Some initial 
qualitative work has been undertaken by the project team to begin to assess this 
but is not reported here.  In other jurisdictions, utility may not be the method of 
assessing health outcome and it may be worth investing in either some direct 
elicitation of patients’ willingness to pay for the technology in key jurisdictions 
or collecting data on willingness to pay for comparable technologies. 
In terms of placement in the pathway, the current exercise modelled a plausible 
clinical scenario for the use of the tests in the United Kingdom.  This involved 
testing for both TNFi and rituximab response and assuming that everyone is 
treated with TNFi apart from those patients predicted to respond to rituximab 
but not to TNFi.  It is plausible that rituximab could be prescribed to the group 
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predicted to respond to both which may result in cost savings (depending on 
relevant price differentials).  It may also be plausible to look at testing for 
response to both agents earlier in the treatment pathway in some jurisdictions if 
clinicians are prepared to prescribe bDMARDs to patients either before or with a 
shorter exposure to cDMARDs.  The tests may have greater potential value used 
earlier and in conjunction with a test for non-response to cDMARDS.  If such a 
test could identify non-responders to cDMARDs who would respond to bDMARDs 
then this could considerably accelerate treatment decisions and prevent 
structural damage and disutility (and other consequences such as loss of 
employment).  This more aggressive treatment approach may be suitable in a 
younger age group where employers’ insurance schemes may take productivity 
losses into account and be prepared to fund more expensive treatment 
regimens. 
Evidence generation strategies was the second area that the development-
focused HTA exercise aimed to inform.  The one-way sensitivity analysis 
identified treatment response and costs of both the test and treatments as key 
parameters.  Neither costs nor effectiveness were highly sensitive to test 
accuracy parameters.  The next stage in development involves the validation of 
the transcriptomic signatures using a panel.  If the signatures continue to show 
the same level of accuracy, then a further evidence generation stage will be 
required.  The developers need to consider how to design this evidence 
gathering in the most efficient way.  Prospective trials are not always required 
by regulators and early contact with relevant regulatory/scientific bodies to 
ensure that evidence generated would meet all regulatory requirements is 
recommended.  Levin (2015) explains how this single, harmonised approach has 
been developed in the MaRS Excite programme in Ontario, Canada (MARS, 2020).  
NICE also offer a scientific advice service (NICE, 2018e) to advise developers 
about the kind of evidence that would be required to demonstrate the value of 
the technology.  It may be possible to use other repositories of samples and 
observational data to extend the retrospective validation of the signatures to a 
wider range of bDMARDs and to include both sero-positive and sero-negative 
patients.  It may also be valuable to consider likely price differentials and 
clinical guidelines in alternative jurisdictions in order to prioritise the test into 
those jurisdictions where the technology could be most valuable.  A partnership 
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with one of the pharmaceutical companies active in the area may provide access 
to extensive global knowledge of these aspects.  
The final decision which the exercise aimed to inform was a decision whether to 
continue to invest or a so-called go/no-go decision.  At both the initial and the 
second stage the tests generated additional response to bDMARDs in the short 
term.  This indication of clinical utility means that the technology is likely to 
have an economic value to some patients/clinicians in some jurisdictions.  The 
cost-utility analysis suggested that the technology would meet the criteria to be 
made available in the UK NHS provided it was assessed as a companion 
diagnostic.  However, the utility gain generated was quite small and the ICER 
was very sensitive to movements in the relative costs of the treatments and to 
the cost of the test itself.  The cost of the test is currently unknown and difficult 
to estimate due to the speed of technological advancement.  The relative cost 
of treatments is also uncertain and varies across jurisdictions due to patent 
expiry, licensing status of biosimilars and the emergence of new modes of action 
in this therapeutic area.  Given that this technology is believed to be a ‘first in 
class’ i.e. no comparable technology exists it would seem reasonable to take an 
optimistic view of its potential and to advise that the development team 
continue to invest. 
In summary, the development team may wish to consider: 
• a wider (treatments and populations) retrospective analysis in large 
observational datasets if blood samples are available 
• a partnership approach with one of the pharmaceutical companies with 
knowledge of global treatment pathways and costing structures 
• contacting licensing/regulatory authorities to ensure next stage of evidence 
generation is acceptable for all purposes 
• engaging with stakeholders to ensure that the test is acceptable to patients 
and clinicians and that design is optimised to maximise impact on response 
rates, use and adherence 
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• including behavioural aspects in any future evidence generation exercise 
• to investigate opportunities to use the test earlier in the treatment pathway 





9 Case study 3 - HTA of extension to molecular 
pathology testing in colorectal cancer 
9.1 Introduction 
This chapter is based upon a manuscript accepted for publication in the 
International Journal of Technology Assessment in Health Care in May 2019.  The 
co-authors are Yun Yi Tan and Janet Graham (clinicians), Gillian McGaffin, 
Graham Smith, Paul Westwood and Nicola Williams (pathologists), David Creed 
(employee of Merck Serono Ltd), Neil Hawkins (health economist) and Ruth 
McLaughlin (previously project manager of Glasgow Molecular Pathology Node).  
Yun Yi Tan undertook the original clinical audit edited the draft for clinical 
content.  Neil Hawkins validated the model and read and approved the 
manuscript.  Ruth McLaughlin was involved in the original design of the project.  
The remainder of the co-authors were members of the expert group and read, 
edited and approved the manuscript. 
The developers for this case study are a team of clinicians and pathologists 
working in the NHS in Scotland.  The study arose following a clinical audit of the 
pathway for molecular pathology results in metastatic colorectal cancer in the 
West of Scotland.  Clinicians were concerned that due to organisational factors 
results of key molecular pathology tests were not known at the time of the 
patient’s initial visit in a high proportion of cases.  The clinicians felt that this 
was resulting in sub-optimal consultations with patients and leading to some 
treatment choices being driven by the need to keep certain treatment options 
open. 
The stance of the HTA is normative in that there is a clear, proposed service 
change and are seeking to evaluate the change against a known set of criteria in 
operation within NHS Health Scotland.  MPEP consider evidence about costs of 
tests individually and for the national population as well as any savings or 
investment in the diagnostic or treatment pathways resulting from the 
introduction of the new test (NHS National Services Division, 2018).  The 
evidence is provided by the NHS staff applying for the extension to molecular 
pathology testing.  There is no requirement for modelling and no resource 
provided to undertake this.  The specific decision to inform is a one-off binary 
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decision, whether or not to extend the testing to a larger patient population.  
Although the logical core decision rule should be to allow the extension if it 
provides improved health outcomes for a given budget, it is unclear the extent 
to which the evaluation process provided for by MPEP facilitates a full 
evaluation.  In particular, it is unclear whether the system enables proposers of 
extensions to testing to demonstrate the full effects of a change throughout the 
diagnostic and treatment pathways and on both health outcomes and costs.  The 
evaluation process is not developed as it is for pharmaceuticals and companion 
diagnostics which are assessed by the Scottish Medicines Consortium (SMC) 
against published criteria (Scottish Medicine Consortium, 2018a).  Medicines (and 
their companion diagnostics) are mandated if they are recommended by the SMC 
and they are likely to be recommended provided they have an incremental cost-
effectiveness ratio below a known threshold.  This means that an increased cost 
of testing can be mandated as long as there is a corresponding increase in health 
outcomes.  For stand-alone diagnostics there is no parallel procedure.  Formal 
health economic evaluation is not undertaken for non-companion diagnostics 
although cost implications are clearly taken into account in some manner.  It is, 
therefore, possible that the core decision rule is more concerned with the 
impact of accepting the test on the budget for molecular pathology testing 
rather than on the cost-effectiveness of the change for the diagnostic and 
treatment pathway as a whole. 
The absence of a health economic evaluation framework for stand-alone 
molecular testing means that there is no established burden of proof for this 
work and that there is little resource available for the analysis or for evidence 
gathering/generating activities.  Thus, the similarity to development-focused 
work arises from the absence of a clear structure of evaluation for stand-alone 
molecular tests and the committed resource that accompanies such a structure. 
Colorectal cancer (CRC) is second only to lung cancer in incidence in Scotland 
(ISD Scotland, 2018a).  3,700 cases were diagnosed in 2016 and it was the cause 
of 1,687 deaths in 2017 (ISD Scotland, 2018a).  Cancer services in the National 
Health Service (NHS) in Scotland are organised on a regional basis with the West 
of Scotland region accounting for 1,682 (45%) of the incident cases in 2016 (ISD 
Scotland, 2018a).  The West of Scotland Cancer Network (WoSCAN) serves a 
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population of 2.5 million people (approximately 46.5% of the Scottish 
population) (WOSCAN, 2018).  Cancer care in the West of Scotland region is 
delivered at 15 hospitals funded by 4 regional health boards (WOSCAN, 2018) 
supported by a centralised molecular pathology laboratory funded on a national 
basis (NHS National Services Division, 2018).  Molecular biomarker testing in CRC 
was standardised across Scotland in 2015 when the Molecular Pathology Steering 
Committee approved a national patient testing pathway whereby all patients 
with metastatic disease were offered testing for mutations in KRAS, NRAS 
(collectively referred to as RAS) genes, both of which encode proteins involved 
in the epidermal growth factor receptor (EGFR) pathway, and in the BRAF gene, 
which is a downstream effector of the RAS genes.  The aim of this national 
pathway was to ensure both equity of service across Scotland and also effective 
patient stratification for prognostic or therapeutic purposes.  
RAS and BRAF testing in the West of Scotland are currently carried out on 
request after the confirmation of metastatic disease and through the multi-
disciplinary meeting (MDM) where clinical colleagues discuss a patient’s results 
and treatment.  This is believed to be the current practice in most NHS settings 
(NICE, 2018b).  RAS mutation status impacts upon treatment options as only 
patients with RAS wild-type disease (i.e. no NRAS or KRAS mutations) would be 
offered epidermal growth factor receptor inhibitors (EGFRi) - such as 
panitumumab and cetuximab - and these drugs must be given in conjunction 
with an infusional intravenous (IVI) chemotherapy regimen including a 48-hour 5-
fluorouracil (5-FU) infusion administered through a central venous catheter as an 
outpatient.  Approximately 50% of patients have RAS mutated disease and can be 
offered non-infusional regimes using oral capecitabine with intravenous 
oxaliplatin (oral+IV) instead of infusional 5-FU with similar clinical benefit 
(Cassidy et al, 2008; Ducreux et al, 2011).  Patients with BRAF mutations have a 
significantly poorer prognosis and require a different treatment regimen (BRAF 
mutant patients have an estimated overall survival of 6-9 months, compared to 
over 36 months estimated overall survival for RAS and BRAF wild type patients).  
Therefore, there is a significant impact on the level of information that can be 
given at a first consultation when the RAS and particularly BRAF mutation status 
are not known (Yuan et al, 2013). Internal audit data from the West of Scotland 
also demonstrate that due to the poor prognosis conferred by mutant BRAF 
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status; these patients are unlikely to reach second line therapy and would be 
best served by entry into clinical trials or consideration of triplet chemotherapy 
first line.   
As patients are appointed to oncology clinics as soon as possible after the 
diagnosis of metastatic colorectal cancer, the results of genetic tests are often 
unavailable at the first oncology appointment. Patients usually expect to discuss 
their diagnosis, prognosis and management plan at their first appointment, and 
also expect to start systemic treatment at the earliest opportunity, particularly 
if they have high symptomatic burden. Without the genetic test results, 
definitive information about prognosis and the treatment plan cannot be given. 
To avoid delays in treatment, patients fit for all therapies are often consented 
for insertion of a peripherally inserted central venous catheter (PICC) and 
commenced on an IVI chemotherapy regimen while awaiting the RAS test result 
in case they become eligible for the addition of EGFRi. Even so, patients with 
RAS wild-type disease will require a further consultation with medical staff in 
order to consent to the additional EGFRi.  Patients with BRAF-mutant disease 
may have missed the opportunity to participate in clinical trials specific to their 
disease.  Patients with RAS mutant disease are highly likely to remain on IVI 
chemotherapy once commenced, which is more expensive than the oral+IV 
alternative as well as being more invasive and inconvenient for patients.  
Clinicians suggested that a potential solution to the delays in availability of test 
results and consequent sub-optimal interventions would be to incorporate KRAS, 
NRAS and BRAF gene testing into the routine tests undertaken on diagnosis for all 
patients, including those without metastatic disease.  This reflex testing strategy 
would serve a further purpose of improving the information available to study 
the RAS and BRAF mutation colorectal cancer patient cohorts as they represent 
large areas of unmet clinical need.  Screening patients in the first line setting 
offers the opportunity to correlate response to adjuvant chemotherapy, disease 
free survival and primary tumour site with mutation status in order to advance 
the standard of care for these patients.  Screening of patients at diagnosis for 
the presence of mutations in RAS and BRAF would also offer the opportunity for 
increased entry of patients onto clinical trials in the adjuvant setting.  Reflex 
testing of all new colorectal cancer diagnoses would allow the implementation 
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of a robust system for the collection and processing of deoxyribonucleic acid 
(DNA) for this patient cohort; thus providing a repository of diagnostic material 
that can potentially be used for extended testing for patients wishing to enter 
future clinical trials or for selection of appropriate patient cohorts for future 
therapies associated with a molecular companion diagnostic marker.  However, 
this extension to testing would increase costs for the nationally-funded 
molecular pathology service so an economic evaluation of the change in 
downstream treatment costs and health outcomes was requested.    
The aim of economic evaluation is to consider the costs and consequences of a 
course of action in order to determine whether this use of resources is better 
than the next available alternative (Drummond et al, 2015).  The objective of 
this study was to consider whether the strategy of reflex testing all CRC patients 
for RAS and BRAF status on diagnosis would be cost-effective compared to 
testing patients on request.    
9.2 Methods  
This case study comprises a clinical value assessment and an economic value 
assessment.  The initial clinical value assessment was based on a clinical audit of 
the pathways for CRC molecular pathology testing.  Further evidence generation 
took place through the activities of a multi-disciplinary panel and mining of 
routine data sources.  As the panel were satisfied that the extension in testing 
would only lead to an improvement in health outcomes, the economic value 
assessment took the form of a cost-minimisation analysis.   
The initial step in the process was to form a multi-disciplinary project team 
including molecular pathologists, clinician and health economists.  An employee 
of Merck, the manufacturer of cetuximab was also part of the project team as 
the company collect a substantial body of evidence on CRC and are 
knowledgeable about molecular pathology practice on an international basis.  
This multi-disciplinary team was important to ensure that all relevant 
considerations were included.  The current and proposed treatment pathways 
for newly diagnosed patients were mapped in outline using clinical guidelines 
from the National Institute for Health and Care Excellence (NICE, 2014) and the 
Scottish Intercollegiate Guideline Network (SIGN, 2018) and input from 
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clinicians.  These pathways were set out as a decision tree with a 26 week time 
horizon as this is in line with first-line treatment duration.  This time-horizon 
was felt to be sufficient to capture any differences in costs.  A UK NHS 
perspective was adopted.  Clinical outcomes were not modelled as in the 
judgement of the project team clinical outcomes would only be improved by the 
change from the current to the proposed pathways.  This is because outcomes 
from oral and infusional chemotherapy regimens are equivalent (Cassidy et al, 
2008; Ducreux et al, 2011) and outcomes would improve due to reduction in 
adverse events and reduction in quality of life associated with the insertion of a 
PICC line. 
Figure 9-1 shows both the current pathway whereby patients are tested for 
NRAS/KRAS/BRAF at confirmation of metastatic disease and the proposed 
pathway where all patients are tested at diagnosis.  The first split of the tree 
indicates the decision whether to follow the current or the proposed pathway.  
The second split in the current pathway shows the division between metastatic 
and non-metastatic disease.  For patients with metastatic disease the next split 
divides those who have resectable (operable) disease from other metastatic 
patients.  For some patients with unresectable disease IVI chemotherapy would 
be inappropriate, for example due to patient fitness, and this is shown as the 
third split in the decision tree.  For the remainder of patients with unresectable 
disease, some have a RAS/BRAF result known at their first oncology 
appointment.  If the result is known, PICC lines are inserted appropriately and 
chemotherapy started according to NRAS/KRAS status.  Where the result is 
unknown, PICC lines are inserted and IVI chemotherapy commenced (in case 
EGFRi can be added once the result is known).  For patients with non-metastatic 
disease at diagnosis, the model only includes the cost of later NRAS/KRAS testing 
which is done for patients who later relapse.  Where results are not known at 
the initial clinic visit a further clinic visit is required to inform the patient of 
test results and implications.  This is not represented in Figure 9-1 to retain 
clarity of presentation. 
In the proposed pathway (the lower branch of the decision tree) all patients are 
tested for NRAS/KRAS/BRAF status at diagnosis of CRC (reflex testing).  This 
allows a simplification of the metastatic, unresectable disease branch as all 
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results are known.  In the proposed pathway, all patients with no mutations (all 
wild-type) will have PICC lines inserted and receive IVI chemotherapy.  Some 
patients with mutations will continue to receive IVI chemotherapy where the 
clinician recommends this.    
Data to populate the decision trees was taken from national and regional cancer 
registries, a comprehensive Health Technology Appraisal on treatment with 
cetuximab (NICE, 2018a), SMC Advice on cetuximab (Scottish Medicine 
Consortium, 2018b) , UK NHS reference costs (NHS, 2018) and a micro-costing of 
current and proposed laboratory costs undertaken by the project team.  Some 
assumptions were made by the project team based upon their clinical knowledge 
(proportion of patients who would be clinically unable to receive IVI 
chemotherapy, the proportion of patients whose cancer was metastatic but 
wholly resectable (i.e. both primary tumour and metastatic sites operable) at 
diagnosis, and the proportion of patients whom clinicians would choose to treat 
with an IVI regimen regardless of whether they would later qualify for treatment 
with cetuximab).  Inputs to the model and data sources are set out in Table 9-1.  
PICC and Hickmann line insertion and maintenance incurs costs which include; 
out-patient appointment for siting of line, imaging to ensure placement is 
correct and district nurse support in the form of twice weekly visits for flushing 
and maintenance of the line and port.  PICC and Hickmann lines are also 
associated with adverse side effects such as bleeding, clots, infection risk and 
slippage of line requiring re-siting.  The costs included for these lines are based 
on the costs of PICC line insertion, removal and maintenance.  Costs of adverse 
events are not included in the model.  Costs are not discounted given the short 




Figure 9-1: Decision Tree - current and proposed treatment pathway 
 
 PICC – Peripherally inserted central catheter, IVI – intravenous infusional chemotherapy, 
Oral+IV – Oral and intravenous chemotherapy, CRC – colorectal cancer.  Diamond 
represents a decision node. Circle represents a probability node.  Percentages represent 
the base case estimates (see Table 9-1).  Solid arrow represents branches where treatment 
pathways are identical between the current and proposed strategies, striped arrows 
represent changed treatment pathways  
One-way sensitivity analysis was undertaken whereby certain input parameters 
were varied in turn over a given proportion (whilst all other inputs to the model 
were held constant) to determine the impact of an over or under-estimation on 
the base-case results.  This form of sensitivity analysis was undertaken as this 
allowed decision makers to assess the individual impact of each of the input 
parameters.  One way sensitivity analysis was undertaken for 1) the proportion 
of patients metastatic at diagnosis (range 20% -55% taken from NICE Technology 
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calculated in micro costing exercise to £200 which is the level reimbursed 
previously by Merck to laboratories carrying out these tests and considered to 
include an element of surplus over cost) and 3) the proportion of patients whose 
disease was not metastatic at diagnosis but who subsequently relapse (range 29% 
reduced to zero).   
Where no suitable range could be identified from evidence sources the range 
was varied to determine the highest level at which the cost savings would be 
reduced to zero.  This threshold analysis was undertaken for the proportion of 
patients who are NRAS/KRAS/BRAF wild type, the proportion of patients with 
resectable metastatic disease, the proportion of patients for whom IVI 
chemotherapy would be inappropriate, the proportion of patients prescribed IVI 
chemotherapy regardless of NRAS/KRAS/BRAF status and the proportion of 
results currently known at the multi-disciplinary team meeting.   
Some input variables were not varied as the project team was confident that the 
value was appropriate and supported by good quality evidence.  These variables 
were incidence of CRC in the West of Scotland which is supported by registry 
information and the cost of FOLFOX and XELOX (IVI and oral+IV chemotherapy 
treatments) which was obtained from a comprehensive Technology Assessment 
report (NICE, 2018a).  The costs relating to PICC lines were also not subject to 
sensitivity analysis as they are believed to be under-estimated by the project 
team.  This is primarily because maintenance of a PICC line used in the West of 
Scotland in CRC requires two visits per week by a district nurse which would cost 
more than the £63 allowed in this analysis.  Moreover, no costs are included for 
the adverse events associated with PICC lines, such as blockage and infection.
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Table 9-1: Inputs to the model and data sources 
Epidemiology   
Proportion of patients metastatic at diagnosis [a] 0.31 
Proportion of metastatic patients with KRAS/NRAS wild-type (Scottish Medicine Consortium, 2018b) 0.50 
Proportion of patients for whom IV treatment is not appropriate [b] 0.10 
Proportion of patients with mutations who receive IVI chemotherapy for other clinical reasons [b] 0.30 
Proportion of non-metastatic patients at diagnosis who will relapse [a] 0.29 
Proportion of metastatic patients with resectable primary and metastases [b] 0.10 
Proportion where RAS/KRAS/BRAF status known at first clinic visit [c] 0.20 
Incidence of colorectal cancer in the West of Scotland 2015 1,606 
Costs  £ 
Cost of current KRAS/NRAS/BRAF test [d] 120 
Cost of proposed KRAS/NRAS/BRAF test [d] 120 
Cost of oral+IV chemotherapy (26 weeks) (Scottish Medicine Consortium, 2018b) 5,832 
Cost of IVI chemotherapy (26 weeks) (Scottish Medicine Consortium, 2018b) 9,893 
PICC line insertion (NHS, 2018) 377 
PICC line removal (NHS, 2018) 176 
PICC line maintenance (NHS, 2018) 63 
Total PICC line cost [e] 2,191 
Clinic visits (NHS, 2018) 197 
Number in brackets is the reference to the source of the data where a reference is included.  Letters refer to the notes below:  
[a]Data provided by David Creed, co-author (unpublished) 
[b]Expert opinion from cross-disciplinary project team 
[c]Data from internal audit performed by Janet Graham and Yun Yi Tan (co-authors) 
[d]Data from micro-costing analysis undertaken by Gillian McGaffin (co-author) at Glasgow Molecular Pathology Laboratory (2018) 
[e]Calculated as insertion+removal+(26xmaintenance) 
IVI – intra-venous infusional chemotherapy regimen, oral+IV – oral and intravenous chemotherapy regimen, PICC – peripherally 




The base-case analysis indicated that the process change would save £397 per 
patient which equates to £637,332 per annum in the West of Scotland.  This 
saving results primarily because approximately 7% of patients (n=112) were 
predicted to avoid PICC line insertion and IVI chemotherapy which more than 
outweighs the additional cost of testing for those patients with non-metastatic 
disease at diagnosis and who do not relapse.  Those avoiding PICC line insertion 
and IVI therapy can be seen from Figure 9-1 as in the current strategy the 
striped arrowheads showing IVI treatment total 24% (3%+1%+10%+10%), whereas 
under the proposed strategy IVI treatment totals only 17% (4%+13%).  Additional 
testing costs are incurred for 49% patients being the difference between testing 
100% patients under the proposed strategy compared to 51% (31% metastatic plus 
29% relapsed of 69% non-metastatic) under the current strategy.  Testing costs 
are anticipated to reduce under the new testing strategy as a result of increased 
volumes and this test cost has been included as both current and proposed test 
cost in order to ensure estimates of cost savings are conservative. 
Sensitivity analysis showed that the overall cost saving was not highly sensitive 
to any individual parameter when varied within ranges judged feasible by the 
project team.  The threshold analysis showed that the assumptions made about 
the proportions of patients falling in each category could vary considerably 
before the overall cost saving was reduced to zero.  This is because the cost 
saving from diverting an individual patient from IV treatment and PICC insertion 
is high compared to test costs so that only a small number of patients need to be 
diverted in order for the proposed change to deliver cost savings.   Table 9-2 




Table 9-2: Base-case results, sensitivity and threshold analysis 
Base case  £ 
Cost saving per patient 397 
Cost saving for the West of Scotland (annual incidence n=1,606)  637,332 
Additional costs of testing (49% of 1,606 patients at £120 per 
test) 94,433 
Cost savings from PICC lines (7% of 1,606 patients at £2,191) 246,312 
Cost savings from treatment with oral+IV rather than IVI 
chemotherapy (7% of 1,606 patients at £4,061 (£9,893-£5,832)) 456,538 
Cost savings from additional clinic visit (7% of 1,606 patients 
at £197) 22,147 
Sensitivity analysis Cost saving in £ 
 
Proportion of patients metastatic at diagnosis [range 20% -55%] 
(Scottish Medicine Consortium, 2018b)  362,629 – 1,236,684 
Proposed test costs [increased from £120 to £200] 570,407 
Proportion of patients whose disease was not metastatic at 
diagnosis but who subsequently relapse [reduced from 29% to 
0%] 549,769 
Threshold analysis Base case 
To reduce cost 
savings to zero 
Proportion of patients who are NRAS/KRAS/BRAF wild type 50% 93% 
Proportion of patients with resectable metastatic disease 10% 82% 
Proportion of patients for whom IVI chemotherapy would be 
inappropriate 
10% 87% 
Proportion of patients prescribed IVI chemotherapy regardless 
of NRAS/KRAS/BRAF status 
30% 90% 





9.4 Discussion  
A strength of this study is that it demonstrates the use of economic evaluation to 
assess a change of process at a regional level.  This change of process is likely to 
be cost saving for the region and suggests that this approach may offer a means 
of delivering process change, efficiencies and perhaps disinvestment on a wider 
scale within healthcare services.  Key aspects of the study in this regard were 
the local focus, the buy-in of a cross-disciplinary expert project group 
representing the different service areas affected and the presentation of both 
qualitative and quantitative information to the decision makers. 
Previous adaptations to molecular pathology testing in Scotland have not been 
supported by health economic analysis.  This analysis was made possible through 
the involvement of Glasgow Molecular Pathology Node (GMP Node), a 
collaboration between the University of Glasgow, NHS Greater Glasgow and 
Clyde and commercial partners, funded by the Medical Research Council and the 
Engineering and Physical Sciences Research Council.  This study demonstrates 
the value of such translational research bodies in facilitating the introduction of 
molecular pathology tests into clinical practice.  The GMP Node provided a 
forum for clinicians and pathologists to collaborate and funded the health 
economics aspect of the study.   
Further strengths of the study are that it was relatively quick and resource light, 
as a result of the suitability of a costs-only analysis, the simplicity of the model 
and the approach to evidence gathering.  A costs-only analysis was possible as 
outcomes were only likely to be improved by the availability of more information 
or earlier information.  The model was simple as it considered only costs and had 
a relatively short time horizon.  Evidence was based on easily available national 
resources and local experience informed by the expert project team.  One-way 
sensitivity analysis was appropriate as the cost saving was relatively large and 
not sensitive to any individual parameter.  It also allowed decision makers to 
assess the importance of individual parameters.  Had the result been more 
sensitive then multi-way sensitivity analysis may have been appropriate.  
Probabilistic sensitivity analysis was not appropriate given the number of 
assumptions made by the project team as this may have given an impression of 
false precision.    
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A limitation of the study was the extent to which the modelling relied upon 
assumptions made by the expert project team.  This study will be followed by a 
practical pilot project which will assess the validity of the assumptions.  Given 
the fast-moving environment of molecular pathology testing this change in 
process is likely to happen in any event if trials of PDL1+/- CTLA4 inhibitors 
become the standard first-line metastatic treatment for therapy for patients 
with micro-satellite instability high metastatic cancers (National Cancer 
Institute, 2018).  The use of these same agents in the adjuvant setting is 
beginning to be investigated in clinical trials such as POLEM (Clinical Trials 
Register, 2017). 
The decision to be informed in this study was whether the extension of the 
pathology testing for CRC in the West of Scotland should be funded.  This study 
found that an extension of testing for RAS/BRAF to all patients diagnosed with 
CRC in the West of Scotland is likely to deliver cost savings as reductions in 
downstream treatment costs would more than outweigh the additional cost of 
testing.  Although the same finding may be true in other locations the study’s 
findings are not directly generalizable as they are dependent upon existing local 
treatment pathways, the organisation of local cancer services and capacity and 
organisation of molecular pathology services.  The savings are delivered because 
cancer services in the region are dispersed across a number of sites with key 
clinicians providing services in more than one location.  The result of this is that 
organisational change is more complex and other ways of achieving the cost 
savings are not possible.  By way of contrast, molecular pathology services are 
centralised in one laboratory with a high throughput so that economies of scale 
can be achieved. 
The immediate implication of this study for policy-makers is that, dependent on 
local context, downstream treatment efficiencies may be realised through 
changes to molecular pathology testing arrangements.  More generally, economic 
evaluation coupled with a cross-disciplinary project group may offer a method of 
increasing efficiency of treatment pathways.  This example was relatively 
straightforward as outcomes could be assumed to be improved and the process 
change could be justified on cost saving alone.  Other situations are likely to be 
more complex.  In this study, an increase in spending is required in one area of 
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the treatment pathway in order to deliver savings elsewhere.  In order for this 
approach to be useful in delivering treatment pathway efficiencies policy makers 
will need to consider the incentives of all budget holders across the treatment 
pathway and other stakeholders.  In Scotland, incentives are more 
straightforward than in many other contexts, although, even in this nationally 
funded system, test costs are borne nationally whereas savings will be realised 
by the regional health boards who meet the costs of cancer treatment.   Other 
aspects which may be of importance in certain local contexts are capital 
expenditure required and any capacity constraints.  In this case, no capital 
expenditure was required and capacity could be increased in Glasgow Molecular 
Pathology Laboratory; these aspects were costed as part of the micro-costing 
analysis. 
Next steps for the developers in this case include further clinical audit to 
ascertain the veracity of the assumptions made in this analysis.  This audit is 
likely to extend outside of the West of Scotland region to determine whether the 
finding is applicable to other areas of Scotland.  Given the fast-moving nature of 
the molecular pathology testing environment, MPEP will be required to review 
testing requirements for CRC again in the near future.  It will be important for 
any review to be supported by an appropriate level of health economic analysis 




10 Case study 4 - Assessment of triage tests when 
existing test capacity is constrained: application 
to an imaging test to aid diagnosis of malignant 
melanoma 
10.1 Introduction 
An adapted version of this chapter, entitled ‘Evaluation of triage tests when 
existing test capacity is constrained: application to rapid diagnostic testing in 
CoVID-19’ co-authored by Neil Hawkins, is in preparation.  
Where development is technology-driven (i.e. the technology has been 
developed without a clear setting or position in the clinical pathway identified), 
a first step in assessment is the consider the optimum positioning of the 
technology.  Diagnostic tests sometimes replace existing tests, but they also may 
be added to the diagnostic pathway or may act as a triage test where the result 
of the new test determines which patients undergo an existing test.  This is 
illustrated in Figure 10-1 below. 
Figure 10-1: Roles of tests and positions in existing diagnostic pathways  
 
+ve – test positive, -ve – test negative. Reproduced from Bossuyt et al (2006) with 
permission. 
The introduction of a triage test does not aim to improve the diagnostic 
accuracy of the current pathway.  Rather, it reduces the use of existing tests 
that may be more invasive, cumbersome or expensive than the existing test or 
for which the patient may need to wait (Bossuyt et al, 2006).  An example of a 
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triage test is a blood test measuring levels of D-dimer in patients with pulmonary 
embolism (Bossuyt et al, 2006; Page, 2006).  The ‘reference’ diagnostic test is 
computed tomography (CT), which is highly accurate.  However, CT is expensive, 
requires skilled staff to undertake it and capacity is constrained, so patients may 
need to wait before they are tested.  Although D-dimer has low specificity 
(around 50%), it has high sensitivity and negative predictive value (above 99%) 
(Page, 2006).  This means that although D-dimer does not pick up all patients 
who are disease negative, when there is a negative result, it is highly likely that 
the patient is disease negative.  As the test is cheap and there is no waiting 
time, D-dimer has potential as a triage test to rule out pulmonary embolism. 
Tests may be classified as either “rule-in” tests, intended to confirm that a 
patient has a specific disease or as ‘rule-out’ tests, intended to confirm that a 
patient does not have a disease. “Rule-in” tests require high specificity and 
“rule out” tests, high sensitivity.  This relationship is known as the SPIN and 
SNOUT rule (SPecific test when positive rules IN the disease - SPIN and Sensitive 
test when Negative rules OUT the disease’ – SNOUT) (Baeyens et al, 2019).  The 
extent to which a ‘rule-in’ or ‘rule-out’ test is preferred will depend on the prior 
probability of disease and the consequences, both to the patient and in terms of 
healthcare resource use, of false positives and false negatives.  In this chapter, 
the use of ‘rule-in’ and ‘rule-out’ test in triage testing is explored in contexts 
where the existing ‘reference’ test capacity is both constrained and 
unconstrained.  The chapter sets out to demonstrate that, if facilities for 
reference testing are restricted, there may be a role for a triage test to enrich 
the prevalence of disease in the tested population and improve the efficiency of 
the reference testing process.  A simple modelling approach is presented which 
can be used to explore the use of a triage test prior to a reference test.  Two 
situations are contrasted where the availability of the reference test is capacity 
constrained or non-constrained.  It is shown that the relevant metrics of test 
value, and the value of a test with given characteristics, vary depending on 
whether existing reference test capacity is constrained or not.  Generic models 
are developed then applied in a case study using test data for a diagnostic test 
for malignant melanoma.  The models presented in this chapter are not intended 
to provide definitive estimates of the clinical value and cost-effectiveness of a 
test, this typically requires the careful identification and synthesis of evidence 
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and the development of detailed decision-analytic or cost-effectiveness models 
which requires both time and significant resource.  Such models are often highly 
context specific.  Rather, the models presented here are simple models that can 
be readily used to provide an indication of the potential value of a test whilst it 
is under development or during some form of expedited review.  Such models 
are likely to be useful during the development of a test and provide a guide as to 
whether further investment in the development of a test is warranted and what 
studies are required to provide sufficient evidence to support the uptake and 
commercialisation of a test. 
The context for the case study is malignant melanoma (MM).  Here, the 
diagnostic pathway in the UK involves screening by primary care practitioners 
and onward referral to specialist dermatologists.  Due to the number of referrals 
from primary care, meeting the two-week targets set for specialist 
dermatologist review in England is challenging.  In some areas these targets are 
not being met.  Even where they are being met, the level of demand on 
specialists’ time may result in patients with other skin conditions being forced to 
wait.  As many of the patients referred with suspected MM will ultimately prove 
to be negative, there is a high opportunity cost in terms of health lost whilst 
patients with other conditions are waiting for specialist appointments.   
A commercial company developing an imaging test using machine learning to 
identify MM approached Neil Hawkins to undertake health economic assessment.  
The company’s initial aim had been to offer a test in primary care which would 
safely prevent onward referral of a proportion of the suspicious moles.  They had 
carried out an initial clinical study involving patients who had been referred to 
specialist dermatologists.   
10.2 Methods 
A decision analytic model was developed that predicted true and false positive 
and negative rates for a triage test (T) with given sensitivity (SENS), specificity 
(SPEC) and prevalence. In this case, sensitivity and specificity were defined 
strictly in terms of the probability that the triage test predicts positive and 
negative test results for a patient receiving the existing or ‘reference’ test that 
is used to determine the future treatment of a patient.  In this notation, P[R+] 
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(probability of testing positive in the reference test) is effectively the 
prevalence as it is assumed that the reference test is 100% accurate.  It is 
assumed that a patient testing positives or negatives with the reference test is 
disease positive or disease negative respectively. 
 
𝑆𝐸𝑁𝑆 = 𝑃[𝑇+|𝑅+] 
 
𝑆𝑃𝐸𝐶 = 𝑃[𝑇−|𝑅−] 
 




Figure 10-2: Decision tree comparing triage and no triage strategies 
 
Two ‘use cases’ are considered.  One where the reference test capacity is 
constrained and currently fully utilised and one where the reference test 
capacity can be varied in the short term according to demand. 
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10.2.1 Reference test capacity unconstrained use case 
Where the reference capacity is unconstrained, the reduction in the number of 
reference tests undertaken and the number of false negative results arising from 
the use of the triage tests can be estimated.  The reduction in the proportion of 
patients requiring the reference test following the triage test (the probability 
that a patient tests negative on the triage test) is given by: 
1 − (𝑃[𝑅+] × 𝑆𝐸𝑁𝑆 + (1 − 𝑃[𝑅+]) × (1 − 𝑆𝑃𝐸𝐶)) 
In these expressions P[R+] is the probability of the reference test being positive 
(equivalent to prevalence in this simple model where the reference test is 
assumed to be 100% accurate).  SENS means sensitivity of the triage test and 
SPEC, specificity of the triage test.  The proportion of missed cases, patients 
who test negative on the triage test but would have tested positive on the 
reference test, is given by: 
𝑃[𝑅+] × (1 − 𝑆𝐸𝑁𝑆) 
The reduction in the proportion of patients requiring the reference test and 
associated cost savings will need to be traded off against the missed cases. 
10.2.2 Capacity constrained reference test use case 
Where the reference capacity is constrained, rather than comparing the 
reduction in proportion of patients requiring the reference test and missed 
cases, the total number of true positive cases that are identified using the triage 
test is compared with the number identified using a reference test only strategy.   
The probability of testing positive at triage testing (𝑃[𝑇+]) is estimated: 
𝑃[𝑇+] = 𝑃[𝑅+] × 𝑆𝐸𝑁𝑆 + (1 − 𝑃[𝑅+]) × (1 − 𝑆𝑃𝐸𝐶) 
 
In this expression P[R+] is the probability of the reference test being positive 
(equivalent to prevalence in this simple model where the reference test is 
assumed to be 100% accurate).  SENS means sensitivity and SPEC, specificity.  
This provides an estimate of the proportion of patients for whom reference 
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testing is indicated following the triage test. The number of patients who can 
actually be tested will depend on the available capacity.   
The relative maximum population size (𝛿𝑡𝑟𝑖𝑎𝑔𝑒) that can be tested using the 






The probability of testing positive at the reference test following triage testing 
is then calculated: 
𝑃[𝑅+|𝑇+] =
𝑃[𝑅+] × 𝑆𝐸𝑁𝑆
𝑃[𝑅+] × 𝑆𝐸𝑁𝑆 + (1 − 𝑃[𝑅+]) × (1 − 𝑆𝑃𝐸𝐶)
 
 
This assumes that there are sufficient untested patients under the status quo to 
exhaust reference test capacity following triage testing.  To compare the status 
quo and triage test scenarios the number of identified cases and missed cases 
from the expanded populations is estimated.  For the reference test only 





For the triage test strategy, the proportion of identified cases from expanded 





The difference between these proportions represents patients who would have 
tested positive under the reference test, but were unable to receive the test 
due to the capacity constraint. It is assumed that 𝑃[𝑅+] is the same for patients 
who were able to, and not able to, access the reference test.  Finally, the 
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increase in the probability of identifying a case from the expanded population 
that arises from the use of the triage test can be estimated.  This increased 
probability of detecting a case can be traded off against the cost of the triage 








10.3 Case study 
10.3.1 Background 
10.3.1.1 Epidemiology 
In 2016, malignant melanoma was the fifth most common cancer for males and 
females in Scotland (ISD Scotland, 2018a).  The incidence rate for males was 
28.9 per 100,000 years at risk and for females 24.6.  The corresponding mortality 
rates were 4.6 for males and 2.1 for females.  Incidence rates for males 
increased by just under 30% over the last decade.  For females, there was no 
evidence of an increasing trend over the past decade but substantial increases 
had occurred previously (ISD Scotland, 2018a) including a 7-fold increase 
between 1976 and 2009 (NICE, 2015).  MM is most common in people over 50 
years of age but 20% of cases occur in young adults (NICE, 2015).  80% of cases 
are thought to be linked to ultra-violet exposure from the sun and sunbed use 
(NICE, 2015).  Incidence of MM is lower in lower socio-economic groups (NICE, 
2015).  Cancer survival for MM is relatively good as most cancers present at an 
early stage (ISD Scotland 2018a).  Prognosis is poor for cancers presenting at a 
late stage although advances in treatment have been made in recent years 
(SIGN, 2017). 
10.3.1.2 Clinical pathway 
Early detection of melanoma is important as early treatment is usually curative 
(SIGN, 2017).  Suspicious lesions are generally noticed either by the patient or a 
family member or by a clinician in the course of another consultation (SIGN, 
2017).  The current diagnostic pathway in Scotland, requires the clinician in 
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primary care to urgently refer the patient if any of the major features of the 7-
point checklist lesion system (Table 10-1) or any of the features in the ABCDE 
system (Table 10-2) are present.  The presence of the minor features from the 7-
point checklist should increase suspicion (SIGN, 2017).  Diagnosis of melanoma is 
difficult (SIGN, 2017).  There is evidence that the accuracy of diagnosis varies 
according to a clinician’s experience and that there is considerable variation in 
the sensitivity of the diagnosis (SIGN, 2017).  In secondary care, assessment 
using dermoscopy by trained healthcare professionals is recommended but the 
precise pathway may vary by healthcare setting (SIGN, 2017).  Positive 
dermoscopy leads to biopsy and pathological analysis (SIGN, 2017).   
Table 10-1: The 7-point checklist lesion system (SIGN, 2017) 
Major features Minor features 
Change in size of lesion Inflammation 
Irregular pigmentation Itch/altered sensation 
Irregular border Lesion larger than others 
 Oozing/crusting of lesion 
 
Table 10-2: The ABCDE lesion system (SIGN, 2017) 
A Geometrical Asymmetry in two axes 
B Irregular Border 
C At least two different Colours in lesion 
D Maximum Diameter >6 mm 
E Evolution/change in lesion 
 
In the UK, various targets are in place to try and improve health outcomes for 
patients diagnosed with cancer.  In England and Wales, there is a two-week 
target for referrals from primary care to first appointment in secondary care.  In 
Scotland, there is a 62-day target from referral to first cancer treatment and a 
31-day target from the decision to treat to treatment starting (ISD Scotland, 
2018b).  In the quarter to 30 June 2018, 97.7% of patients with melanoma 
started treatment within the 62-day target and 95% of patients were treated 
within 31 days of the decision to treat (ISD Scotland, 2018b).  
Referrals cause a heavy burden on specialist dermatology services and a high 
proportion of referrals for suspicious lesions are benign.  An overview of 52 audit 
studies of skin cancer referrals under the 2-week rule found that melanoma and 
squamous cell carcinoma accounted for only 10% to 12% of referrals, with the 
remainder being benign lesions (CCG Cancer Assessment, 2017/18).  In England, 
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there has been exploration of the potential of teledermatology (Eastham and 
O’Shea, undated; PCC, 2013) to combat this.  Teledermatology involves the use 
of imaging technology in primary care to allow the triage of suspected cases of 
skin cancer including melanoma.  One study suggested that up to 50% of referrals 
could have been avoided if teledermatology had been used in primary care prior 
to referral (Cox, 2004). 
10.3.1.3 Technology and initial clinical study  
The technology assessed in this case study is the melanoma test (name changed 
for confidentiality reasons).  It is a photographic image analysis system using 
iPad technology (iPad Air2 device) and proprietary signal processing (using the 
melanoma test app) (melanoma test clinical study report 004, unpublished, 
hereafter ‘CSR4’).  The software creates numerical values for five defined 
characteristics of the image, some of which are not visible to the naked eye 
(CSR4).  Library images of benign and malignant pigmented lesions were used by 
the developers to establish thresholds within an algorithm which were then 
tested in a hospital-based study in three hospitals (Wishaw General Hospital, 
University Hospital, Hairmyres and University Hospital, Monklands, all in 
Lanarkshire, Scotland)(registered clinical trial protocol and CSR4).  1,200 
patients were recruited over a 12-month period from April 2015 from the 
population of patients referred to specialist dermatologists from primary care 
with suspicious lesions.  Data from 400 patients was used to calibrate the 
software and data from the remaining 800 was used for validation.  The 
classification by the melanoma test was compared to clinical diagnosis by 
inspection and biopsy result, if one was performed (CSR4).  A population, 
intervention, comparator, outcome (PICO) summary for CSR4 is set out in Table 
10-3. 
Table 10-3: PICO summary for clinical study report 4 (unpublished) 
Population Patients referred to specialist dermatologists with suspicious lesions 
Intervention Test with melanoma test, +ve result = referred, -ve result = not referred 
Comparator All patients referred 
Outcome Proportion of patients correctly referred  
Referrals avoided 
PICO – population, intervention, comparator, outcome 
Four possible categories of diagnosis are of interest for the clinician.  These are 
(from least to most serious: benign, dysplasia, other malignancies and 
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melanoma.  The developers investigated four alternative thresholds (termed 
‘discriminant functions’) which are set out in Table 10-4.  D1 is the narrowest 
discriminant function and is set as if only MM is of interest to clinicians.  Each 
subsequent function will capture more of the other results of interest 
(melanoma, other malignancies and dysplasias) but will also include a greater 
proportion of false positives and will not reduce the number of referrals to the 
same extent.  D1 and D2 were selected as the discriminant functions of interest 
in order to compare the relative performance of D1 (rule-in test with high 
specificity relative to sensitivity) and D2 (rule out test with high sensitivity 
relative to specificity) in conditions with and without constraint on specialist 
referral. 
Table 10-4: Discriminant functions specified by developers  
Discriminant 
function 
Dysplasia Other malignancies Melanoma 
D1   At least one measurement 
beyond the range for 
melanoma 
D2  At least one measurement 
beyond the range for 
other malignancies 
At least one measurement 
beyond the range for 
melanoma 
D3 Excluding 90% of 
dysplasias 
At least one measurement 
beyond the range for 
other malignancies 
At least one measurement 
beyond the range for 
melanoma 
D4 Excluding all dysplasias At least one measurement 
beyond the range for 
other malignancies 
At least one measurement 
beyond the range for 
melanoma 
Shading indicates the discriminant function applied in this chapter. 
Table 10-5: Test performance for discriminant functions D1 to D4 
Threshold Sensitivity Specificity 
D1 - at least one measurement beyond the range for melanoma  46% 63% 
D2 - at least one measurement beyond the range for melanoma and 
for other malignancies  
82% 23% 
D3 - at least one measurement beyond the range for melanoma and 
for other malignancies and excluding 90% of dysplasia 
92% 18% 
D4 - at least one measurement beyond the range for melanoma and 
for other malignancies and excluding all dysplasia  
100% 8% 
Shading indicates the discriminant functions of interest in this chapter. 
10.3.2 Method 
Decision tree models were developed which compared the current (refer all) and 
alternative test and refer strategies for both non-constrained and constrained 
resource scenarios (identical to the generic case in Figure 10-2).  In the proposed 
pathway (the higher branch of the decision tree), all patients are tested using 
the melanoma test.  Those with a positive result are referred to a specialist 
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dermatologist.  Those who do not meet the threshold (negative result) are not 
referred.  In both positive and negative test result arms there is the possibility 
of the test result being correct or incorrect resulting in missed cases of 
dysplasia, other malignancies and melanoma.  The only difference between the 
constrained and non-constrained decision trees is the constraint on specialist 
dermatologist appointments.  This means that a proportion of patients referred 
in the ‘no triage test’ arm will not see the specialist dermatologist so no 
diagnosis will be made. 
The time horizon for the decision tree covered the diagnostic process up to 
referral.  Inputs to the model include the sensitivity and specificity associated 
with the D1 and D2 discriminant functions (see Table 10-5) as well as the 
prevalence of all the conditions of interest (23.5% from CSR4).  For the purposes 
of this analysis, test accuracy is assessed as the ability to distinguish all the 
conditions of interest.  So 82% sensitivity (see Table 10-5) means that at a 
threshold set to identify all suspicious lesions with at least one measurement 
beyond the range for melanoma or other malignancies the test will only identify 





Table 10-6 sets out the results of a reference test only strategy with a reference 
plus triage test strategy including melanoma test as both rule in and rule-out 
tests in the event that specialist dermatologist appointments are not 
constrained.   
Table 10-6: Results with dermatologist appointments non-constrained  
Strategy/Parameters 









Rule out test 
(Sens 82%,  
spec 23%) 
Rule in test 
(Sens 46%,  
spec 63%) 
Positive at triage - 78.2% 39.1% 
False negative rate at triage - 4.2% 12.7% 
Reduction in reference testing - 21.8% 60.9% 
Percentage of reference tests 
positive 
23.5% 24.6% 27.6% 
Number of reference tests 
required 
1000 782 391 
Missed cases 0 42 127 
Sens – sensitivity, spec - specificity 
Table 10-7 sets out the results assuming appointments are constrained.  For the 
reference capacity constrained case, the relative expansion of the population 
and the number of cases identified is greater with the higher specificity, ‘rule-
in’ test.  Although, the number of false negatives at triage is also greater with 
the ‘rule-in’ test due to the lower sensitivity, this does not equate to missed 
cases. The total number of cases identified is still higher with the rule-in test 
due to the expansion of the tested population.  For the unconstrained reference 
capacity case (see Table 10-6), the higher specificity ‘rule-in’ test leads to the 
greatest reduction in the number of reference tests required, however the ‘rule-
in’ test also leads to the greatest number of missed cases.  The higher sensitivity 
‘rule-out’ test minimises the number of missed cases but is less efficient in 





Table 10-7: Results with dermatologist appointments constrained  
Strategy Parameters 









 Rule-out test 
(Sens 82%,  
spec 23%) 
Rule in test 
(Sens 46%,  
spec 63%) 
Probability test positive at 
triage 
- 78.2% 39.1% 
False negative rate at triage  4.2% 12.7% 
Percentage of reference tests 
positive  
23.5% 24.6% 27.6% 
Maximum relative expansion of 
coverage1 
- 1.28 2.56 
Maximum number of patients 
triage-able before reference test 
capacity (1,000) exhausted 
- 1,279 2,557 
Number of positive reference 
tests 
235 246 276 
Incremental increase in cases 
found due following triage  
- 11 41 
False negatives at triage - 54 324 
Sens – sensitivity, spec - specificity 
The value of the melanoma test technology as a rule in or rule out triage test 
can be estimated assuming specialist dermatology resource was not constrained 
(see Table 10-8).  The cost of £137 for a specialist dermatology referral was 
taken from public sources relevant for Scotland (Curtis and Burns, 2017).  It was 















Value of test 
Refer all 0% 0% N/A 
Triage using D1 – rule in - at least one measurement 
beyond the range for melanoma  
61% 13% £84 
Triage using D2 – rule out - at least one measurement 
beyond the range for melanoma and for other 
malignancies  
22% 4% £30 
 
When resource is constrained the value of the triage test is in increasing the 
number of cases diagnosed rather than in reducing the number of specialist 
dermatologist appointments required.  An economic value assessment would 
need to compare the downstream costs and outcomes resulting from each 
strategy in order to determine whether a triaging strategy was potentially cost-
effective. 
10.4 Discussion 
Where the reference test capacity is constrained, the assessment of the 
opportunity cost of a triage strategy depends on the cost of the triage testing 
and an assessment of the value of the additional cases identified. The number of 
additional cases identified is maximised by maximising specificity. Arguably 
sensitivity is less important as false negatives at triage testing do not directly 
represent missed cases.  As long as there is a sufficient pool of individuals who 
would not be tested under the reference test only regime, the total number of 
cases identified will be greater under the triage strategy. However, there still 
may be a ‘cost’ associated will false negatives at triage testing if these lead to a 
change in behaviour in those who test negative at triage. 
Where the reference test capacity is unconstrained, the assessment of the 
opportunity cost of a triage strategy depends on the cost of the triage testing, 
the costs resulting from a reduction in reference testing, and the ‘cost’ of any 
false negatives at triage testing in terms of worse outcomes. The choice of test 
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will depend on trade-off between cost-savings and missed cases due to false 
negatives at triage.  
When the availability of the gold-standard diagnostic test is constrained, tests 
added to the diagnostic pathway in a triage position do not necessarily need high 
levels of accuracy in order to increase the number of cases diagnosed.  This has 
implications across a wide range of disease areas.  The model presented in this 
chapter provides a simple way of assessing whether a particular test may have 
potential to increase diagnoses.  This chapter has shown, using a simple model, 
that the value of a triage test, in terms of additional cases diagnosed, depends 
upon whether the availability of the gold-standard (or reference) test is 
constrained.  Where resource is not constrained, a triage test will result in 
missed cases and an overall reduction in diagnoses unless its accuracy is high.  
However, where the availability of the reference test is constrained, there is 
potential for tests with relatively low accuracy to improve levels of diagnosis 
and reduce missed cases.  The levels of test performance required depend upon 
the extent to which the capacity of the reference test is constrained.  Levels of 
test performance can be lower and still deliver benefits as the reference test 
numbers available reduce as a proportion of the population to be tested.  This 
finding has relevance across a wide range of diseases and settings.  For example, 
in tuberculosis approximately 3.6 million cases of active disease go undiagnosed 
annually, partly due to limited access to confirmatory molecular tests 
(Nathavitharana et al, 2019).  A further example is in colorectal cancer.  In the 
UK, demand for colonoscopy is forecast to increase 10-15% year on year resulting 
in capacity constraints and faecal immunochemical tests have been suggested as 
a possible triage test in symptomatic patients (Westwood et al, 2017).  In 
relation to the COVID-19 pandemic, testing resources have been constrained in 
many jurisdictions.  Required performance levels for RDTs have been set 
sufficiently high (for example, the Medicines and Healthcare Products Regulatory 
Agency (MHRA) in the UK have set performance standards of minimum 98% 
sensitivity and specificity for tests used as ‘immunity passports’ and in 
‘seroprevalence studies’ (MHRA, undated)) that many test manufacturers have 
failed to meet them (Adams et al, 2020) and some tests have been returned to 
manufacturers (Jones, 2020).  It has been suggested that there is a need to be 
creative in testing strategy. (Pettit et al, 2020; Peto, 2020; Rodriguez, 2020).  
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The results set out in this chapter suggest that there may scope to use tests with 
lower performance effectively in some testing pathways.   
Evaluation of alternative testing strategies using cost-effectiveness analysis 
typically requires a complex model with parameter estimates for health 
outcomes and resource use.  This resource intensive process takes time and 
expertise and results may be difficult to generalise as diagnostic and clinical 
pathways vary across and within jurisdictions.  The model presented is not 
intended to be an alternative to a comprehensive cost-effectiveness analysis.  
Rather, it is intended as a model that could be used during the development of a 
test to determine whether further investment is appropriate and to guide design 
and evidence generation strategy.  However, a potential further use of the 
simple model may be to inform decision-makers responding to the current 
COVID-19 pandemic, who need to evaluate a large number of tests in a wide 
range of testing scenarios.  The model could help to narrow the range of 
alternatives to be explored in more detailed modelling   
This is the first simple model to demonstrate the benefit of triage tests when 
availability of reference tests is constrained.  The only inputs required for the 
model are prevalence, sensitivity and specificity, population and number of 
reference tests available.  Assuming the incremental net (accounting for 
resource use) health benefit for treated positive cases compared with untreated 
positive cases is greater than the incremental net health benefit for treated 
negative cases compared with untreated negative cases, maximising the total 
number of true positive reference tests will maximise net health benefit.  In 
general, treated negative cases will be associated with a negative incremental 
health benefit as they will be associated with wasted resources and sometimes 




11 Case study 5 - Economic evaluation of blood 
test to aid diagnosis of prostate cancer in Hong 
Kong 
11.1 Introduction 
This chapter is based on an article published in PLOS One in April 2019.  The co-
authors were Jeremy Teoh, Peter Chiu, Kevin Chan, Chi-Fai Ng (all of whom 
were involved in the initial clinical study (Chiu et al, 2016)) and Robert Heggie 
and Neil Hawkins (health economists who were involved in the validation of the 
model and who read and approved the manuscript). The decision makers for this 
case study are a team of academic clinicians working in urinary medicine the 
Chinese University of Hong Kong.  The study arose following a clinical trial in 
which the decision makers examined the relative merits of different diagnostic 
strategies.  The ultimate aim will be to present a case for reimbursement to the 
public health authority in Hong Kong.  However, at this stage, with clinical 
evidence limited to some retrospective analysis from the previous trial, the 
academic clinicians are making decisions around whether further research is 
likely to be worthwhile and if so, what form it should take.  The decision 
makers’ underlying objective, for this study is to maximise societal return on 
investment from future research.  The output of this HTA study will constitute a 
platform for discussion between the academic clinicians and the Hong Kong 
Public Health Authority about the potential of the test in use in Hong Kong and 
the evidence required for adoption of the technology. 
 
11.2 Methods  
This case study comprises a clinical value assessment and an economic value 
assessment.  As it concerns a commercially-available technology, the iterative 
process is well advanced.  As opposed to simply attempting to articulate a value 
proposition the study seeks to evaluate that proposition in a given jurisdiction 
with the use of some technology and context specific evidence. 
Methods applied in this case study were a health impact assessment (to assess 
clinical value) and a cost-consequence analysis (to assess economic value).  As 
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resources were scarce the health impact assessment relied on input from the 
academic clinician team from Hong Kong to map pathways.  Trial data (both 
published and unpublished) provided input to the cost-consequence model.  
Cost-consequence analysis was selected as the introduction of the test was 
expected to deliver cost savings in the avoidance of a proportion of prostate 
biopsies and their attendant complications.  Although there were improved 
health outcomes from the reduction in biopsy-related complications and the 
disutility from the biopsy itself the introduction of another imperfect test into 
the diagnostic pathway carries a risk of false negatives (missed cancers).  Key for 
the decision-maker is how large a cost saving can be delivered at differing levels 
of acceptance of risk of missed cancer.  Although a full cost-utility modelling 
exercise may be the most accurate way of synthesising these considerations and 
presenting a case for reimbursement to the Hong Kong Public Health Authority, 
such a model is expensive to produce.  Moreover, simple models can be more 
effective tools of communication. 
A simple generic mathematical model was developed to compare the cost 
savings to the consequences of missed cases.  Cost savings are from the 
avoidance of downstream diagnostic costs when a new test is introduced to the 
diagnostic pathway.  Missed cases are the result of false negative results of the 
new diagnostic test.  Both aspects vary with test performance. 
11.3 Results  
Prostate Cancer (PCa) is the second most commonly diagnosed cancer in men 
worldwide (Mottet et al, 2017).  The incidence of PCa in Chinese men is 10 times 
lower than the rate in men from Western Europe but it has increased rapidly in 
recent years (Chiu et al, 2016; Chen et al, 2014). Positive biopsy rates are lower 
in Asian men (15-25%) compared with Western European men (30%) and cancer 
tends to be diagnosed later (Chiu et al, 2016; Chen et al, 2014).  The first steps 
on the current diagnostic pathway in Hong Kong for suspected PCa are a digital 
rectal examination (DRE) and the prostate specific antigen (PSA) blood test.  In 
men whose DRE is normal but whose PSA levels are between 4-10 ng/ml the 
current diagnostic pathway requires a transrectal ultrasound-guided (TRUS) 
biopsy. Such biopsies are invasive and carry considerable risks of post-procedure 
complications including fever, acute urinary retention, haematuria and 
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haemospermia (Chiu et al, 2016).  As positive biopsy rates are low, many 
biopsies are carried out unnecessarily under the current diagnostic set-up (Chiu 
et al, 2016).  
The Prostate Health Index (PHI) is a commercially available blood test 
manufactured by Beckman Coulter Inc. which has been recently approved by the 
United States FDA for use in patients with PSA of 4-10 ng/mL and normal DRE.  
The test uses a combination of different forms of PSA (tPSA, fPSA and [-2] 
proPSA (p2PSA) and has shown improved ability to predict presence of PCa and 
clinically significant PCa at biopsy (Le et al, 2010; Loeb and Catalona, 2014).  In 
a recent study reported elsewhere, Chiu et al (2016) found that PHI had a better 
performance than PSA-based diagnostic models in the Chinese population. The 
study found that in a population of men aged 55-75 years, if a 10% risk of missing 
PCa during screening was accepted, 30.3% of biopsies could be avoided using PHI 
compared to 16% using PSA.  If a 20% risk of missing PCa was accepted, 47.5% of 
biopsies could be avoided compared with 20.8% using PSA-alone. Data from the 
whole cohort in this study (including those outside the screening age group of 
55-75 years) suggested that in the population with a PHI score of under 25, 3.6% 
would have PCa and 0.5% would have high-grade PCa.  For the population with a 
PHI score between 25 and 35, 7.6% would have PCa and 0.9% high-grade PCa. 
This suggests that it may be possible to introduce the PHI test with a threshold 
value of 35 after DRE and PSA testing in those men with normal DRE and a PSA 
level of 4-10 ng/ml as a rule-out test to avoid unnecessary biopsies if patients 
and clinicians were prepared to accept a risk of missing a high-grade cancer of 
less than 1%.  Men with a PHI over 35 would continue to undergo TRUS biopsy 
and men below this level would undergo an annual PSA test until the age of 78 
when mean survival from PCa exceeds life expectancy (Hamdy et al, 2016; 
Census and Statistics Department, Hong Kong SAR, September 2017).   
The aim of economic evaluation is to consider the costs and consequences of a 
course of action in order to determine whether this use of resources is better 
than the next available alternative (Drummond et al, 2015).  Although there 
would be additional costs due to the introduction of the test, short term savings 
would be made on biopsies avoided and the treatment of adverse events arising 
following biopsy.  Health outcomes would be positively impacted for those 
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patients avoiding negative biopsies and its attendant complications.  However, 
there would be an increased risk of missed cases of cancer in the group who 
avoid biopsy.  This study presents a cost-consequence analysis of the 
introduction of the PHI test at PHI thresholds of 25, 35 and 55.   
The current strategy (biopsy all) was mapped and two alternative diagnostic 
strategies (biopsy none and test then biopsy) for men with normal DRE and PSA 
levels 4-10 ng/ml using information supplied by Hong Kong clinicians (the 
decision-makers in this case study).  For the test-then-biopsy strategy the costs 
and consequences were estimated for three different cut-off levels for the test.  
These pathways were set out as a decision tree with a time horizon covering the 
diagnostic process up to biopsy (see Figure 11-1). A Hong Kong public health 
service perspective was adopted.  Health outcomes differ between the three 
strategies due to the direct impact of the biopsy and adverse effects following a 
proportion of biopsies and the proportion of cancer cases that are missed.  
Health outcomes relating to the biopsy procedure itself or complications of the 
procedure are not considered in this study but they would be positive under each 
of the testing strategies as they reduce as the number of biopsies reduces.  The 
proportion of missed cancers which would be likely to result from each testing 
strategy was calculated and presented as well as the costs of the alternative 
strategies.  
Figure 11-1 shows the current strategy under which all patients undergo TRUS 
biopsy, a strategy where no patients undergo biopsy and the proposed testing 
strategy.  In the proposed pathway (the lowest branch of the decision tree) all 
patients are tested using PHI.  Those with a positive result undergo TRUS biopsy.  
Those with PHI scores under the threshold (negative result) do not undergo 
biopsy.  In both positive and negative test result arms there is the possibility of 
the test result being correct or incorrect resulting in missed cases of cancer.  For 
each strategy cost savings were calculated on the basis of the number of 
biopsies avoided. 
Clinical data to populate the decision trees and costing data for all costs apart 
from the PHI test were collected as part of the study reported by Chiu et al 
(2016).  Sensitivity and specificity for three different thresholds of PHI score are 
shown in Figure 11-2.  Any accident and emergency attendances and length of 
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hospital stay (where appropriate) following biopsy were recorded.  This resource 
usage was valued using costs from the Annual Report for 2016-7 of the Hospital 
Authority Hong Kong (2017).  The PHI test cost was based on the cost of the test 
at a Hong Kong clinic to a private user.   Costs are not discounted given the short 
time horizon of the economic evaluation.  
Figure 11-1: Decision Tree comparing diagnostic strategies  
 
DRE –Digital Rectal Examination, PHI – Prostate Health Index, PSA - Prostate Specific 
Antigen, TRUS – Transrectal Ultrasound-guided biopsy.  Diamond represents a decision 
node. Circle represents a probability node.   






Table 11-1: Inputs to the model and data sources    
Epidemiology and PHI test performance   
Prevalence 10.9% 
Sensitivity of PHI test at cut-off 25 [1] 88.7% 
Specificity of PHI test at cut-off 25 [1] 36.5% 
Sensitivity of PHI test at cut-off 35 [1] 61.3% 
Specificity of PHI test at cut-off 35 [1] 77.5% 
Sensitivity of PHI test at cut-off 55 [1] 12.9% 
Specificity of PHI test at cut-off 55 [1] 97.4% 
Proportion of patients suffering an adverse event after biopsy 
[2] 0.07 
Proportion of patients suffering an adverse event who require 
hospitalisation [2] 0.38 
Costs  HK$ 
Cost of PHI test [3] 3,000 
Cost of adverse event – Accident and Emergency Department 
Attendance [4] 1,300 
Cost of adverse event - hospitalised [5] 23,116 
Cost of TRUS biopsy [6] 10,900 
 
Notes 
[1] Data collected in Chiu at al study (2016) 
[2] Unpublished data from study reported in Chiu et al (2016) - 39 patients 
attended Accident and Emergency Department from a cohort of 569 
undergoing biopsy 
[3] Based on the cost of the test to a private patient at a Hong Kong clinic  
[4] Cost of Accident and Emergency Attendance from Annual Report 2016-7 
Hospital Authority (2017)  
[5] 4.67 days - mean length of stay for patients requiring hospitalisation (Data 
collected in Chiu et al study (2016) these data unpublished).  Valued at 
HK$4,950 per day Accident and Emergency Attendance from Annual Report  
2016-7 Hospital Authority (2017) 
[6] Cost of TRUS biopsy based on hospital finance department analysis 
(unpublished) 
 
HK$ - Hong Kong dollars, PHI – Prostate Health Index, TRUS – Transrectal 
Ultrasound-guided   
 
One-way sensitivity analysis was undertaken whereby input parameters were 
varied in turn by 50% of base case value in both directions (whilst all other 
inputs to the model were held constant) to determine the impact of an over or 
under-estimation on the base-case results.  This form of sensitivity analysis was 
undertaken as this allowed decision makers to assess the individual impact of 
each of the input parameters.  Where sensitivity analysis showed that the result 
was sensitive to an individual parameter threshold analysis was undertaken.  
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This involved varying the range to determine the highest level at which the cost 
savings would be reduced to zero. 
A total of 569 patients were included in the study by Chiu et al (2016).  62 of 
them were diagnosed with prostate cancer of which 16 were high grade cancers.  
Using a cut-off of 35, the introduction of the PHI test into the diagnostic 
pathway for men with normal DRE and PSA levels 4-10 ng/ml would save 
HK$5,500 per patient (see Table 11-1).  At this cut-off the study data (Chiu et 
al, 2016) indicated that cancer in 4.2% of the population (including 0.53% with 
high grade cancers) may be missed.  The majority of the saving results from 
approximately 75% of patients avoiding TRUS biopsy as their PHI score was under 
35.  A further cost saving of HK$511 results from a reduction in adverse events 
following biopsies.  If the cut-off for PHI testing were increased to 55 over 95% 
of biopsies could be avoided resulting in an overall cost saving estimated to be in 
excess of HK$8,000.  However, applying a cut-off of 55 to study data, prostate 
cancer in 9.5% of the population would have been missed including 2.1% with 
high grade cancer.  If the cut-off is reduced to 25 around a third of biopsies 
could be avoided with just over 1% of all cancer cases missed including less than 
0.2% of high-grade cancers.  At this cut-off level cost savings are reduced to 
HK$914.  At all cut-off levels the introduction of PHI results in cost savings 
although these are greater at higher cut-off levels as more biopsies are avoided.  
Testing costs for PHI are included in the analysis at HK$3,000 and it is proposed 
to test all patients in this population.  Testing costs may reduce under the new 





Table 11-2: Cost-consequence analysis of alternative diagnostic strategies 
Strategy Biopsy rate Cost of biopsies 
(HK$) 

























Biopsy all 100% 10,900 0 698 11,598 - - - 
PHI test for all - cut off 25 66.26% 7,222 3,000 463 10,685 -914 1.23% 0.18% 
PHI test for all - cut off 35 26.71% 2,912 3,000 187 6,098 -5,500 4.22% 0.53% 
PHI test for all - cut off 55 3.69% 402 3,000 26 3,428 -8,170 9.49% 2.11% 
Biopsy none 0% 0 0 0 0 -11,598 10.90% 2.81% 
 1 
 
PHI – Prostate Health Index, HK$ - Hong Kong dollars 
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Sensitivity analysis showed that the overall cost saving was sensitive to the cost 
of biopsy, the cost of the PHI test and the specificity of the PHI test (Figure 
11-3).  No individual parameter, when varied within a range 50% above or below 
the base case would alter the conclusion that the introduction of the test is 
likely to be cost saving.  Threshold analysis for these parameters determined 
values at which the proposed strategy would be cost neutral.  These were 24% 
for the specificity of the PHI test (base case 77.5%), HK$3,400 for cost of biopsy 
(base case HK$10,900) and HK$8,500 for the cost of the test (base case 
HK$3,000).  Table 11-3 summarises the base case results and the results of 
sensitivity and threshold analyses.  Reducing the sensitivity of the PHI test whilst 
holding specificity constant results in more missed cases (all grades of cancer in 
7.2% of the population missed at 34% sensitivity, compared to 4.2% in the base 
case of 61%) but increases cost savings as more biopsies are avoided.  Lower 
specificity (with constant sensitivity) results in the same level of missed cases 





Table 11-3: Results, sensitivity and threshold analysis 
Base case (PHI cut-off 35)   
Cancer cases missed – all grades (high grade) n=24/569 (3/569) or 4.2% (0.5%)  
Cost saving per patient HK$5,500  
Made up of:  
Additional costs of testing  (HK$3,000)       
Direct cost savings from biopsies (circa 73% of 
patients at HK$10,900) 
HK$7,988       
Cost savings from reduction in adverse events  HK$511        
Sensitivity analysis Base case 
 
Range (+/- 50%) Results of 
sensitivity analysis 
(HK$) 
  Lower Upper Lower Upper 
Sensitivity of PHI test 61% 31% 100% 5,888 5,011 
Specificity of PHI test 78% 39% 100% 1,499 7,824 
Prevalence of all grades of 
cancer 
11% 5% 16% 5,748 5,257 
Proportion of patients 
experiencing adverse events  
7% 3% 10% 5,242 5,757 
Proportion of patients with 
adverse event requiring 
hospital  
38% 19% 58% 4,831 5,724 
Proposed test costs (HK$) 3,000 1,500 4,500 7,000 4,000 
Cost of biopsy (HK$) 10,900 5,450 16,350 1,506 9,494 
Costs of adverse events 
without hospitalisation (HK$) 
1,300 650 1,950 5,467 5,533 
Costs of adverse events with 
hospitalisation (HK$) 




Value for proposed strategy to be cost 
neutral  
Specificity of PHI test (at 
61% sensitivity) 
78% 24% 
Proposed test costs (HK$) 3,000 8,500 
Cost of biopsy (HK$) 10,900 3,400 
HK$ - Hong Kong Dollars, PHI – Prostate Health Index 
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Figure 11-3: Impact of sensitivity analysis on base case savings 
A&E- accident and emergency department, HK$ - Hong Kong dollars, PHI – Prostate Health 
Index 
11.4 Discussion 
The study demonstrates the use of simple economic evaluation in a preliminary 
assessment of a diagnostic technology using local data. The study was relatively 
quick and resource-light as a result of the simplicity of the model and the 
availability of locally relevant data from a previous study. Evidence was taken 
from a single clinical study (Chiu et al, 2016) and micro-costings from a single 
hospital.  One-way sensitivity analysis was appropriate as it allowed decision 
makers to assess the importance of individual parameters.  A simplifying 
assumption was made that all men in the population currently undergo TRUS 
biopsy.   
A significant limitation of this study is that data have been taken from a 
retrospective analysis of a cohort taken from a single clinical trial.  A further 
limitation is that the model does not take account if a proportion of cases where 
patients and clinicians decide that biopsy is not their preferred option (in the 
current diagnostic strategy).  In order to change the conclusion of the base case 
analysis (at a PHI cut-off of 35) just under 50% of men would need to refuse 
biopsy.  The proportion of men not undergoing biopsy is believed to be 
substantially lower than this.  
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This study found that the adoption of the PHI test for patients with negative DRE 
and PSA score 4-10 ng/ml in Hong Kong has the potential to deliver significant 
cost savings although there are implications with a proportion of all grade 
cancers missed.  The cost savings arise because the PHI test stratifies men into 
those requiring TRUS biopsy and those who can avoid biopsy and enter the 
monitoring programme.  As biopsy and the adverse events associated with it are 
expensive to deal with, a strategy which avoids a relatively small proportion of 
biopsies has the potential to deliver savings which exceed the costs of testing all 
the patients in this population but this must be balanced with the risks of missed 
cases and the longer term cost and clinical outcomes. 
The results are consistent with three previous economic evaluations of PHI.  The 
first study by Nichol et al (2011) was a budget impact analysis of PHI plus total 
PSA and percent free PSA compared to PSA alone.  This study evaluated the 
impact on 1-year total costs of PHI plus PSA to PSA alone in a screening 
programme from a US societal perspective in men 50-75 years old.  Using 
thresholds for PHI testing of 2ng/ml and 4ng/ml they estimated cost savings of 
US$356,647 and US$94,219 respectively in a notional insurance company cohort 
of 100,000 men.  90% of the overall savings came from avoiding unnecessary 
biopsies.  A further study by Nichol et al (2012) extended their previous analysis 
to a cost-utility analysis with a 25-year time horizon.  This extended analysis 
found that PHI plus PSA dominated PSA alone strategy for both 2ng/ml and 
4ng/ml thresholds delivering cost savings of US$1,199 and US$443 respectively 
together with utility gains of 0.08 and 0.03.  Both Nicholl et al studies used data 
relevant to the US population and are not directly applicable to a Chinese 
population.  The final economic evaluation study identified was Heijnsdijk et al 
(2016) who assessed the cost-effectiveness of using a PHI cut-off of 25 as an add-
on to PSA with a cut-off of 3ng/ml in a European screening population aged 50-
75.  This study found a reduction in negative biopsies of 23%, a reduction of 17% 
in costs of diagnosis and 1% in total cost of prostate cancer.  Although these 
results support the results of the study care must be taken as the clinical and 
cost-effectiveness of PHI in the Hong Kong setting is dependent upon 
epidemiology specific to the Chinese population as well as local treatment 
pathways, the organisation of local services and the capacity and organisation of 
molecular pathology services. 
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This case-study was a preliminary cost-consequence analysis that indicates that 
the PHI test is potentially cost-effective in that it is not “dominated” by current 
practice (i.e. costs more with worse outcomes). This represents necessary but 
not sufficient condition for cost-effectiveness. Further research is needed to 
compare the potential long-term cost and clinical consequences of missed 
cancer diagnoses against the short-term benefits.   
Nicholl at al (2011) suggests that the negative consequences of missed cases are 
limited as they are likely to be found in subsequent screenings (Crawford and 
Abrahamsson, 2008). Effectively false negatives represent delayed rather than 
missed diagnoses. Moreover, cancers missed tend to have relatively-low Gleason 
scores and most cancers found 2-4 years after an initial screen are still curable 
(Wolters et al, 2010; Hugosson et al, 2003; van der Cruijsen-Koeter et al, 2003; 
Hoedemaeker et al, 2001; Postma et al, 2004; Hugosson et al, 2004; Schroder et 
al, 2008).  However, the extent to which these conclusions hold in a Chinese 
population requires further study.   
The immediate implication of this study for policy-makers is that in the Hong 
Kong context, PHI could be a cost-saving addition to the diagnostic set-up for 
prostate cancer in men with PSA levels of 4-10ng/ml and negative DRE.  
Although health outcomes have not been fully quantified, the analysis suggests 
that, at the proposed cut off of 35, sensitivity could be retained such that all 
grade cancer would missed in only 4.2% of the population and high-grade cancer 
in only 0.53% whilst a high proportion of biopsies would be avoided.  The use of 
the PHI test in Hong Kong appears to warrant further investigation. 
The decisions to be informed were whether further research would appear to be 
justified and if so, what form should that research take.  Moreover, the study 
aimed to inform reimbursement strategy for the development team.  As the 
study suggested that the introduction of PHI into the diagnostic pathway in this 
population had the potential to deliver significant savings then it would appear 
that further research would be justified.  The current study suggests that results 
are sensitive to test performance and the costs of the biopsy and the test itself.  
The cost of the biopsy is known from a micro-costing exercise so is unlikely to 
vary to the extent that it has been varied in the present study.  The cost of the 
test can be established once volumes are known and through further dialogue 
233 
 
with the suppliers.  The key parameters for future research are, therefore, 
sensitivity and specificity of the test in the relevant population.  The 
development team should also continue dialogue with the Hong Kong Health 
Authority, patients and clinicians to determine their views of an acceptable level 
of missed cases to ensure that a prospective study is designed at a cut-off which 
is acceptable to key stakeholders.  This dialogue with the ultimate decision-
maker (the Hong Kong Health Authority) also ensures that the study is designed 
to meet their evidence requirements.  A useful design would be a randomised 
controlled trial where one arm of the study has the PHI test and one arm does 
not.  Both arms would continue on to biopsy but clinicians would have an 
opportunity to state whether or not they would have not biopsied.  A study type 
which would be useful would be a feasibility study which examined practical 
issues such as likely volumes, budget and staffing implications, how samples 
would be handled and time taken for turn-around.  A resource analysis would 
also be useful as this would build-in the impact of the change in diagnostic 
pathway on the existing pathway as the introduction of the test would reduce 
numbers requiring biopsy, thus demand on TRUS facilities.  Unless these 
facilities (staff, equipment, space) were able to be redeployed in the short term 







This chapter summarises the main findings, contributions and limitations of the 
thesis (Section 12.2, 12.3 and 12.4).  It also suggests what the implications of 
the research are and sets out some recommendations for future research 
(sections 12.5 and 12.6).  It addresses research questions 5 and 6.  
5. What are the wider implications of the results of the study? 
6. What recommendations for policy and future research arise from the 
study? 
12.2 Main findings of the thesis 
12.2.1 Features of DF-HTA 
A list of ten features characterising DF-HTA was proposed.  Four of the features 
(target audience, decisions to inform, available evidence and timing) had been 
included in previous frameworks distinguishing early and mainstream HTA 
(Ijzerman and Steuten, 2011) or classical HTA (Pietzsch and Paté-Cornell, 2008).  
A further six features were added (underlying user objective, decision space, 
business model, resources available for analysis, stance of analysis and burden of 
proof).  The last two features are critical to understanding the particular nature 
of DF-HTA.  The analyst takes a positive stance of analysis, effectively putting 
him or herself into the shoes of the developer to maximise the potential of the 
technology.  This is particularly evident as much development is ‘technology-
driven’ i.e. the invention precedes the identification of the precise clinical 
need.  The first task of the analyst is to ‘position’ the technology in the most 
favourable clinical indication and place in the care pathway.  This may involve 
considering multiple potential positions in what has been termed an ‘exploratory 
analysis’.  In DF-HTA the burden of proof is not established by any external body 
in the sense that there is no methods guidance and no pre-set criteria to meet.  
The analyst and developer need to consider the decisions to be made and the 
evidence and resources available in planning the analysis.  Any limitations in the 
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evidence available or the methods adopted are discussed with the developers 
and limitations addressed, if appropriate, in later development stages. 
12.2.2 Process of DF-HTA 
A generic process of DF-HTA was proposed identifying clinical value assessment 
and economic value assessment as core activities to be undertaken iteratively as 
a development proceeds.  Research and development and other commercial 
activities were recognised as closely linked but distinct activities.  Information 
flows between each of the activities were identified.  Both research and 
development and other commercial activities inform and are informed by 
clinical and economic value assessments.   
12.2.3 Methods of DF-HTA 
Clarity in the process of DF-HTA is useful to ‘ring fence’ methods available to 
the analyst separating assessment methods from methods used in research and 
development and other commercial activities.  Methods identified as useful for 
DF-HTA were care pathway analysis, qualitative methods of stakeholder 
consultation, literature reviews, multi-criteria decision analysis, discrete choice 
experiments, expert opinion and expert elicitation, cost-effectiveness analysis 
and value of information analysis.  For DF-HTA where resources are limited, less 
formal versions of the methods may be appropriate such as targeted literature 
reviews rather than systematic literature reviews.  Cost effectiveness analysis 
may take the form of cost minimisation analysis or cost consequence analysis 
rather than cost utility analysis.  Simpler modelling techniques, intermediate 
outcomes and short time horizons may be appropriate in DF-HTA.  Estimands 
such as headroom and the thresholds for costs and clinical effectiveness 
(including test performance) required for a technology to be cost-effective in 
the modelled jurisdiction may also be informative in DF-HTA.  There is some 
debate in the academic literature at present about the role of probabilistic 
sensitivity analysis and value of information analysis in early health economic 
modelling.  Although there may be a role for these methods later in the 
development process, simpler approaches appear more appropriate for SME and 
academic developers working outside translational research bodies at early 
stages of technology development. 
236 
 
12.2.4 Illustration of framework using case studies 
The list of features did appear to be able to distinguish DF-HTA when the case 
studies were compared against the list of features.  There is an interesting 
contrast between the three case studies where the features of DF-HTA set out in 
the list are evident and the two case studies where this is not the case.  For 
example, the case study concerning the melanoma test is one which 
demonstrated all the features in the framework.  The cost-consequence analysis 
of the Prostate Health Index, a commercially available test shared three 
features with DF-HTA:  burden of proof (as no specific methodological guidance 
for health economic analysis was followed); limited evidence; and constrained 
resources.  However, in other features the study differed from DF-HTA.  The 
audience included a public payer, the timing was late as the technology was 
commercially available; and the decision space was limited as the indication and 
position in the clinical pathway was known.  Although the methods used were 
similar to those which may be used in DF-HTA (deterministic modelling, use of 
cost consequence analysis) this was primarily driven by the lack of resources 
available.   
12.3 Contributions of the thesis 
The first contribution of the thesis is the development of a framework of DF-HTA 
including features, process and methods.  The list of features builds on the work 
of Pietzsch and Pate Cornell (2008) and Ijzerman and Steuten (2011) who set out 
frameworks of features distinguishing early HTA from classical or mainstream 
HTA.  This thesis makes the argument that the needs of the audience (the 
developer) drive many of the distinct characteristics of the analysis, rather than 
the timing of the analysis.  The proposed generic process of DF-HTA builds on 
the work of Cosh et al (2007) and Markiewicz et al (2014, 2017a).  Cosh et al 
(2007) set out a sequential process for investment decisions for new 
technologies.  Markiewicz et al (2014) classified methods under a number of 
aims which were later termed ‘areas of early assessment’ (Markiewicz et al, 
2017a).  This thesis offers a reconfiguration of Markiewicz et al’s ‘areas of early 
assessment’ as an iterative process of clinical and economic value assessment.  
The summary of suitable methods for DF-HTA built on the work of Markiewicz et 
al (2014) who presented a comprehensive synthesis of methods used in empirical 
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studies from a systematic review of applied studies.  The specific contribution of 
this thesis is to simplify this synthesis by including similar methods under one 
name and excluding methods of research and development and other 
commercial activities.  Building on the work of Vallejo-Torres et al (2008) and 
Chapman (2013), adaptations to methods were suggested for situations where 
resources are constrained.   
The second contribution is to provide five empirical examples, three in DF-HTA 
and two in early economic evaluation.  All concern diagnostic technologies.  A 
number of recent studies have identified the need for development of early 
economic evaluation methods in addressing the potential value of stratified 
medicine approaches (Faulkner et al, 2012; Gaultney, 2014; Ijzerman et al, 
2017).  The case studies do not directly apply the features, process and methods 
identified in the methodological chapters as the case studies were completed at 
various different time points during the iterative development of the 
methodological work.  They do, however, provide an opportunity to illustrate 
the framework of features, process and methods proposed. 
12.4 Limitations 
12.4.1 Literature search 
The main limitation of any review of HTA to inform developers is that the 
majority of work in this area is not published due to commercial sensitivity (Tu 
et al, 2014).  The published studies may represent those where methods applied 
were more complex and/or where more resources were available for analysis.  
The search strategy may also not have identified all relevant examples of 
applied or methodological studies of development-focused HTA.  As the aim of 
the search was to identify features and useful methods of DF-HTA any omission 
would only be a concern if it discussed or applied a new methodological 
approach not discussed anywhere in the identified studies.  Screening of study 
titles and data extraction was done by a single researcher who also decided 
when saturation point had been reached on methodological points.  It is 
probable that a subsequent researcher would select a different set of studies 
from the ones reviewed in this thesis.  Again, this would only be an issue of 
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concern if a significant area of interest was not represented or was 
misrepresented. 
12.4.2 Subjectivity in paper selection and framework 
development 
As the audience in many studies was not made explicit it was difficult to 
separate those studies where the intended audience was the developer from 
other early HTA studies.  The judgement was made by one researcher with 
discussion with supervisors in cases of uncertainty.  The inclusion criteria were 
that the audience was explicitly developers or that some reference was made to 
decisions which were development-focused (such as technology design).  These 
inclusion criteria may have resulted in a smaller pool of applied DF-HTA studies 
as some DF-HTA studies may have been excluded.   
Features of DF-HTA were extracted from a mix of studies with explicit and 
implicit frameworks.  Where the framework was implicit, both the selection of 
the studies to include and the extraction of the features were subjective.  This 
would only have an impact where the selection of a different paper would have 
called into question the inclusion of one of the features or added a further 
feature.  The validation of the framework in future studies by other research 
groups would mitigate this risk. 
12.4.3 Lack of formal methodology and validation  
Development of the framework of features, process and methods of DF-HTA 
involved iterative processes of literature searching, discussion and drafting 
between myself and the supervisors of the thesis.  No formal methodology was 
used although this process shared some features with framework analysis 
(Spencer and Ritchie, 2002; Oliver et al, 2008).  A recent study suggests that this 
method of framework development is not unusual, but a more formal process of 
framework development would have made the steps more transparent for the 
reader and may have improved internal validity (McMeekin et al, 2020).  No 
external validation has been carried out to date.  The validation of the 





12.5.1 Implications for developers 
Evidence suggests that many developers of health technologies do not use formal 
methods of decision-support and do not have in-house capacity and knowledge 
to perform HTA (Craven et al, 2012; Markiewicz et al, 2017a).  The case studies 
in this thesis suggest that there are benefits for developers in consulting an HTA 
practitioner at an early stage in the development process.  HTA is able to inform 
a go/no go decision at any point in development.  In a ‘needs driven’ scenario 
such as the ovarian cancer case study, HTA methods can be used to estimate 
whether there is potential value in pursuing the project.  This evaluation of the 
‘room for improvement’ can take place without any significant resource 
commitment on the potential developers’ part.  Where development is 
‘technology-driven’ it is beneficial to start to ‘position’ the technology and 
articulate value propositions for the technology in the most promising positions 
in the care pathway.  A key aspect of DF-HTA at the earliest stages in 
development is to encourage engagement with potential users and other 
stakeholders as this may impact on technology design and evidence generation 
strategy.  For example, in the melanoma case study, the potential cost savings 
available could be undermined if GPs were risk averse and referred all patients 
with a mole that appeared suspicious using their clinical judgement as well as 
those identified as needing referral according to the new test.  Evidence would 
be required to determine the level of GPs’ risk aversion.   
Two of the case studies contribute generic tools which developers could use 
without the involvement of an HTA practitioner.  The Test and Treat Superiority 
Plot and model (Chapter 7) would be useful for developers of treatment 
response tests as a first hurdle.  The model presented in Chapter 10 is a flexible 
tool for developers of potential triage tests with application whether or not the 
reference testing capacity is constrained.  Often, developers and investors find 
aspects of test performance difficult to communicate.  These simple models 




Discussions with an HTA practitioner may also encourage developers to keep in 
mind the breadth of indications, positions in the care pathway, jurisdictions, 
business models and jurisdictions which may be available to them.   
12.5.2 Implications for practitioners of HTA 
As DF-HTA is a relatively new field, practitioners who have previously 
concentrated on HTA undertaken to support reimbursement or adoption 
decisions may find the framework set out in this thesis a useful introduction to 
the field.  The practitioner could consider the table of features to clarify the 
nature of the study which, if reported, would improve clarity for readers.  The 
generic process (section 5.3.1.2) provides clarity about the role of DF-HTA in 
relation to research and development and other commercial activities.  
Practitioners may find it useful to undertake clinical value assessment as a 
separate exercise to economic value assessment early in the development 
process.  Undertaking care pathway analysis, modelling of clinical outcomes 
and/or engaging with stakeholders may be sufficient to inform developers’ 
decisions at the earliest stage without requiring formal economic analysis. 
HTA practitioners familiar with reimbursement-focused HTA may look to 
undertake a full cost-utility analysis if the evidence is available to complete it.  
It may, however, be a better use of the resources available to use a simpler 
model and use the resource available to conduct, for example, stakeholder 
consultation to explore likely behavioural issues.  The purpose of the HTA 
through the development process is to inform ongoing decision-making rather 
than provide a one-off recommendation.  Simple quantitative models are useful 
as a springboard for discussion. 
Where a simple quantitative exercise is undertaken, for example, a headroom 
analysis, it is important to keep in mind that this has narrowed the focus to a 
particular jurisdiction, indication and business model.  It is often necessary to 
narrow down, for practical reasons, but a technology should not be rejected 
before exploring the full breadth of possibilities in terms of indications, positions 
in pathway, jurisdictions and business models. 
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12.5.3 Implications for policy-makers 
DF-HTA can be used to prioritise research either on a portfolio basis or by 
assessing projects on a stand-alone basis.  Policy-makers should encourage the 
robust articulation of a value proposition (particularly for translational research) 
within funding applications.  Lehoux et al (2017) highlight the disconnect 
between the innovation funding stream and health research funding streams.  In 
particular, they note that innovation funding may not give sufficient focus as to 
whether a potential health innovation is relevant, usable and sustainable.  DF-
HTA may offer an opportunity to align the two agendas.   
The case studies have exemplified the difficulties in translating molecular 
pathology and other precision medicine technologies.  For example, the 
melanoma test illustrated the difficulty in generating context-specific evidence 
at a reasonable cost.  Translational research bodies which facilitate links 
between commercial entities, academic and clinical researchers, pathologists 
and clinicians, regulators and reimbursement agencies may improve the 
translation rate.  Policy-makers should continue to fund translational research 
bodies. 
Full disease models, such as that developed by the Innovation and Value 
Initiative could greatly improve the efficiency of DF-HTA (The Value Initiative, 
2020).  This may have allowed the development of a lifetime horizon in the 
rheumatoid arthritis case study.  Such full-disease models in priority areas could 
be used to evaluate any proposed technology (in technology-driven 
development) as well as determining areas of greatest need to inform specific 
calls for innovation (needs-driven development).  
12.6 Recommendations for future research 
Two of the case studies highlighted the use of similar methods to DF-HTA to 
inform decision-makers about the costs and consequences of expanding an 
existing molecular pathology test or introducing a new triage test into the 
clinical pathway.  The decision-making process for the adoption of molecular 
pathology technologies is not clear and transparent and research into the 
evidence decision-makers rely on would be useful.   
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Publication of further empirical examples of HTA to inform developers would be 
useful, particularly if reporting of the features of the studies was explicit.  
Research exploring the features of in-house and unpublished DF-HTA would be 
useful as well as research exploring the usefulness of DF-HTA to developers. 
This thesis has suggested a framework for DF-HTA comprising features, a generic 
process and analytic methods.  Research into the usefulness and ease of use of 
the framework would be of benefit.  A Knowledge Transfer Partnership has been 
funded by Innovate UK to transfer DF-HTA to an industry partner of the Glasgow 
Molecular Pathology Node and this will provide an opportunity to validate the 
approach.   
The extent to which full disease models have been or could be used to assess the 
value proposition for innovative technologies would be a useful area of research.  
This may also allow a more needs-driven approach to innovation funding as 
called for by Lehoux et al (2017) and Greenhalgh et al (2018).  Specifically, the 
models made available by the Innovation and Value Initiative (the 
valueinitiative, 2020) in non-small cell lung cancer and rheumatoid arthritis 
could be applied to relevant technologies in development to assess the 
feasibility of using this resource. 
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Flowchart of literature review
Total studies with number of development-focused studies in brackets
Duplicates = 2 Duplicates = 391
Excluded  =  42 Excluded = 2,223
Text not available = 5 Text not available = 214
Methods = 10 (10) Methods = 16 (11)
Applied = 17 (13) Applied  = 18 (6)
Methods and applied = 9 (9) Methods and applied = 15 (7)
Included papers = 36 (32) Included papers = 49 (24)
Initial pearl n=1 (1)
Total  = 136 (84)
Duplicates = 1 Duplicates = 443
Excluded = 76 Excluded = 3,603
Text not available = 2 Text not available = 59 Total  = 152 (88)
Methods = 8 (6) Methods = 19 (14)
Applied =  4 (2) Applied = 13 (3)
Methods and applied = 2 (2) Methods and applied = 4 (0)
Included papers = 14 (10) Included papers 36 (17)
Notes
Step 1 is a search of the citations on Google Scholar of the initial pearl article (Ijzerman and Steuten, 2011)
Step 2 is a search of the references of the initial pearl (Ijzerman and Steuten, 2011)
Step 3 is a search of the citations of all the identified articles from steps 1 and 2.
Step 4 is a search of all the references of all the identified articles from steps 1 and 2.
Step 5 is a search of citations of all articles identified as having explicit or implicit features of development-focused HTA (listed in Appendices) in February 2019
Step 2: reference search n=93 Step 4: reference search n=4,141
Methods and applied  = 35 (20)
Combined papers from steps 1-4
Applied = 61 (25)
Step 1: citation search n=85 Step 3: citation search n=2,877
Relevant step 1 papers n=36 (32) Relevant step 3 papers n=49 (24)
Combined step 1 and 2 papers 
n=50 (42)
Combined step 3 and 4 papers 
n=85 (41)
Relevant step 2 papers n=14 (10) Relevant step 4 papers n=36 (17)
Including papers from step 5 - final set
Methods = 56 (43)
Methods and applied  = 30 (18)
Applied = 52 (24)
Methods = 54 (42)
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Appendix 3 – Studies with explicit frameworks 
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and patients”  
 
 
 Informs “market clearance, payment and usage of a technology” 
Authors include these decisions under “aims” of HTA 
“Assess safety, effectiveness, and cost-effectiveness” 
“Limited on no influence on clinical performance’ 
“Usually evidence from 
clinical studies performed 





 Informs about “design and management of a technology, as well as 
regulatory and reimbursement strategy” 
Authors include these decisions under “aims” of HTA 
“Assess likely safety, effectiveness and cost-effectiveness”  
“Potentially significant influence on (future) clinical performance” 
“Evidence from early bench 
and animal testing, early 
clinical experience and 
























Government – “Do we approve new products for market access and for 
what price?” 
Industry – “Develop a value dossier.  What is the best market access 
strategy? What is best possible price given regulatory constraints?” 
Clinical and basic research centres – “How do we get timely access to the 
new products and how do we manage and monitor quality assurance?” 
 
 
 At clinical 
research stage: 
Government – “Should we use public research funding for clinical 
research on new products?” 
Industry – “Where and how to launch the product. How to organise the 
clinical research strategy. Develop the economic evidence alongside.” 
Clinical and basic research centres – “What is the clinical evidence for 




First author Target audience Timing Specific decision HTA to inform Available evidence 








Government – “Should we invest in product development for economic 
growth and health benefits? Is there a market failure?” 
Industry – “Should we invest in R&D and target our products to specific 
patient groups?””  
Clinical and basic research centres – “Should we apply for public funding 
and in what consortia? What is our research focus and does the project 
fit our portfolio?” 
 








Government – “Should we use public resources for further research? To 
which consortia should it be awarded?” 
Industry – “Should we invest in future research, expand our research 
portfolio or partner with other public/private partners? How to obtain 
public funding? 
Clinical and basic research centres – “Should we apply for public funding 
and in what consortia? What is our research focus and does the project 
fit our portfolio?” 
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makers and payers” 
 
NB Annemans makes the 
point that the 
perspective of the model 
should be the payers 
regardless of who the 
model is seeking to 
inform 
 Early modelling informs 
pharmaceutical industry – 
‘Go/No go decisions”, 
“priority-setting 
decisions”, “choice of 
indication”, positioning, 
comparators, length of 
follow-up and other 
elements in the further 
development of drugs”, 
importance of “a given 
parameter” “influence 
future price and 
reimbursement status” 
 
Late HTA informs 
reimbursement decision-
makers (payers) “about 
allocating scarce 
resources”, “decisions 
about formularies” and 
“optimal medical 
treatment guidelines”, 
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Evidence for early 
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expert opinion – 
can compromise 
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“A company considering 






 Whether to invest in a 
new technology or 
continue to invest.  
 
“To avoid investing in 
those devices, which can 




and return on 
investment 
are positive 
Since headroom is 
a “rough and ready 
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“Development of future 
trial design”  
 




data or national 




“First data from 
Phase I/II trials for 
Go/No-go 
decisions”  
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“To avoid investing in a 
technology that could 
never be cost-effective” 
 
“To prioritise between 
several competing 
possibly cost-effective 
concepts or prototypes” 
 
To identify “from early 
stages of development 
those parameters that 
have the largest impact on 
the likely cost-
effectiveness of the 
product” 
 
“To help companies 

























that the new 










“prior beliefs .. 
elicited from a 
group of experts”  
 
















 Early in the 
development 
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“regulators and payers” 
 
“Early MTA” informs 
“Researchers and 
manufacturers” 
 Classical MTA  
To support policymakers 
to “assess the overall 
value of a drug, medical 
device or diagnostic test”. 
 
Early MTA 
“To support researchers 
and manufacturers “to 





and allocating public 
support for new 
technologies”  
“To improve the device 
during the development 
process to produce the 
most beneficial medical 
technology for society” 
“To help design future 
trials” 
 Classical MTA 
“after large clinical 





Early MTA in early 
and mid-stages as 
identified by 
Vallejo-Torres.  





clinical studies”  
Classical MTA 





Early MTA “in 
the early 
phases” of the 
development 
process 
  Headroom 
method is “a 
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 “Translational Health 
Economics” bridges gap 
between decisions to 
“invest in development 
of a technology” and 




To “analyse “value” for a 
potential health 
technology” and decide 
whether “to initiate a 
translation process” 
 
To ‘analyse “uncertainty” 
and to decide which 
methods to use to 
generate evidence about 
value “early on” 
 
To “analyse barriers of 
information and 
motivation in the 
cooperative process of 
translation as well as 
institutions to overcome 
these” 
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care: a case for 
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T1 -basic to 
applied 
research 
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 “Potential applications or 
improvement directions” 
 











estimate impact of 
uncertainty 
Iterative due to 
technology 
being a moving 
target 
   












“Reality check on the 




using a real options 
approach” 
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evidence available 
at outset of 
development.  
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medical tests 




“To decide about further 
development of medical 
tests” 
 
“To set realistic 
performance-price goals” 
 







“Much less data 







a test, new data 
and ideas may 
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“Clinical trial design” 
 
“Market access and 
pricing strategies” 
 
      
CEA – Cost effectiveness analysis. R&D - Research and development.  “quote marks” indicate that the contents are a direct quote from the artic
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Braz (2013) Developers Not stated Unclear Reimbursement
/ regulatory 
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Not stated Some Not 
discussed 
Phase I trial 
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Single 








Investors Not stated Unclear Reimbursement
/ regulatory 
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Technology 
design 
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discussed 
Prototype Single 
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jurisdiction                        
Single 









Unclear Not stated Unclear Evidence 
generation 
strategy            
Technology 
design   








jurisdiction                        
Single 
indication                        
Single 
position in 
























Timing  Clinical 
decision 
space 
















strategy      
Go/no-go - 
ongoing 
investment    
Continue to 










jurisdiction                        
Single 
indication                        
Single 
position in 
pathway                                











design                                                       
Not stated None Not 
discussed 
Concept Single 
jurisdiction                        
Single 
indication                        
Single 
position in 













Not stated Unclear Reimbursement
/ regulatory 
strategy 
Not stated None Not 
discussed 
Prototype Single 
jurisdiction                        
Single 
indication                        
Multiple 
positions in 























jurisdiction                        
Single 
indication                        
Multiple 

































Timing  Clinical 
decision 
space 
Business model Resources 
for analysis 
Kip (2016) Developers Not stated Unclear Reimbursement
/ regulatory 



















jurisdiction                        
Single 
indication                        
Single 
position in 
pathway                   
Multiple 
levels of test 
performance 
and strategies                    
Reimbursement PhD thesis 
Kluytmans 
(2019) 
Developers  Not stated Positive Go/no-go - 
ongoing 
investment    
Not stated Some Not 
discussed 
Prototype Multiple  












Developers Not stated Unclear Technology 
design                                                       
Not stated Some Not 
discussed 
Prototype Multiple 
jurisdictions               
Single 















strategy      
Go/no-go - 
ongoing 
investment    
Not stated Some Not 
discussed 
Unclear Single 
jurisdiction                        
Single 
indication                        
Single 
position in 






























Timing  Clinical 
decision 
space 










Not stated Unclear Go/no-go - 
ongoing 
investment   
Technology 
design 
Not stated Some Not 
discussed 
Prototype Single 
jurisdiction                        
Single 
indication                        
Single 
position in 




















strategy                
Technology 
design 
Not stated Some Not 
discussed 
Prototype Multiple 
jurisdictions          
Multiple 









Positive Go/no-go - 
ongoing 













jurisdiction                        
Single 
indication                        
Single 
position in 
pathway                                






Developer Not stated Positive Technology 
design                        
Go/no-go - 
ongoing 
investment              
Not stated None Not 
discussed 
Concept Multiple 
intervention           
Single 
jurisdiction                        
Single 




























Timing  Clinical 
decision 
space 





























jurisdiction                        
Single 
indication                        
Single 
position in 




















strategy         
Technology 
design 










jurisdiction                      
Single 
























Concept       
Prototype 
Single 
jurisdiction                        
Single 
indication                        
Single 
position in 
pathway                                
Reimbursement 











Positive Go/no-go - 
ongoing 









jurisdiction                        
Multiple 
indications                        
Single 
position in 
pathway                                
Reimbursement 


























Timing  Clinical 
decision 
space 











Positive Go/no-go - 
ongoing 
investment        
Technology 













jurisdiction                        
Single 
indication                        
Single 
position in 
pathway                                
Not specified.  
Model assumes 
value of 
innovation is a 





























jurisdiction                        
Single 
indication                        
Multiple 
positions in 
pathway                                
Reimbursement 





















design                                                       













jurisdiction                        
Single 
indication                        
Single 
position in 
pathway                                
Reimbursement None 
Singh (2010) Industry Maximise 
return on 
investment 
Positive Go/no-go - 
ongoing 









jurisdiction                        
Single 
indication                        
Single 
position in 
pathway                                
Reimbursement 
used as 























Timing  Clinical 
decision 
space 







Positive Go/no-go - 
ongoing 






Pre Phase I 
trials 
Single 
jurisdiction                        
Single 
indication                        
Single 
position in 
pathway                                
Reimbursement 












strategy       
Go/no-go - 
ongoing 













Concept       
Prototype 
Single 
jurisdiction                        
Single 
indication                        
Single 
position in 
pathway                                
Reimbursement 
used as 





























jurisdictions         
Multiple 












Unclear Not stated Unclear Go/no-go - 
ongoing 
investment    
Potential for 
development 





jurisdiction                        
Multiple 
indications                        
Single 
position in 
pathway                                
Willingness to 
























Timing  Clinical 
decision 
space 




Unclear Not stated Unclear Evidence 
generation 
strategy                   
Technology 




Not stated Some Not 
discussed 
Clinical 




jurisdiction                        
Single 
indication                        
Single 
position in 
pathway                                




Unclear Not stated Unclear Reimbursement
/ regulatory 
strategy    
Go/no-go - 
ongoing 
investment     
Not stated None Not 
discussed 
Prototype Multiple 
jurisdictions           
Specific 



















design                                                       







jurisdiction                        
Single 
indication                        
Single 
position in 
pathway                                








Methods from review articles Methods useful in DF-HTA 
included in Table 5-2 
Notes 




Literature review/analysis Literature review Included 
Peer review 
 
Excluded as relevance not clear 
User profiles building Qualitative methods of user 
interaction 
Included as Qualitative methods of user interaction 
Focus groups 
 
Included as Qualitative methods of user interaction 
Interviews (e.g. experts) Expert opinion and expert 
elicitation 
Included as Expert opinion and expert elicitation 
Informal discussions 
 
Included as Expert opinion and expert elicitation 
Qualitative weighing of relevant factors 
 
Excluded as unclear what method involves 
Use cases writing 
 
Included as Qualitative methods of user interaction 
Key informant interviews 
 
Included as Qualitative methods of user interaction 
Strategic planning methods: PEST, SWOT 
 
Excluded – as strategic planning is primarily a commercial activity although these methods may 
be useful to structure qualitative methods of user interaction.   Discussed under qualitative 
methods of user interaction. 
Soft-systems methodology 
 
Excluded - research and development process 
Expert panels/elicitation 
 
Included as Expert opinion and expert elicitation 
Technology profiling/uncertainty profile and 
evidence profile) 
 
Excluded  - research and development process 
Workshops 
 
Included as Qualitative methods of user interaction 
Surveys 
 
Included as Qualitative methods of user interaction 
Research and development portfolio 
management 
 
Excluded - other commercial activities 
Brainstorming sessions 
 
Excluded - research and development process 
Users-producers seminars 
 
Included as Qualitative methods of user interaction 
Usability tests 
 
Excluded - research and development process 
Users feedbacks 
 
Excluded - research and development process 
Clinical trials 
 
Excluded - research and development process 
Choice-based conjoint analysis (Discrete 
choice modelling) 





Excluded – horizon scanning is a process using methods such as literature review and 
stakeholder engagement to identify emerging technologies.  It may be useful in DF-HTA to 
identify barriers to diffusion and relevant comparators for economic evaluation.  Discussed 
under literature review in Section 5.3.3.3. 
Preliminary market research 
 
Excluded - other commercial activities 
Bench studies 
 






Included under Cost-effectiveness analysis 
Cost-effectiveness analysis Cost-effectiveness analysis Included 
Probabilistic sensitivity analysis 
 
Included under Cost-effectiveness analysis 
Potential years of life lost 
 
Included under Cost effectiveness analysis 
Cost-benefit analysis 
 
Included under Cost-effectiveness analysis 
Cost-utility analysis 
 
Included under Cost-effectiveness analysis 
Opportunity costs (used as indicators to which 
relative weights are assigned) 
 
Excluded as relevance not clear 
Road-mapping process (Multi-path Mapping) 
 
Excluded - research and development process 
Scenarios building 
 
Included under Cost-effectiveness analysis 
Return on investment  
 
Excluded - other commercial activities.  Discussed under cost effectiveness analysis as 
headroom estimates can inform return on investment calculations 
Technological forecasting based on 
epidemiological data 
 
Excluded - other commercial activities 
Rudimental analysis of costs 
 
Included as cost-minimisation analysis under Cost-effectiveness analysis 
Multi-criteria Decision Analysis (Analytic 
Hierarchy Process) 
Multi-criteria Decision Analysis Included 
Expected value of perfect information 
 
Included under Value of information analysis 
Bayesian modelling/statistics (data pooling, 
random effects analysis) 
 
Included under Cost-effectiveness analysis 
Probabilistic risk analysis 
 
Excluded - research and development process 
Real options analysis 
 
Excluded - other commercial activities.  Discussed under Cost effectiveness analysis as 
headroom can be combined with a form of real options analysis. 
Best-worst scaling 
 
Included as Discrete choice experiments 
Decision tree analysis 
 
Excluded as forms part of other modelling approaches discussed in Cost effectiveness analysis 




Payback from research analysis 
 
Excluded - other commercial activities 
Strategic business case 
 
Excluded as umbrella term 
Health impact assessment  
 
Excluded as umbrella term 
Multi-criteria Decision Analysis (Analytic 
Hierarchy Process) 
 
Excluded as duplicate 
Choice-based preference methods (discrete 
choice experiments and conjoint analysis) 
 
Included as Discrete Choice Experiments 
Real options analysis 
 
Excluded as duplicate 
Health economic modelling 
 
Included under Cost-effectiveness analysis 
Horizon-scanning systems 
 
Excluded as duplicate 
Clinical trial simulation 
 
Excluded - research and development process.  Discussed under Value of Information. 
Value of information analysis Value of Information Analysis Included 
Methods from Redekop and Mikudina (2013) 
  
Early health economic modelling 
 
Included under Cost-effectiveness analysis 
Clinical trial simulation 
 
Excluded as duplicate 
Multi-criteria Decision Analysis 
 
Excluded as duplicate 
Headroom 
 
Included under Cost-effectiveness analysis 
Bayesian analytical framework  
 
Included under Cost-effectiveness analysis 
Value of Information analysis  
 
Excluded as duplicate 
Methods from Miller (2005) 
  
Clinical Trial Simulation 
 
Excluded as duplicate 
Option Pricing 
 
Excluded as synonymous with real option analysis  
Investment Appraisal 
 
Excluded as umbrella term 
Threshold analysis  
 
Included under Cost-effectiveness analysis  
Value of information analysis 
 
Excluded as duplicate 
Methods from Hartz and John (2008) 
  
Early health economic modelling 
 
Excluded as duplicate 
The Bayesian Analytical Framework 
 
Excluded as duplicate 
Value of information analysis 
 
Excluded as duplicate 
Clinical trial simulation 
 
Excluded as duplicate 
Methods from Bartelmes (2009) 
  
Analytic Hierarchy Process 
 
Included as Multi-criteria Decision Analysis 
Stated-preference methods 
 
Included as Discrete choice experiments 
Expert systems 
 





Excluded - other commercial activities 
Bayesian methods 
 
Excluded as duplicate 
Decision analytic models (e.g. Markov models) 
 
Excluded as duplicate 
Pharmacokinetic and pharmacodynamic 
modelling 
 
Excluded - research and development process 
User-centred design 
 
Excluded - research and development process 
Failure and reliability analysis 
 
Excluded - research and development process 
Real-options analysis 
 
Excluded as duplicate 
Pre-protocol research 
 
Excluded - research and development process 
Tracker-trials 
 
Excluded - research and development process 
Constructive Technology Assessment 
 
Excluded as umbrella term 
Iterative economic evaluations 
 
Included under Cost-effectiveness analysis 
Evaluation frameworks for information 
technologies 
 
Excluded as not development-focused 
Methods from Graziadio (2020)   
Articulating value propositions  Included as outcome in Qualitative methods of user interaction 
Care pathway analysis Care pathway analysis Included 
Clinical validity studies  Excluded as research and development 
Clinical utility studies  Excluded as research and development 
Cost-effectiveness analysis  Included 
Cost-consequences analysis  Included under Cost-effectiveness analysis 






Appendix 7 - Examples of economic evaluation 










































Cost savings  
OWSA 
Scenario analysis 


















ICER Scenario analysis Building on 
previous work 
by the same 
group 













regulatory strategy   












































Technology design                         























































using point of 




regulatory strategy   

























strategy                                      
Go/no-go - ongoing 
investment 





5 year time 
horizon 
Net health benefit Simulation for 
uncertainty in 
costs.  Point 
estimates for 
other parameters. 




















regulatory strategy   









put herself in 
the position 
of assessing at 


































Not stated CUA - 
Markov 


















































































risk in patients 































strategy    
Prototype  CUA -
Decision 
tree 


























strategy            
































strategy       
Go/no-go - ongoing 







Quality of life 
Complications 
Costs 

















heart valve in 
CVD 
Technology design for 
cost-effectiveness                                                      

































cancer cell trap 














































Costs per cancer 
case avoided ICER 
OWSA 
PSA  



















heart attack  
Reimbursement/ 








































Go/no-go - ongoing 





























Technology design for 





















































































Go/no-go - ongoing 



















Neck collar in 
motor neurone 
disease 
Go/no-go - ongoing 
investment 





4 year time 
horizon 
Threshold cost for 
cost-effectiveness 
















point of care 




Technology design                        

















for different risk 
groups 
PSA 


















































































































Go/no-go - ongoing 























type 2 diabetes 
Technology design – 
required test 


































Technology design - 
required test 



























































































pins in hallux 
valgus 
Evidence generation 
strategy       














































Go/no-go - ongoing 





Headroom Scenario analysis 
 





Lab on a chip - 





regulatory strategy  
Evidence generation 
strategy  
Technology design                         
































strategy                   
Technology design                             




CUA –  
Decision 
tree 














CCA – cost-consequence analysis, CEA – cost-effectiveness analysis, CMA – cost-minimisation analysis, COPD – chronic obstructive pulmonary 
disease, CTC trap – circulating cancer-cell trap, CUA – cost-utility analysis, CVD – cardio-vascular disease, EVPI – Expected value of perfect 
information, EVPPI – expected value of partial parameter information, ICER – incremental cost-effectiveness ratio, MCDA – multi-criteria decision 
analysis, MRI – magnetic resonance imaging, OWSA – one-way sensitivity analysis, PSA – probabilistic sensitivity analysis, QALY – Quality 




Appendix 8 - Studies where expert elicitation has 







Method/participants Parameters elicited Purpose 
Davey (2011)  Meetings 
Unspecified number of 
vascular surgeons and 
interventional radiologists 
Clinical treatment routes, 
disease context, current 
treatments and current 
technology characteristics 
To identify the drivers for 
clinical success 
Breteler (2012) Interviews 
18 neurologists 
Likely test performance, 
position in diagnostic 
pathway, acceptance by 
patients, technical success 
To populate a real options 
analysis  
Weiser (2013) Self-administered 
questionnaire 
38 rheumatologists 
Characteristics required of 
new imaging modality in 
Rheumatoid Arthritis 
To direct the development of 
photo-acoustic imaging in 
rheumatoid arthritis  
Haakma (2014) Bayesian belief elicitation 
18 radiologists 
True positive and true 
negative rates for new 
imaging technology 
To populate a cost-
effectiveness model 
Huygens (2016) Delphi panel  
10 cardiothoracic surgeons, 
cardiologists and a 
biomedical scientist 
Conceptual model for cost-
effectiveness analysis of 
Tissue engineered heart valve 
in cardiac surgery 
First step to cost-
effectiveness model that will 
investigate the performance 
and costs requirements for a 
new heart valve technology  
Kip (2016) Expert elicitation by 
questionnaire.   
10 cardiologists. 
 
The effect of the new 
biomarker on hospital 
discharge rates and 
interventions performed 
To populate cost-
effectiveness models to guide 





Method/participants Parameters elicited Purpose 
Girling (2007) Bayesian prior distributions 
elicited in group setting 
5 cardiologists 
Survival prospects of patients 
treated with second 
generation device 
To investigate the survival 
benefit required for 
technology to be cost-
effective 
Leal (2007) Expert elicitation using 
computer-based tool pooled 
using linear opinion pooling 
7 experts comprising 
cardiologists, clinical 
geneticists and laboratory 
scientists 
Probability distributions for 
test performance, population 
at risk, detection by 
cardiology services, 
effectiveness of interventions 
To populate an early health 
economic model to inform 
decision making for new 





12 authors of clinical studies 
on the genotyping of interest  
Response rates to treatments 
for depression following 
genetic testing 
To predict the extent to 
which pretesting for 5-
HTTLPR would improve 
health outcomes 
Terjesen (2017) Delphi panel by two round 
questionnaire 
8 clinicians and/or 
researchers 
Probability of cross-
contamination from use of 
existing technology 
To confirm a core aspect of 
the value proposition/clinical 
need 




Appendix 9 - Studies where multi-criteria decision 
analysis has been applied in development-focused 




First author (date) Method/participants Criteria identified Purpose 
Hummel (2000) Team Expert Choice – a group 
decision support system 
based on AHP 
Cardiologist, 6 engineers 
(chemical, mechanical and 
electrical), surgeon, and 
veterinarian. Group 





Ease of use 
Applicability 
To guide development 
and diffusion of the 
Pulsatile Catheter Pump  
Hilgerink (2011) AHP 
Panel composed of medical, 







To assess the added value 
of photo-acoustic imaging 
in the diagnosis of breast 
cancer 
Hummel (2012) AHP 
Panel of biomedical 
engineers and orthopaedic 
surgeons  
Costs (materials and 
treatment) 
Effectiveness (quality of 
life, pain, back function, 
self-esteem, medical and 
technical complications) 
To predict the health 
economic performance of 
new non-fusion surgery 
in adolescent idiopathic 
scoliosis 




Long term patient safety 
Complications 
To prospectively evaluate 
if and when, the 
bioartificial pancreas 
becomes an alternative 
to transplantation 
methods in diabetes type 
1  
Koning (2012) MCDA (using a basic version 
of AHP) 
Microbiology physician, 
laboratory manager, head of 
the department, hospital 
management 
Clinical performance 
(accuracy, time to 
diagnosis, range of micro-
organisms) 
Cost of ownership 
Impact on workflow 
To populate performance 
criteria for an early 
health economic 
evaluation of an 
electronic nose 
technology 
De Graaf (2015) MCDA with Stochastic multi-
criteria acceptability analysis 
adapted to incorporate 
ordinal data. 
Participants were researchers 
from the specific project 
Reduction in downstream 
costs 
Added quality adjusted 
survival 
Cost 
Feasibility of treat-all 
Competition 
Ease of implementation 
 
To support priority 
setting within a research 
team looking at 
biomarkers in Diabetes 
Type 2 prevention. 
Prior to research being 
undertaken 
AHP – Analytic Hierarchy Process, MCDA – Multi-criteria Decision Analysis 
Early HTA 
First author (date) Method/participants Criteria identified Purpose 
Lambooij (2013) AHP 
Stakeholder groups of nurses, 
patients, physicians, 
managers, health-care 
insurers and policy makers 
Improvement in efficiency 
Health gains 








innovations in hospital 
care 
AHP – Analytic Hierarchy Process, MCDA – Multi-criteria Decision Analysis
343 
 




The probability of response to treatment A is pA and the probability of response is 
pB. A test is available that will predict response to treatment A with sensitivity 
(Sens) and specificity (Spec). The probability of response to treatment B is 
independent of the test result.  
The decision problem is illustrated by Figure AP10-1. 
Figure AP10-1: Generic decision model 
 
The difference in expected response between the test and treat strategy and the 
optimal treatment strategy is given by:  
max(𝑝𝐴, 𝑝𝐵) − 𝑝𝐴. 𝑝𝐵 + 𝑆𝑒𝑛𝑠. 𝑝𝐴 − 𝑆𝑒𝑛𝑠. 𝑝𝐴. 𝑝𝐵 + 𝑆𝑝𝑒𝑐. 𝑝𝐵 − 𝑆𝑝𝑒𝑐. 𝑝𝐴. 𝑝𝐵   Eqn. 1 
The threshold sensitivity at which the expected response from the test and treat 





   Eqn. 2  
Resp|Test+ve





Test - ve/treat B
No resp
Resp









The threshold sensitivity at which the expected response from the test and treat 







     Eqn. 3 
This can be used to establish thresholds for the sensitivity and specificity at which 
the test and treat strategy will be superior to the optimal treat only strategy. This is 
a function of the odds ratio for treatment A vs treatment B.  
